BIODISTRIBUTION AND IMPLICATIONS OF EXPOSURE TO GOLD NANOPARTICLES by BALASUBRAMANIAN SURESH KUMAR
  
 
BIODISTRIBUTION AND IMPLICATIONS OF EXPOSURE 


































 BIODISTRIBUTION AND IMPLICATIONS OF EXPOSURE 










BALASUBRAMANIAN SURESH KUMAR 







A THESIS SUBMITTED  





DEPARTMENT OF CIVIL & ENVIRONMENTAL 
ENGINEERING 








This doctoral thesis would not have been possible without a lot of help and support from the 
kind people around me. I would like to thank them for their contributions and 
encouragement:  
First and foremost, I am heartily thankful to Professor Liya Yu and Professor Wei-Yi Ong 
whose expertise and guidance enabled me to understand the field of engineered nanomaterials 
and their biointeractions through various routes of exposure. Despite their hectic schedule, 
they are always available and willing to help me whenever I needed. Their advice, critical 
evaluation and open-minded discussion equipped me to pursue excellence in research and 
complete my thesis work.  
Further, I would like to express my gratitude to Professor Lin-Yue Lanry Yung who 
generously shared his knowledge on synthesis and characterization of gold nanoparticles.  
I am indebted to thank all my buddies from Prof Yu’s research group (Dr. Yang Liming, 
Dr. Lim Jaehyun, Dr. Gao Yonggang, Dr. Amrita Pal, Dr. Feng Huajun, Mr. Nguyen Duc 
Minh, and Mr. Dipo Tamliang Riang) for their support, help and valuable discussions. 
Especially, I owe my deepest gratitude to Dr Yang Liming who has made his support 
available in a number of ways my studies.  
I also extend my thanks to many staffs and students from Prof Ong’s research group (Dr. 
Jinatta Jittiwat, Ms. Pan Ning, Ms. Yueh-Li Tan, Ms. Seok Wei Lim, Mr. Kay Wee Poh) for 
their help and support on animal work and microarray analyses. 
I wish to express my warm and sincere thanks to the laboratory staffs at Division of 
Environmental Science and Engineering, especially Mdm. Susan, Mr. Suki, Mr. Sidek, Mdm. 
Hwee Bee and Ms. Mary for their help to create a conducive environment for carrying out my 
ii 
 
laboratory work smoothly. 
It gives me a great pleasure to thank my family. I am deeply grateful to my father, Mr. T. 
Balasubramanian and my mother, Mrs. B. Maruthavalli who support me significantly 
throughout my life with their unceasing love, care, and support. In particular, I sincerely 
express my heartfelt gratitude to my sister, Mrs. Hemapriya Ramakrishnan and my uncle, Mr. 
Ramakrishnan Shokkanarayanan; without their efforts and inspiration, I would not pursue my 
graduate studies and join in National University of Singapore. I owe my loving thanks to my 
nephew, Mr. Amsakumaran Ramakrishnan for his smile and love which often helped me to 
forget my worries. I also wish to appreciate my brothers, Mr. Venkatesh Balasubramanian 
and Mr. Rajesh Balasubramanian, and my sister-in-law, Mrs. Priya Venkatesh for their 
understandings and support in all these years taking care of all family responsibilities 
allowing me to focus on research and complete my thesis.  
Last but not least, the financial support from the National University of Singapore is 
greatfully acknowledged. 
 






TABLE OF CONTENTS 
ACKNOWLEGEMENTS……………………………………………………… i 
TABLE OF CONTENTS………………………………………………………. iii 
SUMMARY……………………………………………………………………... v 
LIST OF TABLES……………………………………………………………… vii 
LIST OF FIGURES…………………………………………………………….. ix 
NOMENCLATURE.………………………………………………………….. x 
CHAPTER 1 INTRODUCTION………………………………………………. 1 
1.1 Background and motivation……………………………………… 1 
1.2 Objectives………………………………………………………….. 5 
1.3 Rationale of individual objectives…...…………………………… 6 
1.4 Organization……………………………………………………….. 19 
CHAPTER 2 LITERATURE REVIEW……………………………………… 20 
2.1 Types of engineered NPs.………………………………………… 20 
2.2 Gold nanoparticles (AuNPs)……………………………………… 21 
CHAPTER 3 EXPERIMENTAL……………………………………………… 43 
3.1 Material synthesis and characterization…………………………. 43 
3.2 Inhalation exposure in vivo……………………………………….. 48 
3.3 Intravenous injection exposure in vivo…………………………... 53 
3.4 Perfusion and harvesting of tissues………………………………. 54 
3.5 Quantification of Au in tissues…………………………………… 55 
3.6 Microarray analyses………………………………………………. 56 
CHAPTER 4 RESULTS AND DISCUSSION………………………………... 58 
iv 
 
4.1 Characterization, purification and stability of AuNPs…………. 58 
4.2 Inhalation exposure in vivo……………………………………….. 68 
 4.2.1 Translocation and effects of AuNPs………………………….. 68 
 4.2.2 Size effects of AuNPs………………………………………… 75 
4.3 Intravenous injection exposure in vivo…………………………... 86 
CHAPTER 5 CONCLUSIONS AND FUTURE WORK…………………….. 100 
5.1 Conclusions and implications……………………..……………… 100 
5.2 Recommended future work ……………………………………… 104 
BIBLIOGRAPHY……………………………………………………………..... 108 
APPENDIX……………………………………………………………………... 124 










To examine biodistribution after exposure to 20-nm gold nanoparticles (AuNPs) and 
resultant impacts on organs with accumulated AuNPs, this work exposed rats to 
AuNPs through inhalation exposure and intravenous injection. Prior to exposure tests, 
synthesized AuNP solution underwent thorough characterization. Impurities were 
quantified; a newly identified non-AuNP component (acetate) enables completion of 
the stoichiometric equation of AuNP synthesis through the citrate reduction method. 
An optimal purification procedure was selected after systematic tests. A 
centrifugation operated at 7000 g for 20 min achieved satisfactory recovery of AuNPs 
and almost full removal of impurities. The treated AuNP solution remained stable for 
20 days when it is stored in the dark at 4
o
C.  
After 15-day exposure to airborne AuNPs of an original size of 20 nm, the lungs 
showed the highest accumulation of Au. Compared to 5-day exposure where Au was 
detected only in lung and olfactory bulb, the accumulation of Au in more than 20 
organs at 15-day exposure demonstrates translocation of nanoparticles from the lungs 
to other organs. At similar doses of airborne AuNP in terms of number concentrations 
and agglomerated peak diameter aerosolized, inhaled AuNPs with an original size of 
7-nm AuNPs distributed in 22 organs, more than that of 20-nm AuNPs (18 organs), 
particularly in more areas of the brain, including olfactory bulb, hippocampus, frontal 
cortex, straitum and cerebellum. The microarray analyses of the lungs and kidneys of 
rats exposed to airborne 20-nm AuNP showed changes in >30 genes (such as 
cytochrome c oxidase subunits, RT1 class II, locus Bb, myoglobin, thyroid hormone 
responsive protein, etc.). They are mainly related to functions of smooth muscles, 
antigen recognition, secretion and growth. 
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To compare with inhalation exposure and to address the potential impacts of 
introducing nanoparticles through intravenous injection, 20-nm AuNPs were injected 
once and the resultant biodistribution was examined at four time points, 1 day, 1 
week, 1 month, and 2 months post injection. Injected AuNPs showed persistent 
accumulation of Au in liver and spleen. However, Au accumulation in the lungs 
decreased within 1 month. Significant accumulation of Au in kidney occurred when 
Au in feces and urine decreased. Coincident with the delayed accumulation in kidney, 
significant accumulation of Au in blood occurred two months post injection. 
Microarray results showed changes in >60 genes of liver and spleen related to 
detoxification, lipid metabolism, cell cycle, defense response, and circadian rhythm. 
Differing from inhalation exposure, injected AuNPs exhibited increased 
accumulation of Au in liver, rapid clearance of Au in lung with non-detectable Au in 
brain, evidencing that exposure routes are important of determining the distribution 
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1.1 Background and motivation 
Nanotechnology has been developed worldwide, enabling unique products containing 
nano-sized materials for industrial, commercial and biomedical applications. 
Engineered nanomaterials (or nanoparticles, NPs) have become an important 
emerging element in the global economy. It is estimated that >140 billion worth 
(USD) of products containing engineered NPs were sold in 2007 (Holman et al. 
2007). Due to its increasing manufacturing and usage, the global investment on 
engineered NPs is expected to exceed 1 trillion US dollars by 2015, which will be 
accompanied with an employment of two million workers globally in nanotechnology 
related industries (Roco 2006).  
The massive generation of nanomaterials and relevant products increase the 
likelihood of releasing NPs into the environment. This could potentially expose the 
workers and consumers to engineered NPs during production, usage and disposal of 
products (or wastes) containing engineered NPs. Since more than 800 new materials 
involving engineered NPs are in a wide variety of consumer products (Woodrow 
Wilson International Centre for Scholars, http://nanotechproject.org), specific 
guidelines for proper handling engineered NPs, and data on potential impacts of 
engineered NPs on environment and human health are needed.  
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Differing from natural NPs (e.g., volcanic emission) and incidental NPs (e.g., 
emissions from combustion engines) in the environment (UNEP 2007), engineered 
NPs are particles purposefully engineered with specific properties through “bottom-
up” (such as self-assembly – creation of NPs from atoms and molecules) or “top-
down” (such as milling – creation of NPs from macroscale components) approaches 
(USEPA nanotechnology white paper 2007). Although there is much debate about the 
definition for nanoparticles, an engineered NP generally can be defined as 
intentionally produced particle that has a dimension of 1-100 nm and has properties 
differing from the corresponding bulk materials with the identical chemical 
composition (US National Science and Technology Council 2004; The Royal Society 
and The Royal Academy of Engineers 2004). 
Compared to corresponding materials in bulk, engineered NPs possess unique 
electronic, magnetic and optical properties depending on their size, shape, charge and 
surface chemistry (Luther 2004). Engineered NPs often exhibit high reactivity 
because of more surface expressed molecules, larger surface area and higher particle 
number per unit mass (Nel et al. 2006). These interesting physico-chemical properties 
at the nanoscale enhance the use of NPs in various applications (e.g., soil and water 
remediation, diagnosis and treatment) and products such as catalysts, solar cells, 
cosmetics, sunscreens, tooth pastes, wrinkle free fabrics, and so on (Huynh et al. 
2002; Jain 2005; Brayner 2008; Borm and Berube 2008). However, some of the 
unique properties may also cause adverse impacts on humans and natural ecosystems 
(Zhao et al. 2007). For example, the larger surface area and associated surface 
reactivity lead to catalytic and oxidative reactions with biological systems and may 
induce toxicity (Limbach et al. 2007). Knowledge of how individual characteristics of 
engineered NPs influence their behavior and induce toxicity in various environments 
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is relatively limited (SCENIHR, Scientific Committee on Emerging and Newly 
Identified Health Risks 2009), yet is important to facilitate continual development and 
employment of nanotechnologies with sustainability and safety. Apart from unique 
physical and chemical properties of engineered NPs, exposure conditions (such as 
dose, duration and routes) can also determine the consequent impacts of engineered 
NPs.  
Engineered NPs can intentionally or unintentionally enter into the body via three 
major exposure routes: inhalation, ingestion and dermal contact; for medical purposes, 
injection (intravenous, intraperitoneal, intramuscular) can be an additional route of 
exposure (Oberdörster et al. 2005). Once entering into the body, engineered NPs 
would first interact with biological components (e.g., proteins) and then be distributed 
to and accumulated in various organs if the engineered NPs were neither soluble in 
local environment nor metabolized or removed through phagocytosis or endocytic 
processes (Borm et al. 2006). Note that solubility of engineered NPs depends on 
properties of local environment (e.g., pH, ionic strength) (Borm et al. 2006).  
As the size of engineered NPs can be similar to biological molecules, they can 
interact with tissues, cells, organelles, and functional biomolecular structures (e.g., 
DNA) and induce oxidative stress and cell injury (Oberdörster et al. 2005; Donaldson 
et al. 2006). Some engineered NPs can enter and stay in cells for an unknown period 
before moving to other organs or being excreted (Fischer and Chan 2007). 
Understanding biodistribution of engineered NPs in bodies and the mechanism of 
uptake by cells are important to investigate potential adverse effects of engineered 
NPs and to optimize future design of engineered NPs for biomedical applications. In 
view of the diversity of emerging engineered NPs, a systematic study in vivo on 
biodistribution of engineered NPs in bodies can serve as a basis to assess potential 
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health impacts on targeted organs and to assist investigation of interaction 
mechanisms between cells and engineered NPs in vitro. 
Significant exposure to engineered NPs in the working environment can be 
through inhalation (Oberdörster et al. 2005; Hoet et al. 2004), which allows various 
substances to enter bodies through translocation from the lungs. Adult lungs contain 
airways with an equivalent length of 2300 km and 500 millions of alveoli which 
contain a surface area of ~140 m
2
 (Stone et al. 1992) providing an abundant 
deposition platform for inhaled engineered NPs. In addition to inhalation exposure, 
biomedical applications of therapeutics (e.g., drug and gene delivery, radiotherapy) 
and diagnosis (e.g., biosensing and bioimaging) intentionally introduce engineered 
NPs in humans through injection which is an important route of exposure (Aillon et 
al. 2009). Hence, this thesis focuses on biodistribution and potential impacts of 
engineered NPs through inhalation and injection exposure.  
Before the objectives are specified below, the model engineered NPs employed in 
this study needs to be first explained. Gold nanoparticles (AuNPs) are chosen as 
model engineered NPs because bulk gold is one of the noble metals and is chemically 
inert. Compared to other metallic materials (such as CdSe), AuNPs are advantageous 
of being free from intrinsic toxicity. In addition, Au is generally insoluble and rarely 
present in biological tissues, easing the quantification of its presence in tissues using 
available techniques with minimal interference. Moreover, the wide applications of 
AuNPs demonstrate the relevance of examining potential impacts of NP material on 
human health. Due to their unique optical, electronic, and molecular-recognition 
properties, AuNPs are currently employed in a wide range of products including 




AuNPs have also a long history of biomedical use through ingestion (Higby 
1982). The Chinese have used red colloidal Au as a “drug of longevity” since 2500 
B.C. In India, colloidal Au was used in Ayurvedic medicine for rejuvenation under 
the name of “Swarna Bhasma” (gold ash) during the Vedic age (Richards et al. 2002). 
Au compounds were adopted as a drug for vigor of youth (Mahdihassan 1985) and for 
treating rheumatoid arthritis (e.g. Auronofin) (Walz et al. 1983; Brown et al. 2007; 
Tsai et al. 2007) as well as tuberculosis (Kean et al. 1985). AuNPs are also used as 
drug carriers (Ferrari 2005) and photothermal agents for cancer therapy (El-Sayed et 
al. 2006). Hence, AuNPs are an appropriate nanomaterial to evaluate impacts of 
exposure to engineered NPs on human bodies.  
1.2 Objectives 
To investigate the potential health impacts of nanomaterials (NPs), this study aims to 
examine the biodistribution of gold nanoparticles (AuNPs) in rodents through 
inhalation and intravenous (i.v.) injection. Specific objectives of this research work 
are to 
1. characterize synthesized 20-nm AuNPs, including evaluation of the optimal 
purification process, stability, and oxidation state of purified AuNPs;  
2. investigate the biodistribution of AuNPs (in two sizes) in rats after inhalation 
exposure and resulted changes in gene expression of selected target organs; 
and 
3. investigate the biodistribution of AuNPs in rats after i.v. injection and effects 




1.3 Rationale of individual objectives 
The importance and uniqueness of individual objectives are elaborated below with 
relevant background information.  
Objective 1: Characterization, purification and stability of AuNPs. AuNPs are 
some of the most widely utilized engineered NPs in bioimaging and biomedical 
therapeutics due to their intense surface plasmon resonance (Jain et al. 2007; Sperling 
et al. 2008). The strong binding affinity of AuNPs to thiols, disulfides and amines also 
facilitate their conjugation with biomolecules (e.g. DNA and antibodies), useful in 
development of various biomedical applications including biosensors and drug 
delivery (Katz and Willner 2004; Ojea-Jiménez and Puntes 2009). AuNPs of size <5 
nm exhibit high catalytic activities as more reactive atoms are close to the particle 
surface, ideal for oxidation of CO, reduction of nitrogen oxides, and decomposition of 
amines, hydrocarbons and organic halogens (Haruta 1997). 
AuNPs are often synthesized through reduction of Au (III) derivatives (Handley 
1989; Carabineiro and Thompson 2007). The citrate reduction method is well known 
for its simple procedure, yielding stable and reproducible AuNPs of narrow size 
distribution (Gross 2008). This method was pioneered by Turkevich et al. (1951) to 
synthesize 20-nm AuNPs through reduction of HAuCl4 via trisodium citrate, and was 
adopted by Frens et al. (1973) to generate AuNPs ranging from 16–150 nm by 
adjusting the gold-to-citrate concentration ratio. Despite the wide application of this 
method, systematic and comprehensive characterization of the synthesized AuNP 
solution has not been conducted. Since 1981, more than 230 published studies have 
employed AuNPs generated from the citrate reduction method, with scarce data on 
non-AuNP components in the reaction system although some byproducts (such as 
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ketoglutaric acid) in the synthesized AuNP solution have been reported (Turkevich et 
al. 1951; Kumar et al. 2007). Excess citrate and non-AuNP components (e.g. chloride 
ions) are expected to remain in the product solution, and should be characterized and 
removed before use. This is particularly important for tests of effects of AuNPs on 
biological tissues since non-AuNP components can cause interference with 
misleading results. For example, during an in vitro assessment of cytotoxicity, the 
presence of citrate, rather than AuNPs, reduced viability and impaired proliferation of 
human alveolar cells (Uboldi et al. 2009) and the presence of excess CTAB 
(cetyltrimethylammonium bromide) molecules rather than Au nanorod itself, induced 
cytotoxicity in human colon carcinoma cells (Alkilany et al. 2009). Residual non-
AuNP components such as sodium or chloride ions also compromised the catalytic 
reactivity of AuNPs to decompose hydrocarbons (Haruta 1997; Bond and Thompson 
1999). 
Several purification methods have been adopted to remove non-AuNP 
components, including centrifugation (Slot and Geuze 2007; Wulandari et al. 2008) 
ion-exchange (Zhang et al. 2010), solvent extraction (Shalkevich et al. 2010), dialysis 
(Aqil et al. 2008), and diafiltration (Sweeney et al. 2006). Of these, centrifugation is 
most commonly used to remove non-AuNP components probably because of easy 
availability of the instrument. This purification method also offers more flexibility to 
vary the final volume of the treated AuNP suspension. Table 1.1 summarizes the 
centrifugation speed and duration employed in various studies to purify AuNPs 
synthesized through the citrate reduction method. Although the centrifugation 
parameters cover a wide range of g-force (g) of 2300–20,800 g (or 2000–40,000 rpm) 
and duration of 5 min–3 h (Table 1.1), the use of different parameters (e.g., rpm vs. g-
force) in the reports challenge attempts to cross-compare among the studies. Even if a 
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Table 1.1 Studies employing centrifugation to prepare AuNPs synthesized through citrate reduction method. 
Source  AuNP size Centrifugation parameter Application/Study  
Slot and Geuze 1981 15.5 nm 15,000 g for 45 min -as probes for immunoelectron microscopy 
Fleming and Walt 
2001 
14.5 nm Centrifugation (thrice) -as substrates for biochemical assays 
Hazarika et al. 2004 
 
15 nm 20,800 g for 20 min (twice) -functionalized with DNA for biodetection 
Kim and Lee 2004 55–65 nm 3500 rpm for 2 h -coated with hydrogels for drug delivery  
Lin et al. 2004 17.1 nm 15,700 g for 10 min (twice) -functionalized with neutral and positively 
charged thiols for better optical sensitivity  
Murphy et al. 2004 13 nm  13,200 rpm for 30 min 
(twice) 
-linked with oligonucleotides for gene 
analysis 
Schneider and Decher 
2004, 2008 
13.5 nm 7000 rpm for 3 hours -coated with polyelectrolytes for biomedical 
applications 
Kim et al. 2007 30 nm 16,800 g for 30 min (twice) -coated with PEG as contrast agent for 
imaging 
Liang et al. 2007  17 nm 11,930 g for 20 min -conjugated with DNA for biodetection 
McMahon and Emory 
2007  
45, 75 and 
100 nm 
5500 g for 15 min 
(thrice) 
-functionalized with mercaptoacetic acid 
and attached with dicyclohexylamine for 
phase transfer to organic solvents  
Wang et al. 2007 20 nm high-speed centrifugation -fabrication of Au/PVP nanofiber 
composites 
Wybranowski et al. 
2008  
24 nm 6000 rpm for 20 min -coated with serum proteins for drug 
delivery 
Eck et al. 2008 15 nm 16,000 g for 30 min -coated with PEG as labeling agent for 
cancer tissues 
Diegoli et al. 2008  15 nm 3500 rpm for 10 min -interaction with naturally occurring organic 
macromolecules 
Gomes et al. 2008 11.5 nm 30,000 g for 25 min -for preparation of bionanoconjugates  
Guan et al. 2008 18 nm  8000 rpm for 30 min -for detection of Pb
2+
  
He et al. 2008 16, 20, 28, 
38, 43 and 
55 nm 
2000 rpm for 2 hours -coated with PEG as fluorescent probes for 
cancer cell imaging  
Sonavane et al. 2008 15, 50, 100 
and 200 nm 
40,000 rpm for 30 min 
(thrice) 
-examine effects of size on biodistribution 
via injection  
Stakenborg et al. 2008 14, 22, 30 
and 35 nm 
centrifugation (thrice) -functionalized with DNA for molecular 
diagnostics 
Wulandari et al. 2008 20 nm 10,000 rpm for 30 min (few 
times) 
-examine structure of adsorbed citrates  
Abdulla-Al-Mamun et 
al. 2009 
22 nm high speed (twice) -as photothermal agent to kill epithelial 
carcinoma cells 
Brun et al. 2009 37.5 nm 2300 g for 20 min (twice) -as radio-sensitizers for cancer treatment 
Dobrovolskaia et al. 
2009 
30 and 50 
nm 
18,000 g for 30 min -coated with blood for drug delivery 




Liang et al. 2009 10 nm 16,000 rpm for 15 min 
(twice) 
-as probes for detection of catalase activity 
Qu and Lü 2009 20 nm 10,000 rpm for 20 min -for cytotoxicity tests 
 Zhai et al. 2009 22 nm 4000 rpm for 10 min -for fabrication of multi-layered AuNP films 
Zhang et al. 2009 20 and 50 
nm  
low speed centrifugation 
(twice) 




20 nm 7000 g for 20 min (twice) -examine biodistribution and gene 
expression changes via injection 
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similar unit expression was adopted, the centrifugation forces and durations were 
seemingly selected arbitrarily. For example, AuNPs of 30 nm were centrifuged for 30 
min with a g-force ranging from 16,800-18,000 g (Table 1.1). Those of 20-nm were 
centrifuged at a speed of 10,000 rpm but the duration and numbers of washes before 
use varied (Table 1.1). Although the g-force required for centrifugation is inversely 
correlated with the size of AuNPs to be precipitated (Slot and Geuze 2007), some 
studies treated AuNPs of various sizes using the same centrifugation parameters 
(Table 1.1). Furthermore, there was little attempt to examine the resultant purification 
efficiencies of the treated AuNPs. 
Only one out of 29 studies summarized in Table 1.1 briefly described the 
purification efficiencies of treated AuNP solution without information on residual 
non-AuNP components in the treated solution. It has been reported that 1.3% of the 
citrate in the synthesized AuNP solution remained after the purification process which 
is appromixately 11.8 mg/L of citrate in the treated solution (Schneider and Decher 
2004) and could result in unwanted effects. Since the purified AuNPs have reduced 
capping reagent (citrate) over the particle surface, their uncharacterized stability raises 
questions about the actual size (aggregation) of the AuNPs during following 
applications. 
To address the above mentioned issues, individual non-AuNP components in 
synthesized AuNP solution were first identified and quantified for this objective. The 
newly identified organic byproduct and apportionments for individual non-AuNP 
components in the synthesized AuNP solution were further verified. Following the 
determination of an optimal purification process to separate AuNPs from undesired 
components, the effects of storage conditions (temperature) on stability of the purified 
AuNP suspension were examined. The oxidation state of the treated 20-nm AuNPs 
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was investigated to ensure consistent integrity of AuNPs employed in a variety of 
tests. This is the first study that systematically characterizes synthesized AuNP 
solution in detail with recommended purification procedures and experimentally 
proven stability. The optimal purification processes shown in this work can provide a 
platform for comparison with studies employing similar nanomaterials.  
Objective 2: Biodistribution and effects resulting from inhalation exposure of 
AuNPs. The increased use of engineered NPs in recent years raises concerns on 
impacts on environment and public health. However, a fundamental question of why 
or how engineered NPs are associated with the potential impacts is yet to be fully 
understood (Maynard et al. 2006). To examine the potential effects, it is necessary to 
understand how NPs accumulate in bodies, translocate into secondary organs, and 
excrete out of a system after exposure (Kreyling et al. 2009).  
Inhalation exposure to airborne AuNPs is possible during production, use and 
biomedical applications which employ this material. The wide use of AuNPs in 
industrial and biomedical applications may expose people to airborne AuNPs. For 
example, under closed-gas phase conditions airborne AuNPs are involved in various 
processes for catalytic and nanoelectronic applications such as evaporation 
condensation, aerosol assisted chemical vapour deposition, and spray pyrolysis (e.g., 
(Magnusson et al. 1999; Karlsson et al. 2004; Palgrave and Parkin 2006; Montero et 
al. 2009). It is unclear whether these processes expose airborne AuNPs to workers. 
However, previous studies showed that airborne NPs (such as carbon nanotubes, 
CNTs) in the workplace during production and clean up the reaction system involving 
aerosolized CNTs (Maynard et al. 2004; Demou et al. 2009). Since AuNPs are sold in 
powder form (Sundararajan and Rao 2009) and used in spray paints, deodorants, etc. 
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(Dekkers et al. 2007), consumers and workers can be exposed to airborne AuNPs 
through inhalation.  
In biomedical applications, engineered NPs can be intentionally delivered via 
inhalation as drug carriers to treat respiratory diseases or as imaging agent to diagnose 
lung tumours (Card et al. 2008). Since AuNPs have been demonstrated as an effective 
drug carrier (Paciotti et al. 2006), and a better contrast agent for imaging than 
conventional component (e.g. iodine) (Hainfeld et al. 2006), it is foreseen that 
continual advances in nanomedicine can exploit AuNPs for inhalation therapy. For 
example, the delivery of an immune activator (5′PPP-ssRNA) carried by AuNPs 
through inhalation appeared to be effective to treat against influenza virus in human 
bronchial respiratory epithelial cells (Chakravarthy et al. 2010). However, the 
knowledge on biodistribution and associated implications resulting from inhalation 
exposure to airborne AuNPs needs to be explored in detail to properly evaluate the 
safe use of AuNPs in various industrial and biomedical applications. 
Although impacts of inhalation exposure to AuNPs on humans are needed, only 
one study so far reported the distribution of Au in lung and blood after inhalation 
exposure (Takenaka et al. 2006); they showed that lung was the primary target organ 




) through inhalation for 6 h 
(Takenaka et al. 2006). This study also showed an increase of Au in blood (0.4±0.1-
0.7±0.3 μg/L) throughout the examined period (up to 7 day after 6 h inhalation 
exposure) compared to control (0.1±0.07 μg/L), indicating that Au might be 
translocated to different organs. Hence, to address the impacts of inhalation exposure 
to airborne AuNPs for the 2
nd
 objective, biodistribution of inhaled AuNPs and 
relevant implications on gene expression were carried out in two phases. The first 
phase of this objective examined distribution of 20-nm Au in >25 organs from 7 
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Table 1.2 Summary of in vivo studies reporting size-dependent toxicity of engineered NPs. 
Reference Size of particle Route of exposure Dose Duration  Findings 







up to 1000 µg/rat 24 h post 
exposure 
  Compared to 250-nm TiO2, 21-nm TiO2 
showed greater pulmonary inflammation, longer 
residence time in the lung, efficient translocation 
to pulmonary interstitium after inhalation 
exposure 
  Consistent with inhalation study, instilled 
12-and 21-nm TiO2 showed greater toxicity 




21-, 250-nm TiO2 
 
Inhalation 
MMAD: 0.71 μm (for 
21 nm) and 0.78 μm 







250 nm); 6 h per day, 
5 days per week for 12 
week 
64 week post 
exposure 
Brown et al. 
2001 




125 µg/rat, 1 mg/rat 24 h post 
exposure 
  More inflammation in 64 nm compared to 
202- and 535-nm polystyrene particles 
Kreyling et al. 
2002; 2009 






















nm) for 1 h 
6 h – 7 day post 
exposure 
(Kreyling et al. 
2002); 24 h post 
exposure(Kreyling 
et al. 2009) 
  Lavageable and translocated fraction of 
15-nm iridium from the lung were 
consistently higher than 80-nm iridium at all 
time points 
 20-nm iridium exhibited wider distribution 
than 80-nm iridium 
Hillyer and 
Albrecht 2001 
4-, 10-, 28- and 58-
nm AuNPs 
Oral 200 mg gold/kg water 7 days   4-nm AuNPs exhibited widespread organ 
distribution than larger AuNPs 




(~ 300 nm)  
Inhalation MMAD: 
1.44 μm (for 21 nm) 




; 6 h per day, 
5 days per week for 13 
week 
52 week post 
exposure 
  21-nm TiO2 exhibited pulmonary lesions 
in rats while pigment-grade TiO2 did not 
induce lung inflammation 
Renwick et al. 
2004 
29- and 250-nm 
TiO2; 14- and 260-




125 µg/rat, 500 µg/rat 24 h post 
exposure 
  Effect of 29-nm TiO2 or 14-nm CB was 
greater than those of 250-nm TiO2 or 260-
nm CB 
  Compared to larger particles, nano 
counterparts induced neutrophil infiltration 
and epithelial damage; diminished 
phagocytic ability of alveolar macrophages; 
induced macrophages to migrate towards 




Table 1.2 Summary of in vivo studies reporting size-dependent toxicity of engineered NPs (continued). 
Reference Size of particle Route of exposure Dose Duration  Findings 
Chen et al. 
2006 
19-21 nm TiO2, 180-
250 nm TiO2  
Intratracheal instillation 0.1 mg/mouse; 0.5 
mg/mouse 
3 day-2 week post 
exposure 
  Compared to larger TiO2, 19-21 nm TiO2 
showed lung lesions (e.g. alveolar 
enlargement) and induced proinflammatory 
cytokines (e.g. IL-1, TNFα) related to 
particle toxicity 
Choi et al. 2007 4.36 – 8.65 nm (Cys 
coated quantum dots 
(CdSe/Zns) 
Intravenous injection 10 pmol/g animal wt. 
(rat or mice) 
0-4 h post exposure   QDs ≤ 5.5 nm (hydrodynamic diameter) 
excreted via kidney into the bladder within 
4 h and suggested 5.5 nm as threshold size 
for renal excretion 
Schipper et al. 
2007 
12 and 21 nm (PEG 
coated and uncoated 
quantum dots 
(CdSe/ZnS)) 
Intravenous injection 25 pmol per mouse 1-36 h post exposure   PEG coated and uncoated QDs exhibited 
insignificant effect on biodistribution 
Wang et al. 
2007 
25-, 80- and 155-nm 
TiO2 
Oral 5g/kg mouse wt. 2 weeks post 
exposure 
  25 and 80 nm exhibited significant liver 
and kidney injury than 155-nm TiO2 
Grassian et al. 
2007 
5- and 21-nm TiO2 
 
Inhalation (geometric 
mean dia: 119.5 – 122.9 
nm (for 5 nm); 138.8 – 





 24 h post exposure   Through inhalation and instillation 21-
nm TiO2 induced more inflammatory 
response (increased neutrophil infiltration, 
increased proinflammatory cytokines) than 
5-nm TiO2 Intratracheal instillation 5-30 µg/mouse (for 5 
nm); 25–150 µg/mouse 
(for 21 nm) 
Inoue et al. 
2006 
14-, 56-nm CB Intratracheal instillation 4 mg/kg mice wt. 24 h post exposure   Compared to 56 nm, 14-nm CB induced 
proinflammatory cytokines (e.g. IL-1, MIP-
1α) related to particle toxcity 
De Jong et al. 
2008 
10-, 50-, 100- and 
250-nm AuNPs  
Intravenous injection 77-120 μg 24 h post exposure   10-nm AuNPs exhibited widespread 
organ distribution than larger AuNPs 




Intravenous injection 1000 mg/kg mice wt. 24 h post exposure   15-nm AuNPs exhibited widespread 
organ distribution than larger AuNPs 
Semmler-
Behnke et al. 
2008 






26.5μg/50μL (for 1.4 
nm); 2.7μg/50μL (for 
18 nm) 
24 h post exposure   1.4 nm exhibited widespread organ 
distribution; differences in biodistribution 




Table 1.2 Summary of in vivo studies reporting size-dependent toxicity of engineered NPs (continued). 
Reference Size of particle Route of exposure Dose Duration  Findings 
Cho et al. 
2009a 
4- and 100-nm 
AuNPs (PEG coated) 
Intravenous injection 4.26 mg/kg mice wt. 30 min post exposure  Similar biological effects (in terms of 
gene function) in liver was observed 
after both 4- and 100-nm AuNP 
exposure 
Chen et al. 
2009 
3-, 5-, 8-, 12-, 17-, 
37-, 50- and 100-nm 
AuNPs 
Intraperitoneal injection 8 mg/kg mice wt./week > 50 day post 
exposure 
  3-,5-,50- and 100-nm AuNPs did not 
induce any toxic effects; 
  8-, 12-, 17- and 37-nm AuNPs 
induced severe sickness (fatigue, loss of 
appetite, fur colour change, weight loss) 
Sadauskas et al. 
2009 
2-,40- and 100- nm 
AuNPs 
Intratracheal instillation 0.24 mg (for 2 nm); 
1.16 mg for 4 nm; 1.2 
mg (for 100 nm);5 
intratracheal doses in 3 
weeks) 
3 week post exposure   Compared to 40 and 100 nm, 
translocation of 2-nm AuNPs in to liver 
was higher (1.4-1.9% of administered 
dose) 
 
Terentyuk et al. 
2009 
15-, 50- (PEG 
coated) and 160-nm 
(nanoshell) AuNPs 
Intravenous injection 57 μg/rat 24 h post exposure   15-nm AuNPs exhibited wide spread 
distribution 
 
Zhang et al. 
2009 
20-,40- and 80-nm 
AuNPs (coated with 
thiotic aid anchored 
PEG)  
Intravenous injection 0.1-4.4 mg/kg mouse 
wt.  
48 h post exposure   Compared to 40 and 80 nm, 20-nm 
AuNPs exhibited prolonged blood 
circulation, lowest uptake in liver and 
spleen, significantly higher uptake in 
tumor 
Toya et al. 2010 200-nm and 3.9-µm 
CeO2 
Intratracheal instillation 34 mg/kg rat wt. 3-180 days post 
exposure 
  200-nm CeO2 induced pulmonary 
toxicity (inflammation, granulomas, 
mobilization and impairment of alveolar 
macrophages together with slight 
degrees of Type II epithelial cell 
hyperplasia and collagen deposition) 
than coarse CeO2 
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major body systems after inhalation exposure and associated changes of gene 
expression in lung, and kidney. The first phase of second objective was published as 
Yu et al. (2007) in Nanotoxicology which established a protocol of introducing 
airborne gold nanoparticles to the whole-body exposure chamber. This earlier study 
also provides evidence to design following experiment focusing on a consistent 
exposure duration of 15 days. 
The second phase was mainly to examine size effects of inhaled airborne AuNPs 
on resultant biodistribution. Engineered NPs of smaller size and with large total 
surface area render greater biological activity and potential oxidative stress as well as 
toxicity (Oberdörster 2007). More than 20 studies have attempted to examine size 
effects of engineered NPs on biodistribution and associated impacts through four 
major routes of exposure as summarized in Table 1.2. Majority of the studies 
employed intratracheal instillation (9 studies) followed by injection (8 studies); only 
three and two studies examined results of inhalation and oral exposure, respectively. 
Regardless of exposure routes and doses, surface coating, as well as chemical 
composition, smaller NPs were distributed in organs more widely than larger NPs 
(Table 1.2). Through instillation and inhalation, smaller NPs (20 nm) also induced 
more toxicity (e.g. inflammation) than larger NPs (>200 nm), in addition to being 
more resistant to phagocytosis (Ferin et al. 1992; Oberdörster et al. 1994) (Table 1.2). 
Although one study showed that 20-nm TiO2 caused more severe pulmonary 
inflammation than 5-nm TiO2 of the same dosage (in terms of total mass) (Grassian et 
al. 2007), this is mainly because the crystallinity of the 20-nm TiO2 (rutile/anatase) 
can be more toxic (or reactive) than that of the 5-nm TiO2 (anatase). Since several 
other studies showed that smaller NPs would cause greater toxicity because of their 
higher surface area (Table 1.2), further investigations are needed to examine the 
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toxicity of engineered NPs attributing to size taking into account the interference of 
chemical composition and crystallinity. 
Selecting size ranges of NPs to be examined is important. Among the studies 
examining size effects of engineered NPs through inhalation, most investigated NPs 
were of sizes that can be an order of magnitude different (such as 20 vs. 200 nm), 
which elucidates little of potential threshold size causing toxicity of concerns. This 
can be demonstrated by some studies investigating size effects of engineered NPs of a 
narrow size range through injection or intratracheal instillation. For example, through 
i.v. injection, De Jong et al. (2008) detected 10-nm AuNPs in nine organs including 
brain, while AuNPs of 50, 100 and 250 nm were found in ≤ 6 organ, indicating that 
the threshold size of AuNPs could be within 10 and 50 nm. Through intratracheal 
instillation in lungs, 1.4-nm AuNPs translocated from lung to six organs, while 18-nm 
AuNPs were completely retained in lungs, implying that AuNPs between 1.4 and 18 
nm behaved differently (Semmler-Behnke et al. 2008). Hence it is worthwhile to 
examine the biodistribution of AuNPs between 1.4 and 50 nm.  
It should be noted that most published studies examining size effects on 
biodistribution employed engineered NPs of various sizes with similar mass 
concentration (Table 1.2). These studies actually introduce more smaller NPs in terms 
of total number concentration and surface area. Since toxicity of particles is more 
closely related to surface area than mass (Oberdörster et al. 1994; Höhr et al. 2002; 
Oberdörster et al. 2005), the higher toxicity caused by smaller NPs observed so far 
need to be re-examined with proper control of number concentrations of introduced 
NPs. To address this, the second phase of inhalation exposure study exposed rats to 
airborne AuNPs of two sizes (7 and 20 nm) with similar airborne number 
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concentrations. Biodistribution of Au accumulated in body organs and excreted in 
feces as well as urine were examined after inhalation exposure.  
Objective 3: Biodistribution and effects resulting from i.v. of AuNPs. 
Depending on the first-entry point into bodies, resultant toxicity of engineered NPs 
may vary significantly. Insoluble NPs binding with proteins in the respiratory lining 
fluid may determine subsequent transport of NPs in bodies (Oberdörster et al. 2005). 
Unlike inhaled NPs, through intravenous injection (i.v.), NPs should first encounter 
plasma proteins in blood (e.g., albumins, globulins, fibrinogens, etc.), which may 
result in biodistribution different from inhalation exposure (Muller and Keck 2004). 
Since protein adsorption may also depend on the initial physicochemical properties 
(size, surface area, charge, surface hydrophobicity, etc.) of engineered NPs, in turn, 
adsorbed proteins can modify surface properties of engineered NPs, and further affect 
interactions of NPs with biological systems (Muller and Keck 2004). Hence, health 
effects of engineered NPs resulting from inhalation exposure vary from that through 
injection.  
AuNPs have been intentionally injected for biomedical applications such as 
carrying drugs for treatment of several diseases such as rheumatoid arthritis (Tsai et 
al. 2007). For cancer therapy, AuNPs are employed as a drug carrier (Paciotti et al. 
2006) and photothermal agent (O'Neal et al. 2004). They are also used for enhancing 
the contrast of bio-imaging (Hainfeld et al. 2006). Table 1.3 summarizes more than 12 
in vivo studies examining the biodistribution of AuNPs through i.v. injection with two 
main observations worthwhile to be highlighted: majority studies showed that AuNPs 
accumulated in the liver regardless of size, shape and dose after exposure for up to 7 
days although most studies examined the biodistribution of AuNPs in no more than 13 
organs. Hence, comprehensive examination of accumulation of AuNPs in more 
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Table 1.3 Studies of AuNPs in rodents through exposure of intravenous injection. 
Reference Model Type of AuNPs Study duration Dose  Dose level normalized 
to this study 
Organs/tissues examined  
Hainfeld et al. 2004  Mice 1.9 nm 5  minutes 1350 –  2700 mg/kg 1.3×104 – 2.7×105 5 organs 
Paciotti et al. 2004  Mice 33 nm 
(surface modified with PEG-
thiol) 
Up to 6 hours 0.3 – 0.6 mg/kg 30 – 60 5 organs 
Bergen et al. 2006  Mice 50, 80, 100 and 150 nm 
(Unmodified and surface 
modified with PEG5000-thiol 
or gal-PEG-O-pyridyl 
disulfide) 
2 hours 0.5 – 0.6 mg/kg 45 – 56 3 organs 
 
Hainfeld et al. 2006  Mice 1.9 nm 24 hours 700, 70, 7 mg/kg 700 –7×104 5 organs 
Niidome et al. 2006  Mice nanorods 
(length: 65 nm; width: 11 nm) 
0.5-, 3- , 6-, 12, 24- 
and 72-  hours 
0.98 –  1.52 mg/kg 98 – 151 5 organs 
Balogh et al. 2007  Mice Au composite nanodevices 
(5- and 22-nm positive 
surface; 5- and 11-nm 
negative surface; 5 nm neutral 
surface) 
5 minutes, 1 hour, 
1-, 4-, and 7- days 
 
16  mg/kg 1591 10 organs 
 
Sadauskas et al. 2007  Mice 2 and 40 nm 1-, 4- and 24- hours 0.6 – 3.2 mg/kg 57 – 322 8 organs 
De Jong et al. 2008 Rat 10, 50, 100 and 250 nm 24 hours 77 – 120 μg 25 – 36 13 organs 
Huang et al. 2008  Mice Au-Au2S NPs 7 days 10 mg/kg 995 10 organs 
Sonavane et al. 2008  Mice 15, 50, 100 and 200 nm 24 hours 1000 mg/kg 9.9×10
4
 9 organs 
Cho et al. 2009b  Mice 13 nm 
(PEGylated) 
5-, 30- minutes, 4-, 
24- hours and 7 
days 
0.17 – 4.26 mg/kg 17 – 424 7 organs 
Sadauskas et al. 2009  Mice 40 nm 1 day, 1-, 3- and 6- 
months 
1.4– 1.6 mg/kg 138 – 161 Only in liver 
Terentyuk et al. 2009  Rat 15, 50 and 160 nm 
(PEGylated) 
24 hours 57 μg 19 6 organs 




48 hours 0.1 – 4.4 mg/kg 
 
5 – 437 11 organs 
This study Rat 20 nm 1 day, 1 week, 1 
and 2 months 
0.01 mg/kg 1 28 organs; feces and urine 
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organs (e.g., aorta, cecum and bone) is needed. The second observation is about the 
exposure dose of AuNPs injected; since high doses of AuNPs (0.1–2700 mg/kg) were 
used, results of these studies are more relevant to acute exposure such as accidental 
release of large amounts of AuNPs, rather than common biomedical practices which 
often administer drugs of low doses (<10 μg/kg body weight) to patients each 
treatment (injection) (Leonard et al. 1997; Fukudo et al. 1998). Hence, studies under 
Objective 3 employed lower exposure doses, and examined biodistribution of Au in 
more than 25 organs of rats and excretion in the feces and urine at four time points 
(up to 2 months) after a single i.v. injection of purified AuNPs. 
1.4 Organization 
This thesis consists of five chapters. Following this section, literature review (Chapter 
2) summarizes up-to-date findings of how physico-chemical properties of AuNPs 
associate with the resultant impacts. Chapter 3 describes the experimental setup, 
approach, and analyses employed. Chapter 4 (Results and Discussion) comprises three 
sections: Section 4.1 reports the characterized impurities in the synthesized AuNP 
solution, optimized purification procedure, and stability of treated AuNPs. Section 4.2 
focuses on the biodistribution of AuNPs examined in two phases.  The first phase 
discussed biodistribution of inhaled 20-nm AuNPs and relevant changes in gene 
expression in lungs and kidney. The 2
nd
 phase compares the resultant biodistribution 
of inhaled AuNPs of two sizes (7 and 20 nm). Similar to Section 4.2, Section 4.3 
discusses the biodistribution of AuNPs and changes in gene expression of liver and 
spleen resulting from i.v. injection of the purified 20-nm AuNPs. In conclusion, 




2.1 Types of engineered NPs 
A white paper on nanotechnology issued by U.S. Environmental Protection Agency in 
2007 classified nanomaterials into four categories: (i) carbon-based nanomaterials, (ii) 
metal-based nanomaterials, (iii) dendrimers, and (iv) composites. Following this 
classification, Table 2.1 summarizes 15 types of nanomaterials, including their 
characteristics and applications. Carbon based nanomaterials are available in forms of 
spherical or ellipsoidal fullerenes, and cylindrical carbon nanotubes. Their unique 
properties such as high thermal and electrical conductivity and mechanical strength 
enhance the use of these materials in electronics, membranes, catalysis and 
biomedical applications (Table 2.1). Metal based nanomaterials include metallic (e.g., 
gold, silver, quantum dots) and metal-oxide NPs (e.g., TiO2) (Table 2.1), which carry 
useful optical properties for bioimaging and theraputical applications, in addition to 
other use in commercial products (e.g., cosmetics, toothpaste, packaging, etc.). 
Dendrimers are nanosized polymers that have numerous chain ends and interior 
cavities to hold chemical molecules and tailor for catalytic reactions as well as drug 
delivery (Astruc and Chardac 2001; USEPA 2007). Composites are blends of various 
NPs with or without bulk materials that are purposefully engineered to carry out 
specific functions (USEPA 2007).  
Along with vast applications of nanotechnology is increasing concern about 
intentional or unintentional exposure to engineered NPs which may lead to undesired 
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health effects. For example, NPs can penetrate through cell membranes and 
mitochondria to induce injurious responses (Nel et al. 2006). Evaluation of health 
effects of engineered NPs is challenging because too many variables (such as size, 
shape, crystallinity, solubility, surface chemistry including surface charge, surface 
coatings etc.) affect their interactions with and impacts on biological systems. For 
example, toxicity induced by a particular size of silver nanoparticles (AgNPs) may 
not be comparable to that by other engineered NPs of the same size because of the 
inherent toxicity of toxic Ag
+
 ions which may be released from AgNPs (e.g., Lok et 
al. 2007). It is also important to consider potential synergistic toxic effects of size and 
other factors of engineered NPs such as the presence of residual impurities, fiber like 
characteristics in carbon nano tubes (Shvedova et al. 2003; Donaldson et al. 2006), 
release of free cadmium ions from the core in quantum dots (Derfus et al. 2004), and 
crystalline in titanium dioxide (Shvedova et al. 2003; Warheit et al. 2007).  
Compared to almost all engineered NPs (summarized in the Table 2.1), AuNPs 
have no inherent toxic characteristics and are inert of a size larger than 2 nm (Turner 
et al. 2008), a desirable model material to systematically examine how its 
physicochemical properties are associated with resultant impacts. Hence, this chapter 
reviews the published studies examining physicochemical properties (size, surface 
charge, etc.) and exposure routes of AuNPs with associated biodistribution and toxic 
impacts. 
2.2 Gold nanoparticles (AuNPs) 
Applications and potential exposure. Gold nanoparticles (AuNPs) are used in 
various applications because of their unique optical, thermal and electronic properties. 
Depending on size, shape, and aggregation of AuNPs, AuNPs intensely absorb and 
 22 
 
Table 2.1 Characteristics and applications of nanomaterials. 
S.No Nanomaterials Key characteristics Applications 
1 Carbon based NPs   
  Carbon black   
 Chain-like aggregates of 
carbon nanoparticles
a 
- Excellent electrical conductance;  
- Enriched dispersability
b 
 Fillers for rubber in car tyresa,b 




  Graphite   
 One dimensional or 2-D 
structure of carbon sheets 
having sub-nano thickness 
layers and nano-size 
spacing between the layers
b 
 
- Nano-sized spacing between the layers 








  Carbon nanotubes (CNT 
and Fullerene) 
  
 - Ordered molecule of pure 
carbon in 3-D cylindrical 
structure;  
- Carbon nano tubes, CNT 
of spherical structure as 
fullerene;  
- CNT can be single-wall 
carbon nanotubes 





- ~ 100 times stronger than steel
a
; 













 Composite fibers in polymers, 
basket ball, tennis racquets
d
  
 Membranes for water desalinationd 
 Filters to remove nanosized TiO2
d
,  
 Nanosensors to identify 
contaminants in water systems
d 
2 Metal based NPs   
  Metals   
 Gold - Powerful heaters
e
;  









 Commercial products: 
Cosmetics, anti-aging essence, skin 
cream; soap, eyecream, shampoo, 
toothpaste
g 
 Medical applications: 
Efficient drug carriers
f,h
 and potent 
to treat cancer
f




 Industrial applications: 
Effective support for catalysts with 
base of metal oxides for pollution 
and emission control, fuel cells, and 
sensors to detect poisonous or 
flammable gases or substances in 
solution
j 





 Commercial products:  
Disinfectant roomsprays, laundry 
detergents, water purificants, wall 




 Medical devices: 
Nanosilver coated medical 





Table 2.1 Characteristics and applications of nanomaterials (continued) 
S.No Nanomaterials Key characteristics Applications 
 Iron  
 




 Effective for transformation and 
detoxification of a wide variety of 
contaminants (such as chlorinated 




 Quantum dots   
 A semiconductor nanocrystal 
material comprising hundreds 




- Upon excitation, emission of 
various colored light; smaller the 
dot, higher the energy and intensity 




 Light emitting diodesq 
 Solar cellsr 
 Laserss 




  Metal oxides   
 Titanium dioxide, Zinc oxide  - Transparent
b
;  







 Widely used in sunscreenb,n   
 Photocatalyst: 
 In solar cells
b
 (converting sunlight 
to electricity); 








 Iron oxide, Cerium oxide  - Oxidation catalyst
b 
 




 Enhance combustion efficiencies of 
diesel fuel either alone or in 
combination with cerium oxide
 b
 
 Silicon dioxide 
 







 Fillers in dental fillingsn 




    
3 Dendrimers   
 3-D tree-like nanostructured 





- Numerous chains with unique 








 Drug deliveryu,v 
 Treatment of canceru,v 
 Adsorbents for environmental 




4 Composites   
 Composed of blends of  




- Multi-functions;  
- Enhanced mechanical, optical, 
electrical and magnetic properties
 w
 
 Car partsc,w 
 Packaging materialsc,w 
a Luther 2004; b Park 2007; c US EPA nanotechnology white paper, 2007; d Endo et al. 2008; e Huang et al. 2007; f Ferrari 2005; g Nano 
G&K company information available at http://nanognk.en.ec21.com/company_info.jsp; h Paciotti et al. 2006;i Jain 2005; j Thompson 
2007; k Chen and Schluesener 2008; l Quadros and Marr 2010;  m Li et al., 2006; n Brayner, 2008; o Toma 2004; p Matthews 1992; q Park 
et al. 2001; r Huynh et al. 2002; s Kazes et al. 2002; t Bruchez et al. 1998;u Cheng et al. 2008; v Stiriba et al. 2002;w The Royal Society 
report 2004 available at http://www.nanotec.org.uk/finalReport.htm 
 
 
strongly scatter light. This leads to localized surface plasmon resonance, a 
phenomenon of coherent oscillation of conduction band electrons upon irradiation 
with light. The unique optical property of AuNPs making them a desirable material 
for biological sensing and imaging applications (Jain et al. 2006). In addition, when 
the excited electrons in the conduction band of AuNPs lose (release) energy into the
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surrounding media, substantial amounts of heat generated are applied for 
photothermal therapy to treat cancer cells (Jain et al. 2008). Differing from bulk Au 
which is inert, AuNPs exhibit unique interatomic bond-length and discrete electron 
states (Miller et al. 2006). These properties make AuNPs highly reactive as a 
desirable catalyst for strong oxidation (Thompson 2007).  
In addition to industrial and biomedical applications, AuNPs are also employed in 
commercial products such as touch sensitive screens, high density data storage, solar 
cells, and conductive ink for plastic electronics (Keel et al. 2010). It is estimated that 
global funding of nanotechnologies in particular to develop gold-based technologies 
has been increasing from 4 billion in 2004 to ~ 10 billion (USD) in 2010, and will 
reach 12 billion USD in 2015 (Keel et al. 2010). The increased use of AuNPs 
indicates higher potential of exposing human and environment to this material during 
production processes (e.g., for nanoelectronics) (Magnusson et al. 1999; Messing et 
al. 2009) and during their clinical use in diagnostic and therapeutic applications (Card 
et al. 2008; Chakravarthy et al. 2010). 
Up to date, there are >30 studies showing that physicochemical characteristics 
influence the toxicity of AuNPs through in vitro and in vivo approaches. To 
systematically demonstrate how the resultant impacts are associated with its 
physicochemical properties, these studies are tabulated (Tables 2.2 and 2.3) and 
summarized according to effects of size, surface charge, and surface coating, where 
impacts of the individual properties are further elaborated according to in vitro and in 
vivo studies. How exposure routes affected subsequent biodistribution of AuNPs in 
rodents is also reviewed as the last section of this chapter. 
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Effects of size (in vitro). Some in vitro studies indicated that the toxicity of 
AuNPs is size dependent although various studies showed no observable toxicity of 
3.5-18 nm AuNPs when they were introduced to 12 types of cell lines. Connor et al. 
(2005) showed that 4-, 12- and 18-nm AuNPs did not affect the viability of K562 
human leukemia cell lines, supporting Khan et al. (2007) who reported that AuNPs of 
18 nm induced negligible cytotoxicity and changes in gene expression of human cell 
lines (HeLa). Consistent with these findings, 3.5-nm AuNPs did not induce reactive 
oxygen species nor elicit pro-inflammatory cytokine (tumor necrosis factor (TNF)-α) 
(Shukla et al. 2005) although they likely entered into macrophages through 
endocytosis. Similarly, 10-nm AuNPs induced no changes in phenotype of dendritic 
cells generated from mice bone marrow (Villiers et al. 2010).  
Interestingly, after administered five AuNP sizes (0.8, 1.2, 1.4, 1.8 and 15 nm) to 
four different cell lines (human melanoma, human cervix, mouse fibroblasts, mouse 
macrophages), only AuNPs of 15 nm were non-toxic to the tested cell lines (Pan et al. 
2007) (Table 2.3). The same study showed that 1.4-nm AuNPs triggered necrosis 
much faster than 1.2 nm AuNPs; for example, at 24 h post exposure to 1.4-nm AuNPs 
at 110 μM, > 90% of total cells died, while 50% of total cells died when a higher 
concentration (140 μM) of 1.2-nm AuNPs was introduced (Pan et al. 2007). 
Consistently, Tsoli et al. (2005) showed that 1.4-nm Au clusters were toxic to 11 
different human cancer and healthy cell lines. Four studies reported that larger AuNPs 
(e.g., 13- and 20-nm AuNPs) also induced cytotoxicity. Li et al. (2008) reported that 
20-nm AuNPs inhibit cell proliferation accompanied with down regulation of cell 
cycle and DNA repair genes. Another study showed that AuNPs of 13.1 nm induced 
disappearance of actin stress fibers, and changed cellular protein synthesis as well as 
growth functions (Pernodet et al. 2006). In addition, AuNPs can potentially induce 
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oxidative stress after exposure to 13- and 20-nm AuNPs (Jia et al. 2009; Li et al. 
2010); an increased release of nitric oxide (NO) in serum (up to 1560 μM), indicated 
oxidative stress after exposure to 13-nm AuNPs in blood serum at six different 
concentrations increasing from 10 μM – 910 μM (Jia et al. 2009). Similarly, uptake of 
20-nm AuNPs in lung fibroblasts induced upregulation of genes (e.g., oxidative- 
stress responsive 1, OXSR1 and cyclooxygenase-2, COX-2) related to oxidative stress 
(Li et al. 2010). 
These different findings could be due to variability in cell lines, toxicity assays 
and physicochemical properties of AuNPs used among various research groups (Table 
2.2). For example, when 33-nm AuNPs were exposed to three different cell lines 
(baby hamster kidney cells, human liver carcinoma cells, and human lung carcinoma 
cells), AuNPs induced death response only in human lung carcinoma cells (Patra et al. 
2007). At the same dosage, the human lung carcinoma cells exhibited toxic effects of 
AuNPs within 36 h, which were not observed in liver and kidney cells at 72 hours 
after exposure (Patra et al. 2007). Since AuNPs do not induce toxicity in all tested cell 
lines, a global database of cell-specific cytotoxic effects is needed to assess the 
potential risks and hazards of engineered AuNPs (Patra et al. 2007). In addition to cell 
lines, Table 2.2 shows that cytotoxicity studies employed AuNPs with a dose and 
exposure duration covering a wide range, varying from 0.1 nM–4 mM for dose and 1–
96 h for exposure duration. Hence, variability in dose and exposure duration 
employed in studies could result in different toxicity.  
In addition to cytotoxicity studies, two studies showed that the cellular uptake and 
removal of AuNPs were size dependent (Chithrani et al. 2006; Chithrani and Chan 
2007) (Table 2.2). Among the tested sizes (14-100 nm), 50-nm AuNPs (transferrin 
coated) were uptaken at a higher rate (1294 AuNPs/h) compared to other sizes; for 
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example, the uptake rate of 14- and 74-nm AuNPs was 622 AuNPs/h and 417 
AuNPs/h, respectively (Chithrani et al. 2006). The faster uptake of 50-nm AuNPs into 
cells was due to its short “wrapping time” for the receptors at the cell membrane 
recognize and drive AuNPs to binding sites during endocytosis (Chithrani and Chan 
2007). Through imaging, a single 50-nm AuNPs can directly enter into the cell 
whereas 14-nm AuNPs required at least six-single AuNPs to cluster together before 
cellular uptake (Chithrani et al. 2006; Chithrani and Chan 2007). Differing from the 
trend of endocytosis, the removal of transferrin-coated AuNPs from cells (exocytosis) 
was linearly related to particle size; rate of exocytosis of 14-nm AuNPs was two times 
higher than 74-nm AuNPs, and five times higher than 100-nm AuNPs (Chithrani and 
Chan 2007)  
Effects of size (in vivo). Biodistribution of AuNPs in vivo is size dependent. In 
particular, AuNPs of smaller size can spread among more organs irrespective of 
exposure routes (injection, oral and instillation) and surface coatings (Table 2.3). 
Orally administered AuNPs (4 nm, 200 mg Au/kg of water) crossed gastrointestinal 
(GI) tract of mice and exhibited increased accumulation in many organs (e.g., kidney, 
liver, spleen, lungs, heart, blood and brain) compared to AuNPs of 10, 28, and 58 nm 
(Hillyer and Albrecht 2001). The same group reported that AuNPs of 4 and 10 nm 
accumulated in small intestine through paracellular uptake from the digestive tract 
(persorption).  
Through intravenous (i.v.) injection, AuNPs predominantly accumulated in liver 
and spleen. Semmler-Behnke et al. (2008) reported that 1.4-nm AuNPs were 
accumulated in >10 organs, while 18-nm AuNPs were observed in only six organs. 
Although AuNPs of 10 nm were widely distributed in nine organs in rats, larger 
AuNPs (50, 100 and 250 nm) were mainly accumulated in liver, spleen and kidney
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Table 2.2 Summary of in vitro AuNP studies. 
Reference Cell line AuNP type Dose Duration Approach Findings 
Goodman 
et al. 2004 
Cos-1 mammalian 
cells, red blood cells, 
Eschericia coli 
bacterial cultures 




AuNPs); and with 
carboxylic acid 
(anionic AuNPs)  
0.38 – 3 
μM 
1, 2,5,6 or 
24 h 
Cell viability using MTT, 
hemolysis, bacterial viability 
assays,  
 Toxicity of AuNPs was associated with surface 
charge carried by AuNPs and their interaction with 
cell membrane;e 
 Strong electrostatic attraction of cationic 
AuNPs towards negatively charged membrane 
bilayer lead to membrane disruption  







3.5±0.7 nm prepared 
by borohydride 
reduction and purified 




10 – 100 
μM 
24-72 h Cell viability using MTT assay, 
reactive nitric oxide and oxygen 
species determination, total cell 
proteins quantification, ELISA 
assay, AFM and TEM cell 
imaging 
 AuNPs were not cytotoxic, reduced the 
production of reactive oxygen and nitric species 




K562 human leukemia 4, 12, 18 nm (suface 
modifiers: citrate, 
cysteine, glucose, 
biotin, CTAB  
0.001– 
0.25 μM 
72 h Cell viability using MTT assay, 
TEM cell imaging  
 All tested AuNPs were not toxic 
 CTAB alone was toxic 
Pernodet 
et al. 2006 
Human dermal 
fibroblast 
13.1 nm (prepared by 
citrate reduction 
method) 
0-4 mM 24-144 h Physiological cell response using 
confocal microscopy, mechanical 
response using scanning 
modulation force microscopy, cell 
area and actin distribution, 
migration assay 
 13.1 nm can cross cell membrane and 
accumulate in to vacuoles 
 Adverse toxic impacts 
o Actin stress fibers disappeared 
o Properties of cell spreading and adhesion, 
cell growth and protein synthesis were 
altered 
 
Khan et al. 
2007 
Human cell line, HeLa 18 nm (prepared by 
citrate reduction 
method)  
0.2-2 mM 3-6 h Cell viability using MTT assay, 
TEM cell imaging, gene 
expression profiling 
 HeLa Cells uptake AuNPs 




Table 2.2 Summary of in vitro AuNP studies (continued). 
Reference Cell line AuNP type Dose Duration Approach Findings 
Chithrani 
et al. 2006 
HeLa epithelial cells 14, 30, 50, 74, and 
100 nm (prepared by 
citrate reduction); 




0.2-20 μM 6 h Cellular uptake using TEM cell 
imaging 
 50 nm AuNP exhibited more uptake 





3 types of cell lines 
(STO, fibroblast cells; 
HeLa, ovarian cancer 
cells; SNB19, brain 
tumor cells) 
14, 50 and 74 nm 
(prepared by citrate 
reduction); 20x30, 




0.02 nM 6h Cellular uptake using TEM cell 
imaging; 
 50 nm AuNP exhibited more uptake than other 
sizes due to its minimum wrapping-time during 
endocytosis 
 Cellular uptake of rod-shaped AuNPs decreased 
with increase in aspect-ratio 
 Exocytosis of smaller AuNPs was higher than 
larger AuNPs  
Pan et al. 
2007 









0.8, 1.2, 1.4, 1.8 and 




Up to 5.6 
μM 
72 h Cell viability using MTT assay, 
TEM cell imaging, apoptotic and 
necrotic cell quantification using 
fluorescence-activated cell sorting 
 AuNP toxicity is size dependent 
 Regardless of tested 4 different cell lines, 
o 1-2 nm were toxic;  
IC50 values:30-46 μM for 1.4 nm; 140 μM for 
1.2 nm; 230 μM for 1.8 nm; 250 μM for 0.8 
nm; 
o 15 nm were non-toxic 
Up to 6300 μM, completely non-toxic 




generated from bone 
marrow from C57BL/6 
mice 
10 nm (containing 
sodium citrate and 
poly-(N-vinyl)-2-
pyrrolidone). 
0.5 mM 4-48 h Apoptosis and necrosis analysis 
using flow cytometry, cytokine 
immunoassays  
 AuNPs were non-cytotoxic 
 Phenotype of cells were not changed 
Patra et al. 
2007 
Three cell lines: baby 
hamster kidney cells 
BHK21, human liver 
carcinoma Hep2G, 
human lung carcinoma 
A549  
33 nm (prepared by 
citrate reduction) 
0-120 nM 36 h for 
lung cells; 




Cell viability using MTT assay, 
cellular and nuclear morphology 
change, flow cytometry, confocal 
imaging, Immunoblot analysis of 
poly(ADP-ribose) polymerase 
degradation 
 Cell specific response  
o AuNPs induced death response in A549 but 





Table 2.2 Summary of in vitro AuNP studies (continued). 
Reference Cell line AuNP type Dose Duration Approach Findings 
Li et al. 2007 Fetal lung 
fibroblasts MRC-5 
 
20 nm (prepared by 
citrate reduction) 
0.1-1 nM 24-72 h Trypan blue cell viability 
assay,gene expression 
profiling, TEM imaging 
 
 AuNPs can induce DNA damage, inhibit cell 
proliferation  
 Dowregulated genes: cell cycle and DNA repair 
Jia et al. 
2008 
Blood serum 13 nm (prepared by 
citrate reduction) 
10-910 μM 0-280 s Measurement of S-
nitrosoglutathione 
(GSNO) 
 Increase in release of nitric oxide with the 
increase in concentration of AuNP exposed 
 AuNP exposure potentially induce oxidative 
stress 




cell lines (A549 and 
NCIH441)  
 
9-25 nm (containing 
citrate and PVP) 
0-0.7 mM 24-72 h Cell viability using 
MTT, Ki-67 and LDH 
assays, TEM imaging 
 Presence of sodium citrate residues on AuNPs 
impaired viability, affected cellular proliferation and 






65 × 15 nm 
(containing CTAB, 
PAH, PAA) 
0.6 nM 96 h Cell viability using MTT 
assay, cellular uptake by 
ICP-MS  
 Au nanorods were not toxic 
 Excess CTAB was toxic 
 Overcoating of CTAB with positive or negative 
charged polymers reduced toxicity and affected their 
uptake  
Li et al. 2010 Fetal lung 
fibroblasts MRC-5 
 
20 nm (prepared by 
citrate reduction) 
1 nM 72 h Lipid peroxidation using 
lipid peroxide assay,  
gene expression 
profiling, TEM imaging  
 AuNP exposure resulted the formation of 
autophagosomes 
 AuNP exposure induced oxidative stress related 
genes 
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(De Jong et al. 2008). Similarly, 15-nm AuNPs were accumulated in many organs of 
mice whereas 50-, 100- and 250-nm AuNPs were predominantly accumulated in liver, 
spleen and lung after a single i.v. injection (1000 mg Au/kg mice wt.) (Sonavane et al. 
2008). PEG coated AuNPs also showed similar trend that smaller sizes (15-20 nm) 
were distributed in more organs than larger sized (> 40 nm) AuNPs. Regardless of 
size, liver and spleen always have the largest Au accumulation after i.v. injection 
(Terentyuk et al. 2009; Zhang et al. 2009).  
It is worthwhile to note that although the injected doses of AuNPs of different 
sizes were similar in a study, corresponding number concentration varied 
significantly. For example, for AuNPs of 50–200 nm and 10–250 nm, the 









#/rat (De Jong et al. 2008). 
Thus it remains unclear whether the enhanced biodistribution of smaller AuNPs (5–10 
nm) in the studies is attributed to relatively higher number concentration of injected 
AuNPs.  
In addition to accumulation, size of AuNPs seems to affect the pattern of 
subsequent excretion. Semmler-Behnke et al. (2008) showed that a significant amount 
of small AuNPs (1.4 nm) was excreted via urine (8.6% of administered dose) and 
feces (5% of administered dose), unlike larger AuNPs (18 nm) which were not 
excreted via urine (0.5% of administered dose in feces). Differing from previous 
studies summarized, uptake of AuNPs by Kupffer cells (macrophages) in liver is 
independent of sizes (2 vs. 40 nm) of AuNPs, neither i.v. nor intraperitoneal (i.p.) 
injections (Sadauskas et al. 2007).  
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In addition to biodistribution, toxic impacts of injected AuNPs were reported to a 
limited extent. Based on the following two studies, AuNPs <5 nm appeared to exert 
little toxicity. After a single i.v. injection (7-700 mg Au/kg mice wt) in tumor bearing 
mice, no toxicity on 24 vital organs was observed at 11 or 30 day post injection 
(Hainfeld et al. 2006). The same study showed that 77% of injected AuNPs with an 
original size of 1.9 nm was cleared at 5 h post injection. Interestingly, 64% of Au 
initially (15 min post injection) accumulated in tumors was retained in tumor at 24 h 
post injection when Au was also accumulated in kidney and liver. Through i.p. 
injection (8 mg Au/kg mice wt/week), no toxicity of AuNPs of various sizes (3, 5, 8, 
12, 17, 37, 50 and 100 nm) was caused by both 3-5 and 50-100 nm AuNPs (Chen et 
al. 2009), although AuNPs of intermediate size ranging from 8-37 nm induced severe 
sickness (fatigue, loss of appetite, fur color change, and weight loss). In particular, the 
diseased group (i.e. 8-37 nm AuNP injected mice) exhibited increase in Kupffer cells 
(in liver), loss of structural integrity in lungs, and diffusion of white pulp in spleen 
(Chen et al. 2009), suggesting that toxicity of AuNPs is size-dependent.  
It is worthwhile to note that although size is critical, injection dose of AuNPs can 
substantially affect the resultant toxicity. For example, after daily i.p. injections (40-
400 µg Au/kg mice wt/day) of 12.5 nm AuNPs for 8 days, there was no toxicity in all 
tested six organs including blood, liver, spleen, lung, kidney and brain, although the 
Au uptake by organs depended on dose (Lasagna-Reeves et al. 2010). This differs 
from the study of Chen et al. (2009) who showed that 8-37 nm AuNPs are toxic 
through i.p. injection with a dose (8 mg Au/kg mice wt/week for > 50 days) which 
was ≥ 2.5 times higher.  
It is interesting to note that two sizes (4 vs. 100 nm) of PEG-coated AuNPs 
exhibited similar biological effects in liver at 30 min after a single i.v. injection (4.26 
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mg/kg) (Cho et al. 2009a). This study showed that 170 and 224 genes among 45,000 
genes were significantly changed after the injection of 4- and 100-nm AuNPs, 
respectively. However, there was no pathological change observed in liver. The 
changes in common genes when either size of AuNPs was introduced are associated 
with apoptosis, cell cycle, inflammation, and metabolic process (Cho et al. 2009a). As 
studies showed that PEG coating modifies their retention in the blood and 
biodistribution (as discussed in the next section), it is unclear whether the similar 
biological effects of 4- and 100-nm AuNPs are solely due to size rather than PEG-
coating. 
While several studies examined the effects of size on biodistribution and impacts 
resulting from injection, fewer studies addressed effects associated with instillation or 
inhalation exposure (through lung as the first entry portal) (Table 2.3). Such 
information is important and needed as airborne AuNPs are involved for production 
of nanoelectronics (Magnusson et al. 1999; Messing et al. 2009), in drug delivery 
(Chakravarthy et al. 2010) and imaging within the lungs (Card et al. 2008). Through 
intratracheal instillation, biodistribution of 1.4-nm and 18-nm AuNPs significantly 
differed; while almost all 18-nm AuNPs (>99.8% of administered dose) were 
accumulated in lungs, 8.5% of instilled 1.4-nm AuNPs (91.5% in lung) was 
distributed in kidney (1.2%), urine (1.1%) and blood (0.6%) (Semmler-Behnke et al. 
2008). Similarly, intratracheal instillation of larger sized AuNPs (40 and 100 nm) 
resulted in non-observable accumulation in liver; while 1.4-1.9% of instilled 2-nm 
AuNPs translocated to liver (Sadauskas et al. 2009), potential accumulation in other 
organs such as spleen and kidney were not examined. Although these two studies 
seem to indicate that smaller AuNPs (1.4-2 nm) can undergo a systemic translocation 
through intratracheal instillation, the associated potential health impacts remain to be 
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explored. In fact, no studies have hitherto examined size effects of AuNPs on 
biodistribution and consequent health impacts through inhalation. 
Effects of shape and surface chemistry (in vitro). Chithrani and Chan (2007) 
investigated the mechanism by which spherical and rod-shaped AuNPs (both were 
transferrin-coated) entered into three types of cell lines, and found that AuNPs entered 
into the cell via receptor (or clathrin)-mediated endocytosis regardless of AuNP shape 
(Table 2.2). Nevertheless, Cellular uptake of rod-shaped AuNPs was lesser than that 
of spherical AuNPs. This could possibly be due to the larger surface area of rod-
shaped AuNPs compared to the spherical ones that may reduce their binding to 
receptors and eventually their uptake into the cell (Chithrani and Chan 2007). The 
cellular uptake of rod-shaped AuNPs also depended on the width rather than the 
length of the rod-shaped AuNPs; for all tested cell lines accumulated more rod-shaped 
AuNPs with larger width in the order of 20×30 nm, 14×50-, and 7×42-nm (Chithrani 
and Chan 2007). 
In addition to shape of AuNPs, surface chemistry (or charge) affects the resultant 
toxicity. AuNPs of 2 nm carrying positive charge through functionalized quaternary 
ammonium were toxic, unlike AuNPs coated with negatively charged material 
(carboxylic acids) although both types of AuNPs were given at the same dose to the 
same cell lines (Goodman et al. 2004) (Table 2.2). This can be caused by the 
interaction of cationic surface of AuNPs with negatively charged cellular membranes, 
leading to membrane disruption (Goodman et al. 2004). Studies also showed that 
surface-bound stabilizing agents over AuNPs influenced resultant toxicity. For 
example, synthesis of rod-shaped AuNPs through a widely used seed-mediated 
approach requires ammonium surfactant such as cetyltrimethylammonium bromide 
(CTAB) for the growth of Au nanorods in one direction (Kim et al. 2002; Nikoobakht 
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and El-Sayed 2001; Sau and Murphy 2005). Some studies showed that CTAB, rather 
than Au nanorods, induced cytotoxicity (Connor et al. 2005; Niidome et al. 2006; 
Alkilany et al. 2009). CTAB on surface of 18-nm AuNPs or bound to Au nanorods 
significantly reduced viability of human leukemia cells and human colon carcinoma 
cells (Connor et al. 2005; Alkilany et al. 2009). Similarly, Au nanorods stabilized 
with CTAB induced significant death in HeLa cells (Niidome et al. 2006). All these 
studies also demonstrated that after CTAB was removed, cell death was significantly 
reduced, affirming that CTAB alone is toxic.  
Similar to the impacts of non-Au component such as CTAB, the presence of 
excess citrate in solution as stabilizing reagent over AuNPs could cause cytotoxicity. 
Uboldi et al. (2009) showed that citrate, rather than the size of AuNPs, could reduce 
viability and impair proliferation of human alveolar cells, evidenced by the increase in 
released lactate dehydrogenase (LDH). Hence, characterization and purification of 
synthesized AuNPs are necessary prior to use for various applications and 
toxicological studies.  
Effects of shape and surface chemistry (in vivo). Although the adsorption of 
serum proteins and cellular uptake of AuNPs after exposure to spherical and rod-
shaped AuNPs exhibited different profiles in vitro (Chithrani and Chan 2007), no in 
vivo studies so far have attempted to examine shape effects of AuNPs, although three 
studies individually reported biodistribution resulting from spherical or rod-shaped 
AuNPs coated with similar PEG (MW 5000). Both spherical (15-80 nm, Cho et al. 
2009a; Zhang et al. 2009) and rod-shaped AuNPs (65×15 nm, Niidome et al. 2006) 
exhibited a major accumulation of Au in liver and spleen regardless of exposure doses 
and durations (Table 2.3). Interestingly, exposure to Au nanorods resulted in a much 
higher accumulation in liver than in spleen. While 15-80 nm spherical AuNPs 
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accumulating in the livers was <3 times higher than that in spleen (Cho et al. 2009a; 
Zhang et al. 2009), the amount of Au nanorods accumulated in the livers was >11 
times of that in spleen (Niidome et al. 2006). This seems to suggest that Au nanorods 
could accumulate more in liver compared to those of spherical AuNPs. 
In addition to the shape, surface coatings of AuNPs also determine their retention 
time in the blood circulation as summarized in the following studies. Through i.v. 
injection, coatings such as PEG alter the surface charge of AuNPs to nearly neutral 
and resulted in prolonged circulation (Niidome et al. 2006). The prolonged retention 
of AuNPs in blood resulting from PEG coating is advantageous in future medical 
applications such as in vivo imaging and drug delivery. Other studies on PEG-coated 
AuNPs (in spherical shape) also examined residence time in blood and accumulation 
in liver. PEG-coated AuNPs of 20 nm exhibited a significant uptake by tumors in 
mice accompanied with persistent accumulation of Au in liver and spleen, as well as 
prolonged circulation in blood (32 h) (Zhang et al. 2009). After i.v. injection, PEG-
coated AuNPs of 13 nm also exhibited a long half life (mean: ~30 h) in the blood of 
mice although the accumulation in liver and spleen was persistent up to 7 days with 
response of acute inflammation and apoptosis (Cho et al. 2009b). 
Types of coating (CTAB or PEG) affected resultant biodistribution of Au 
nanorods. Through i.v. injection, Au nanorods coated with PEG alone (without 
CTAB) exhibited a half-life in blood (t1/2) of ~1 h with 35% of the introduced 
materials accumulating in liver at 72 h post injection (Niidome et al. 2006). On the 
other hand, the same study showed that 30% of Au nanorods stabilized with CTAB 
accumulated in liver rapidly at 0.5 h post injection. Since the introduced dose is the 
same, surface charge of Au nanorods could be the determining factor; the surface 
charge of Au nanorods stabilized with CTAB was +41 mV whereas PEG-coated Au 
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nanorod was -0.5±0.4 mV (Niidome et al. 2006), indicating that cationic surface (of 
CTAB) could lead to rapid accumulation in liver, unlike the PEG-coated Au nanorods 
with the surface of a nearly neutral condition. 
Different types of PEG coatings alter consequent residence time in blood and 
accumulation in organs although PEG coating of AuNPs were insensitive to exposure 
routes (i.v. injection vs. intratracheal instillation). Lipka et al. (2010) examined the 
biodistribution of two types of PEG-coated (or PEGylated) AuNPs (PEG-750 Da vs. 
PEG-10k Da) and compared with non-PEGylated AuNPs through i.v. and 
intratracheal instillation in rats. At 24 h post i.v. injection, only PEG-10k-coated 
AuNPs exhibited prolonged retention in blood. Conversely, more (>90% of 
administered dose) 198Au-non-PEGylated AuNPs accumulated in liver and spleen 
followed by 198Au- PEG750 (>80% of administered dose) and 198Au-PEG10k (>50% 
of administered dose). Similar to the resultant accumulation through i.v. injection, 
when 198Au-PEG10k AuNPs were introduced through intratracheal instillation, they 
showed the highest accumulation in blood than other two types of AuNPs. Through 
intratracheal instillation, the resulted biodistribution among the three types of AuNPs 
exhibiting similar accumulation of Au in the lungs with translocation of Au into 
secondary organs (such as heart and kidney) . 
Effects of exposure route (in vivo). While exposure routes impose little effects 
on residence time in blood (last section) when AuNPs are coated with PEG, 
consequent biodistribution depends on how AuNPs are introduced. For example, 24 
hours after i.v. injection, 94% of injected 18-nm AuNPs (and 48% of 1.4 nm AuNPs) 
was accumulated in liver with <0.7% of administered Au in lung. On the other hand, 
through instillation of the same materials in lungs, > 91% of the administered AuNPs 
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remained in the lung with <0.7% of the material in liver (Semmler-Behnke et al. 
2008).  
Data of biodistribution of AuNPs through inhalation exposure are scarce although 
needed. There is only one published study conducting inhalation exposure and 
investigating the resultant distribution of Au in blood, lung and lavage fluid. After 







nm modal mobility diameter), significant amounts of Au accumulated in the lung of 
rats (1945-1512 ng/g) with less than 40% of Au initially retained in lung in lavage 
fluid at day 7 post exposure, indicating that the presence of AuNPs in lung were not 
detected by alveolar macrophages for phagocytosis (Takenaka et al. 2006). Since by 
day 7 after exposure, Au concentration in blood (0.40±0.13 – 0.73±0.29 µg/L) 
corresponded to 0.03-0.06% of Au retained in lung, it indicates systemic translocation 
of AuNPs from the lungs (Takenaka et al. 2006).  
Biodistribution of AuNPs resulting from inhalation exposure cannot be 
superimposed with instillation for Au in the lungs through instillation exposure 
bypasses the removal mechanisms provided by the upper respiratory tract and 
therefore cannot reflect the loading in the lungs caused by inhalation exposure 
(Valentine and Kennedy 2001). Previous studies exposed rodents to CNTs 
demonstrated that inhalation and intratracheal instillation caused variations in particle 
clumping and deposition location in the respiratory system, leading to different 
pulmonary response (Li et al. 2007) although biomarkers associated with 
inflammation (e.g., interleukin -1, tumor necrosis factor-α) and lung injury (e.g., 
lactate dehydrogenase) caused by both inhalation and instillation exposure were of 
similar trends (Osier and Oberdörster 1997). As instillation approach has advantages 
of specific amounts of administrated dose, and is an economical method saving 
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materials as well as facilities required, instillation is suitable to screen relative toxicity 
of different engineered NPs over a range of doses within a reasonable time frame 
(Madl and Pinkerton 2009). To examine or simulate potential hazards experienced in 
occupational environments, biodistribution and associated health impacts resulting 







Table 2.3 Summary of in vivo AuNP studies. 











Mice 4, 10, 28, 58 nm 200 mg gold / 
kg water 
(oral) 













 Size dependent biodistribution with smaller AuNPs readily cross 
gastrointestinal (GI) tract and distribute more in organs than larger 
AuNPs 
 Entry of AuNP into GI tract through persorption  
Hainfeld 




1.9 nm 7, 70,700 
Au/kg mice 
body wt.  
(i.v.) 







5 organs for 
biodistribution, 
24 organs for 
microscopy 
 Useful X-ray contrast agent, 3 fold better than current iodine agent 
 Qualitative results: Through imaging, no accumulation of AuNPs in 
liver and spleen 
 No evidence of toxicity in 24 organs analyzed at 11 or 30 day post 
injection 
 Quantitative results: Major accumulation of AuNPs in kidney 
followed by tumor, liver and muscle; no accumulation in muscles and 
blood; 64% of initially accumulated Au in tumors retained at 24h post 
injection; > 77% of injected Au cleared via urine at 5 h post injection 
Niidome 
et al. 2006 
Mice PEG modified 
nanorods in 
CTAB solution 
(length 65 nm; 
width 11 nm ) 
 
0.98 – 1.52 
mg/kg mice 
body wt. (i.v.) 
0.5 – 72 h ICP-MS 5 organs  PEG modification increases the residence time of Au in blood 
 After 0.5 min, most of Au nanorods stabilized with CTAB 
accumulated in liver where 54% of PEG capped nanorods were found 
in the blood  
 PEG modification decreases the toxicity induced by CTAB 
Takenaka 
et al. 2006 




















 Lavagable fraction of total lung deposition is only 6% on day 7, 
indicating AuNPs are not detected by alveolar macrophages 
 Low but significant fraction of Au (0.03-0.06% of lung 
concentrations) was found in blood 
 Inhaled AuNPs were enclosed in vesicles in the cytoplasm of 
alveolar type I epithelial cells 
 System translocation occurs only at a low degree 
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Table 2.3 Summary of in vivo AuNP studies (continued). 








et al. 2007 
Mice 2, and 40 nm  0.6-3.2 mg/kg 
mice body wt. 
(i.v. for 2 or 
40 nm; i.p. for 
40 nm) 




8 organs  Regardless of size and route, AuNPs were taken up 
primarily by Kupffer cells in liver followed by 
macrophages 
 Au uptake in liver by endocytosis  
 Part of smaller AuNPs may be excreted via urine 
De Jong et 
al. 2008 
Rats 10, 50, 100 and 
250 nm  
77-120 μg 
(i.v.) 
24 h ICP-MS  13 organs  Size dependent biodistribution with smaller size (10 
nm) showing wide distribution in 9 organs 
 Majority of AuNPs accumulated in liver and spleen 
 
Sonavane 
et al. 2008 
Mice 15,50,100 and 200 
nm  
1000 mg/kg 
mice body wt. 
(i.v.) 
24 h ICP-MS  9 organs  Size dependent biodistribution with smaller size (15 
nm) showing more Au accumulation in widespread 
organs than other sizes (50 and 100 nm)  








for 1.4 nm; 
2.7μg/50μL 




24 h Neutron activation 
analysis (NAA)  
10 organs + 
urine 
 Size dependent biodistribution in both route with 
smaller size (1.4 nm) showing widespread distribution; 
1.4 nm cleared through urine and feces 
 i.v.: major accumulation in liver  
 instillation: major accumulation in lung 
Chen et 
al. 2009 
Mice 3, 5, 8, 12, 17, 37, 
50 and 100 nm 
8 mg/kg/week 
(i.p.) 




5 organs  3,5,50 and 100 nm AuNPs did not induce any toxic 
effects 
 8, 12, 17, 37 nm induced severe sickness (fatigue, 
loss of appetite, fur colour change, wight loss) 
 Pathological analysis: Increase of kupffer cells in 
liver, loss of structural integrity in lungs, diffusion of 
white pulp in spleen 
Terentyuk 
et al. 2009 
Rats and 
rabbits 
15, 50 (PEG 
coated) and 160 
nm (nanoshell) 
57 μg (i.v.) 24 h for 






5 organs in 
rabbits; 6 
organs in rats 
 15 nm AuNPs exhibited widespread distribution  
 Major accumulation in liver and spleen 
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Table 2.3 Summary of in vivo AuNP studies (continued). 








et al. 2009 
Mice 2,40 and 100 nm Single 
instillation: 
0.24 mg for 2 
nm; 1.16 mg 
for 4 nm; 1.2 
mg for 100 
nm (5 
intratracheal 
doses in 3 
weeks) 




2 organs  Instilled AuNPs were phagocytosed by lung macrophages 
 Compared to 40 and 100 nm, translocation of 2 nm AuNPs in to 
liver was high (1.4-1.9% of administered dose) 
 Lack of Au accumulation in liver for 40 and 100 nm (less than 
























11 organs  Compared to 40 and 80 nm, 20 nm AuNPs exhibited prolonged 
blood circulation, lowest uptake in liver and spleen, significantly 
higher uptake in tumor  
 Significant accumulation of 20 nm AuNPs in kidney and intestines 
suggesting excretion via urine 
Cho et al. 
2009a 





30  min Microarray and 
real-time PCR 
 
1 organ  Similar biological effects were seen in both 4 and 100 nm AuNPs. 
Cho et al. 
2009b 
















7 organs  AuNPs induced acute inflammation and apoptosis in liver 
 Longer residence time of Au in blood for about 30 h 
 Persistent accumulation of AuNPs in liver and spleen 
 AuNPs were found in Kupffer cells and spleen macrophages 





3.1 Material synthesis and characterization 
Synthesis of gold nanoparticles. Synthesis of AuNPs of 20 nm was carried out 
according to the procedures described by Turkevich et al. (1951). In brief, 95 mL of 
tetrachloroauric acid (HAuCl4) (Sigma-Aldrich, USA) containing 5 mg of Au was 
boiled at 100°C with vigorous mechanical stirring for 20 min. 50 mg of trisodium 
citrate dihydrate (5 mL of 1% solution in water) (Sigma-Aldrich, USA) was then 
added and boiled for additional 20 min before the solution was gradually cooled down 
to room temperature. Gold atoms released from the tetrachloroauric acid during the 
reduction process aggregated to form nanoparticles (NPs), which continued to grow 
until all the tetrachloroauric acid was reduced. A transmission electron microscopy 
(TEM, CM120 Bio Twin, FEI-Philips, Hillsbro, USA) was employed to examine the 
synthesized AuNPs, and showed an average size of 20 nm (Figure 3.1a). To generate 
7-nm AuNPs (Figure 3.1b), 5 mL of 1% (w/v) trisodium citrate dihydrate was 
replaced with 4 mL of 1% (w/v) trisodium citrate dihydrate and 1 mL of tannic acid. 
Purification of synthesized AuNP solution. To remove the non-AuNP 
components along with a maximal recovery of AuNP colloids from the synthesized 
20-nm AuNPs solution, an optimal centrifugation process was obtained based on tests 
of five centrifugation forces (3000, 5000, 7000, 9000 and 11000 g) and five durations 
(10 min, 20 min, 30 min, 45 min and 60 min) by following a purification process 
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           a)                                                                                                                       b)  






FIGURE 3.2 Schematic purification process employed in this study. 
schematically illustrated in Figure 3.2. There were a total of two rounds of 
purification (treatment); the supernatant (S1) resulting from the initial centrifugation 
of 1 mL freshly synthesized AuNPs solution was transferred to a vial and the 
centrifuged AuNP pellets were immediately dispersed in ultrapure water of its 
original volume (P1) (Figure 3.2). S1 was further centrifuged to recover some AuNPs 
(P1.a) which were placed together with the P1 as an AuNP composite solution of the 
round 1 (Figure 3.2). The composite AuNP solution underwent a second round of 
centrifugation by following the same operating procedure as the first round to 
minimize undesirable non-AuNP components and maximize recovery of AuNPs. The 
resultant supernatant (S2) was separated from AuNP pellets and underwent further 
centrifugation to recover additional AuNPs (P2.a) (Figure 3.2). Then, the AuNPs in 
both P2.a and P2 were combined in ultrapure water (1 mL), which is referred as 
“treated AuNP suspension” (Figure 3.2).  
1st round treated AuNP suspension 
 
Synthesized AuNP solution 
 
1st Round: Centrifugation of freshly  
synthesized AuNP solution 
2nd Round: Centrifugation of  AuNP solution after 































For synthesized 7-nm AuNPs, the non-AuNP components were removed by 
adopting the same protocol with a centrifugation force of 66,000 g for 20 min. The 
non-Au components and Au in the purified 7-nm AuNP suspensions were 
investigated. All the characterization data are presented in chapter 4. 
Chemical analysis. Gold in the synthesized solution, treated suspension, and 
supernatants was quantified using an inductively-coupled plasma mass spectrometry 
(ICP-MS) (Perkin Elmer, Massachusetts, USA). This quantification by direct injection 
of samples into ICP-MS showed satisfactory recovery (>90%), consistent with other 
studies (eg., (Allabashi et al. 2009)). Amounts of non-AuNP components (chloride, 
citrate, ketoglutarate, and acetate) in the synthesized AuNP solution and supernatants 
were examined using an ion chromatography (IC) system (ICS 2000, Dionex, USA). 
The IC system consists of an eluent generator, a conductivity detector, and an anion 
self-regenerating suppressor (ASRS Ultra II-4 mm). The IC system is also equipped 
with an AS-11-HC (4 mm) analytical column and an AG-11-HC guard column, which 
were maintained at 35
o
C with an isocratic mobile phase of 20 mM KOH at a flow rate 
of 0.8 mL min
-1
. To analyze non-AuNP components in initially synthesized AuNP 
solutions, a nylon syringe filter (pore size: 0.45 μm) was employed to remove AuNPs. 
This is to ensure that IC columns were protected from interference of AuNPs. An 
internal standard (oxalate, 32.8 µg) was spiked to the synthesized AuNP solution to 
monitor procedural loss and instrument performance. Triplicate tests showed that the 
average recovery of oxalate is 95.2 ± 0.6 % indicating insignificant loss of materials 
through the analysis. 
The total organic carbon (TOC) in the reactant solution (tetrachloroauric acid and 
citrate) and in the solution of synthesized 20-nm AuNPs was measured using a TOC 
analyzer (TOC-V CSH/CSN, Shimadzu, Kyoto, Japan).  
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Stability of treated AuNP suspension. Effects of storage temperature on stability 
of AuNPs were evaluated based on changes in the size of treated 20-nm AuNP 
suspension which were stored at 4°C and room temperature (23°C) for over one 
month. All treated AuNP suspensions were wrapped with aluminum foil and stored in 
the dark throughout the measurement period. The treated AuNP suspensions stored at 
4°C were equilibrated to room temperature prior to measurements. A Zetaplus 
analyzer (90 Zetaplus, Brookhaven Instruments Corp., USA) was employed to obtain 
the hydrodynamic size of treated AuNP suspensions by measuring the dynamic light 
scattering (DLS) of the samples at a fixed angle of 90°. The hydrodynamic size of 
colloids in the suspensions depends on the movement speed of AuNPs due to 
Brownian diffusion in the solution. Triplicate measurements of size were taken for 
each sample at room temperature (23ºC). 
Oxidation state of AuNPs. The oxidation state of AuNPs were examined using 
an x-ray photoelectron spectroscopy (XPS) coupled with a Kratos AXIS His 
spectrometer (Kratos Analytical Ltd, UK) for four types of samples. They were (a) 
treated AuNP suspensions after freeze drying, (b) AuNPs aerosolized from the 
synthesized solution, (c) AuNPs aerosolized from the treated suspensions, and (d) 
treated AuNPs after heat treatment at 500°C. These AuNP samples were prepared as 
follows: a) treated AuNP suspension was loaded over a glass support followed by 
freeze drying at -50
o
C and 0.05 mbar (Martin Christ, Alpha 1-2 LD plus, Germany) 
for more than 8 hours; b) synthesized AuNP solution and treated AuNP suspension 
were individually aerosolized through an aerosol generation system (TSI Model 3940, 
Minnesota, USA), and collected on 25-mm polycarbonate filters (pore size: 0.15 µm, 
Whatman, USA) which were placed on individual stages of a low pressure impactor 
(Dekati, Finland). Portions of the filters loaded with AuNPs were then impregnated 
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over a glass support for XPS analysis; and c) the treated AuNP suspension was loaded 
over a glass support and heated at 500°C for 1 h in a tubular furnace (Nabertherm 
Furnace, Bremen, Germany), where air was employed as a carrier gas at a flow rate of 
2 lpm.  
XPS measurements were conducted in a vacuum of 10
-7–10-9 Torr using a 
monochromatized AlKα X-ray radiation (1486.7 eV photons), at a constant dwelling 
time of 100 ms and pass energy of 40 eV. The anode voltage was 15 mV with a 
current of 10 mA. All the survey scans and the core-level spectra were obtained at a 
photoelectron take-off angle of 90° (α, with respect to the sample surface). Survey 
scans were recorded within a range of 0–1100 eV. To compensate for the effects of 
surface charging, all core-level spectra were referenced to the C 1s hydrocarbon peak 
at 284.5 eV, and the high resolution photoelectron spectra were recorded for 
Au4f. The XPSPEAK software was used to interpret the binding energy of most 
prominent peaks based on a non-linear least-square regression method. 
3.2  Inhalation exposure in vivo  
Animals and exposure intervals. Experiments were carried out by employing rat 
models. Adult male Wistar rats (~ 200–250 g each) were purchased from the Centre 
for Animal Resources, Lim Chu Kang, Singapore with appropriate approval granted 
by the Institutional Guidelines for Animal Care and Use Committee of the National 
University of Singapore. All animals were acclimatized to the exposure environment 
at least 3 days prior to the exposure study. Rats were housed in the inhalation 
exposure chamber without access to food and water during exposure study. Before 
and after the exposure study, they were housed in the animal holding unit (AHU) 
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facility devoted for their residence with surplus food and drink. No abnormalities 
were observed in rats during exposure studies. 
Two separate exposure tests were conducted using rat model to evaluate effects of 
exposure duration of 5 days vs. 15 days. To evaluate effects of exposure durations, 
rats were divided into three groups. Each group has 4 rats. The first group was 
exposed to 20-nm AuNPs for 6 h per day for 5 consecutive days. The second group of 
rats was exposed for 6 h per day for 5 consecutive days per week and for 3 weeks. 
Unexposed animals (as the 3
rd
 group) were used as controls.  
Two separate exposure tests were conducted to evaluate the size effects of AuNPs 
by exposing rats to purified 7- or 20-nm AuNPs for 15 days. Unexposed animals (as 
the 3
rd
 group) were used as controls. Each group has 7 rats. 
Exposure and real time monitoring system. Figure 3.3 shows the schematic 
flow of aerosol generation system including the exposure unit and monitoring system. 
AuNP suspensions were aerosolized through the aerosol generation system (TSI 
Model 3940, Minnesota, USA). Aerosolized NPs passed through a series of two 
dryers and a neutralizer to remove excess water in particles and to balance surface 
charge of all the airborne particles, respectively. 1.5 lpm of the aerosol stream was 
introduced into a diluter to mix with dry compressed air before the mixed aerosol 
stream entered the customized exposure chamber. Based on an air exchange rate of 10 
h
-1
 in the exposure chamber, the flow rate of make-up air was determined to ensure a 
comfortable environment for animals.  
Size distribution and total number concentrations of NPs in the exposure chamber 
were monitored using a scanning mobility particle sizer (SMPS, TSI model 3936) 
throughout each exposure experiment. Exhausts from the exposure chamber were 
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channeled to impingers containing 0.1 M of calcium chloride solution, which 
enforced NPs to undergo aggregation in solution, leaving air stream free from NPs 
before it was released through a fume hood. Additional control experiments were 
conducted to verify NPs attributed to background interference (e.g., impurities in ultra 
pure water). Operation and characteristics of individual units in the experiment setup  
FIGURE 3.3 Schematic experiment setup of exposure and monitoring systems. 
in detail were described below following the order of (1) aerosol generation system, 
(2) exposure chamber design, and (3) aerosol monitoring system.  
Aerosol generation system. The aerosol generation system consists of a 
recirculation mode atomizer (TSI 3076), diffusion driers (TSI 3062) and a charge 
neutralizer (TSI 3012). To aerosolize solutions, filtered clean air is compressed 
through an orifice (0.0135 inch), forming a high velocity jet and a vacuum which 
withdraws solution from a reservoir to atomize the solution into fine droplets. In 
general, 6×10
10 









 Aerosol flow path 
   Clean air flow path 
Mass flow  
controllers 
Scanning mobility particle 
sizer (SMPS) 
Charge  
 neutralizer Atomizer 
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manual, 2005) although the number concentration of airborne particles depends on 
concentrations of solution. Water content of generated droplets is removed through 
diffusion process when airborne droplets pass through a series of two silica gel driers. 
Before the polydispersed airborne particles enter the exposure chamber, the static 
charges over particle surface (due to the atomization process) are equilibrated (zero 
charge of all particles) through a radioactive neutralizer (Kr-85), which provides both 
positive and negative ions to balance the overall charge.  
Animal Exposure Chambers. Two chambers were employed to carry out two 
batches of inhalation studies, and the major specifications of individual exposure 
chambers are listed in Table 3.1. The second whole-body chamber was designed in 
house to host 10 rats. Table 3.2 lists basic requirements (e.g., air exchange rate) and 
guidelines for design and operation of whole-body exposure chambers. In addition to 
fulfilling the basic requirements (e.g., air exchange rate and floor area per animal), 
configuration of each exposure chamber was designed to provide satisfactory 
distribution of flow and airborne NPs. Compared with conventional exposure 
chambers, uniqueness of individual design is also listed along with individual 
parameters (Table 3.2). For example, unlike the conventional cubical chamber, the 
whole-body inhalation exposure chamber was designed with the narrow angled 
conical top and cylindrical exposure section to minimize dead zones of flow in the 
chamber. The whole-body exposure chambers were made of stainless steel to 
minimize wall loss of airborne particles except viewing windows. The viewing 
windows are made of acrylic to provide sufficient lighting to maintain physiological 





Table 3.2 Design consideration and operation of the whole body inhalation exposure system for rodent studies. 
Requirements Design and operation  
 Minimum floor spacea 
     a. Rats (200 – 300 g): 187 cm2 per rat  
     b. Mice (> 25 g )      : 96 cm
2




Floor area: 0.2 m
2
 for 10 (20) rats (mice) to ensure sufficient 
space for tested  animals and to maximize their exposure to 
NPs. 
 Loading of animals/Volume of the chamberb,c 
 5% of the total volume of the chamber; to 
maximize homogeneity of temperature in an 
inhalation system and to minimize interference 
from the animal fur  
 
To hold 10 rats: total volume of rats (0.006 m
3
) to the 
chamber volume (170 L) was around 3.5% 
 
 Ventilation ratec 
At least 10 air changes per hour 
 
 
Flow rate through the chamber: 28.33 lpm  
 Environmenta 
     a. Temperature: 18–26°C  
     b. Relative humidity: 40–70% 
 
 
Constant temperature (21.9– 23.4°C) and relative humidity 
(52.9– 58.8%)  
 Other considerations:  
a. Homogeneous (pre-mixed and laminar) flow in the 
exposure chamber (minimize dead space of flow in the 
chamber):  
-  a conical top and a cylindrical (instead of      
   cubical or hexagonal shaped) body, 
-  a smallest angle of the conical top,  
-  a pre-mixer (to provide fully mixed aerosol flow), 
-  a fine mesh at the inlet (to smoothen and provide a 
uniform flow of aerosols), and 
-  laminar flow in the chamber to minimize shear 
coagulation. 
b.  Stainless steel is used to construct the chamber (to   
     minimize wall loss of materials)   
c.  An excreta collection pan (20 cm below animals) to  
minimise contamination arise from animal wastes  
 
a NACLAR guideline 2004; b Pauluhn 2005; c Cheng 1996.  
 
Table 3.1 Configurations of designed whole body exposure chambers. 
Exposure chamber 1
st
 batch study 2
nd
 batch study 
Shape Cubical shape with pyramidal top 
and bottom 
Cylindrical shape with conical top 
Measurement ports 
 
Six measurement ports  Eight measurement ports  





Air exchange rate 10 per h 10 per h 
Maximum number of rats  4 10 
Flow rates of aerosol flow; make-up 
air 
1.5 lpm; 8 lpm 1.5 lpm; 26.83 lpm 
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Aerosol Monitoring System. To monitor number concentrations and size 
distribution of airborne NPs in the exposure chamber, one of the outlets of the 
exposure chamber around the breathing zone of rats is connected to a SMPS, 
composed of a dynamic mobility analyzer (DMA, TSI 3081) and a condensation 
particle counter (CPC, TSI model 3782). The DMA selects particles based on 
electrical mobility of particles; by controlling the voltage of a central cylindrical 
electrode, particles of a selected size containing desired electrical mobility enter the 
CPC. Other particles are either removed by the central electrode, or discharged from 
the DMA in excess flow. Thus, by changing the voltage of the central electrode, 
number concentrations of individual size particles (10–440 nm) can be measured. 
Two types of DMA (long DMA (TSI 3081) and nano DMA (TSI 3085)) were 
used during the exposure tests. Because NPs below 20 nm tend to undergo significant 
diffusion loss and are absent from the detection of a long DMA (Kousaka et al. 1986; 
Chen et al. 1998), a nano DMA is employed to monitor NPs smaller than 20 nm, 
complementary to the data provided by a long DMA. 
3.3 Intravenous injection exposure in vivo 
Thirty adult male Wistar rats (~ 200–300 g each) were purchased from the Centre for 
Animal Resources, Lim Chu Kang, Singapore. All procedures involving animals were 
approved by the Institutional Animal Care and Use Committee of the National 
University of Singapore.  
A single tail-vein injection of 0.2-mL treated AuNP suspensions (15.1 µg/mL) 
was administered slowly to rats. This dose was based on the blood level of Au, after a 
15 day inhalation exposure to aerosolized 20nm-AuNPs. The average level of Au in 
the blood in these animals (18.7 ng Au/g blood) was used as a basis for calculating the 
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total mass of AuNPs that need to be delivered by i.v. injection into a 200 g rat, 
assuming even distribution of AuNPs throughout the entire volume of the body of the 
rats (calculated by assuming body density is equal to water). The dose (0.01 mg 
Au/kg body wt) used in this study is 5 – 2.7×105 times lower than the studies 
summarized in Table 1.3 (Chapter 1), and could be more relevant to biomedical 
practices.  
Rats were randomly divided into five groups (six in each group) and sacrificed at 
four time points: 1 day, 1 week, 1 month and 2 months after injection of AuNPs. 
Feces and urine samples were collected using metabolic cages for a 24 hour period 
prior to sacrifice. The rats showed no obvious abnormal behavior after AuNP 
injection. A group of six animals that were not exposed to AuNPs were used as 
controls. 
3.4 Perfusion and harvesting of tissues  
Rats were deeply anaesthetized by intraperitoneal injection of 2.3 ml of 6 mg/mL of 
Nembutal. Approximately 2–3 mL of blood was collected through cardiac puncture, 
and rats were perfused through the left cardiac ventricle with normal saline until the 
venous return was clear. Tissues of different parts of the body were harvested as 
follows: olfactory bulb, striatum, hippocampus, thalamus, cerebellum, brainstem, 
tongue, heart (ventricles), lung, thoracic aorta, esophagus (thoracic portion), liver, 
pancreas, spleen, adrenal glands, kidney, bladder, testis, skeletal muscle (quadriceps 
femoris), bone (shaft of femur), skin (shaved skin of the back), stomach, small 
intestine, cecum and descending colon. All instruments and samples were thoroughly 
washed with water during harvesting to minimize adherent AuNPs. The samples were 
placed in cleaned vials for ICP-MS analysis or Eppendorf tubes with RNAlater® 
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(Qiagen, Hilden, Germany) solution for microarray studies.  The vials and tubes were 
snap frozen in liquid nitrogen and stored at -80
o
C until analysis. 
3.5 Quantification of Au in tissues  
Tissue samples were weighed using a dual range balance (Mettler Toledo XS105, 
USA), followed by microwave assisted digestion and ICP-MS analysis. To correct the 
procedural loss including variation in instrument performance, 200 µL of 1 ppm 
cadmium ions (Merck, Germany) was spiked into each tissue sample as the internal 
standard. To facilitate digestion, 2 mL of 69.5% HNO3 (Fluka, Switzerland) and 1.5 
mL of 30% H2O2 (Merck, for trace analysis) were added to individual tissue samples 
in quartz inserts. 5 mL of ultrapure water and 1 mL of 30% H2O2 (Merck, Germany) 
were also added to a Teflon vessel in which the quartz inserts were placed. On 
completion of the microwave digestion, individual samples were diluted to 20 mL and 
transferred to a cleaned vial (Wheaton, USA), and stored in the dark at 4°C prior to 
ICP-MS analysis. Calibration standards of HAuCl4 (Sigma-Aldrich, USA) in five 
concentrations (0.2, 2, 4, 10, and 20 µg/L) were analysed with each batch of samples. 
Possible differences between mean Au levels were elucidated using Student’s t-test or 
one-way ANOVA with Bonferroni’s multiple comparison post-hoc tests. p<0.05 was 
considered significant. 
To examine potential metal contaminants affecting rats, we also analyzed the level 
of other metals including aluminium, arsenic, beryllium, chromium, copper, cobalt, 
manganese, nickel, lead, zinc, and vanadium in lung samples from rats exposed to 
AuNPs for 15 days, and unexposed controls. 
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3.6 Microarray analyses 
Lung and kidney samples from the 15 day AuNPs exposed rats which exhibited 
significant accumulation of AuNPs and unexposed controls were used to examine the 
possible gene changes from inhalation route. Four liver samples from rats injected 
with a single dose of AuNPs were harvested 2 months post injection, and four spleen 
samples of rats injected with a single dose of AuNPs were harvested 1 month after 
injection. The liver and spleen samples were individually matched by tissues from 
four non-injected control animals of a similar weight.  
Gene expression profiles of the tissues were compared using Affymetrix Rat 
Genome 230 2.0 microarrays (Affymetrix, CA, USA). Total RNA was isolated using 
TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer protocols, and 
RNeasy Mini Kit (Qiagen, Inc., CA, USA) was used to purify the RNA. The RNA 
was stored at -80°C. The RNA was then submitted to the BFIG Core facility Lab 
(National University of Singapore, Department of Paediatrics), where RNA quality 
was analyzed using an Agilent 2100 Bioanalyzer, and cRNA generated and labelled 
using the one-cycle target labelling method. cRNA generated from each sample was 
hybridized to a single array according to standard Affymetrix protocols. Four 
microarray chips were used for each treatment condition after 15-day inhalation 
exposure (AuNP exposed or unexposed) in each organ (lung or kidney). A total of 16 
microarrays were used – four arrays each for liver or spleen samples harvested from 4 
rats injected with AuNPs, and likewise for 4 non-AuNPs injected controls. Initial 
image analysis of the microarray chips was performed with Affymetrix GCOS 1.2 
software. The data were exported to GeneSpring v9.0 (Agilent Technologies, CA, 
USA) software for analysis using parametric test based on cross gene error model 
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(PCGEM). Unpaired t-test approach was used to identify differentially expressed 
genes. p<0.05 was considered significant. Differentially expressed genes were 
classified based on their known biological functions using the Database for 




RESULTS AND DISCUSSION 
4.1. Characterization, purification and stability of AuNPs 
Chemical characterization of synthesized AuNP solution. The AuNP solution 
synthesized through the citrate reduction method was experimentally quantified to 
speciate the non-AuNP components. Based on the synthesis reaction (eqn. (1)) 
(Kumar et al. 2007), multiple components including a reactant (citrate) and products 
(e.g., sodium ketoglutarate and sodium chloride) would be expected to remain in the 
synthesized AuNP solution. Table 4.1 shows the concentration of reactants and 
products that were estimated from equation (1) vs. those experimentally measured in 
our laboratory. Overall, the experimentally quantified gold, citrate and chloride in the 
synthesized AuNP solution agree with the concentrations proposed in equation (1) 
(columns (2) and (3), Table 4.1). More than 75% (1.3 out of 1.7 mM) of citrate 
originally employed as reactant remained in the synthesized AuNP solution which 
may help to stabilize the AuNPs (Hazarika et al. 2004). However, experimentally 
quantified ketoglutarate (0.07±0.02 mM) (column (3), Table 4.1) was less than 20% 
of that (0.38 mM) proposed by equation (1) (column (2), Table 4.1), suggesting that 
ketoglutarate was lost at high temperature during the synthesis process. Interestingly, 
acetate (0.32±0.08 mM) was identified in the synthesized AuNP solution (Table 4.1) 
although it is absent from the proposed equations (1 and 2). Acetate should be 
generated through thermal decomposition of ketoglutaric acid since our additional 
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Gold 0.25 0.25 0.25±0.01 0 0 
Citrate 1.70±0.02 1.32 1.30±0.05 122.40±1.44 93.60±3.92 
Chloride 0 1.02 0.98±0.07 0 0 
Ketoglutarate 0 0.38 0.07±0.02 0 4.20±1.20 
Acetate 0 0 0.32±0.08 0 7.68±1.92 
(Total)    122.40±1.44 105.48±4.52 
aExperimentally prepared. 
bEstimated based on equation (1). 
cAmounts remained in the synthesized AuNP solution that were experimentally measured (n=3). 
dTOC values shown in columns (4) and (5) were estimated based on the data given in columns (1) and (3), respectively. 
The experimentally measured TOC of reactants and products was respective 129.5±4.5 mg/L (n=4) and 117.5±3.7 mg/L 
(n=9) with a difference of 12.0±5.9 mg/L.  
 
tests showed that boiling (100°C) ketoglutaric acid solution (0.34 mM) during the 
synthesis of AuNPs resulted in a loss of 89% of the ketoglutaric acid and formation of 
acetate (0.27±0.01 mM). The latter accounts for 32% of carbons of the original 
ketoglutaric acid, a value consistent with the resultant fractions of ketoglutarate and 
acetate quantified in the synthesized AuNP solution, where ~18% of ketoglutarate 
remained and acetate accounted for ~34% of the carbons of the original ketoglutarate 
(equation (1), columns (2) and (3), Table 4.1). The newly identified acetate as one of 
the non-AuNP components suggests that precautions should be taken to avoid 
potential interference (Sun et al. 2005)
 
if the synthesized AuNP solution were 
concentrated for direct use.  
 
To verify whether the organic byproducts in the synthesized AuNP solution were 
successfully speciated and quantified, total organic carbon (TOC) of the reactant 
(comprising tetrachloroauric acid and citrate) and product solutions were measured. 
The latter was compared with the TOC values (column (5), Table 4.1) calculated 
2AuCl3  +  3(
-OCCH2)2C(OH)CO






O  6Cl-  +  3H+ + 3CO2















based on the byproducts which were earlier experimentally identified (listed in 
column (3), Table 4.1). The reactant and product solutions contained TOC of 
respective 129.5±4.5 and 117.5±3.7 mg/L, with a loss of 12.0±5.9 mg/L which can be 
attributed to CO2 and acetone (Kumar et al. 2007) as gas or volatile products. Since 
the lost organic carbons (12.0±5.9 mg/L) is consistent with the difference (16.9±4.7 
mg/L) of TOC between the reactants and identified products (columns (4) and (5), 
Table 4.1), the quantified ketoglutarate and acetate satisfactorily accounted for 
organic byproducts in the synthesized AuNP solution. Hence, the stoichiometry of the 
citrate reduction method for AuNP synthesis can be better described as follows 
(equation 3).  
 
Purification of AuNP solution. Figure 3.2 illustrates the schematic purification 
process employed in this study, which is explained in detail in the experimental 
section (Chapter 3). Based on the removal efficiency of non-AuNP components (in 
supernatants S1.a and S2.a, Figure 3.2) and the recovery rate of AuNPs, optimal g-
force (g) and duration of centrifugation were determined. Although Au in the 
synthesized solution is in the form of 20-nm AuNPs (see next section), AuNPs were 
quantified based on mass concentration of Au, and hence referred to as Au, instead of 
AuNPs in this section. Figure 4.1 shows the effects of centrifugation force (3000–
11,000 g) on removal of four non-AuNP components (in supernatants) from the 
























Bonferroni’s multiple comparison post-hoc tests showed that except 3000 g, the other 
four centrifugation forces removed a similar amount (1.29±0.02–1.35±0.04 mM) of 
FIGURE 4.1 Effects of five centrifugation forces (for 20 min) on removal of non-AuNP 
components (in supernatants). * indicates significant difference (p<0.05) compared to other 
tested centrifugation forces based on one-way ANOVA with Bonferroni’s multiple comparison 
post-hoc tests (n=3). 
citrate (Figure 4.1). Although all five tested g-forces removed comparable amounts of 
byproducts (chloride, ketoglutarate and acetate), the recovery rate of Au varied. 
Centrifugation force of 7000 g recovered 79% of Au in the treated suspension, 
significantly higher than the other four tested centrifugation forces (p<0.05) (Table 
4.2). Higher centrifugal forces of 9000 or 11,000 g resulted in AuNPs that were 
tightly packed or strongly adhered to centrifuge tubes, and lower recovery (Table 4.2). 
This is supported by observations of (Slot and Geuze 1981) who employed a 
centrifugation force of 15,000–125,000 g for 45 min and found tightly packed AuNP 
precipitates on the wall of the tubes. On the other hand, lower centrifugation forces of 
3000 and 5000 g resulted in weak recovery of Au, leaving more than 13% of Au in 







































FIGURE 4.2. Effects of five centrifugation durations (at 7000 g) on removal of non-AuNP 
components (in supernatants). * indicates significant difference (p<0.05) compared to other 
tested durations based on one-way ANOVA with Bonferroni’s multiple comparison post-hoc tests 
(n=3). 
TABLE 4.2 Total Au remained in supernatants and recovered in treated AuNP suspensions. 
Experimental 
condition 






G-force (for 20 min)    
3000 g 0.099±0.02 40±9% 0.09±0.02 37±9% 
5000 g 0.033±0.01 13±6% 0.15±0.02 59±11% 





9000 g 0.006±0.00 2±1% 0.13±0.04 51±17% 
11,000 g 0.003±0.01 1±0% 0.11±0.02 42±9% 
Duration (at 7000 g)    





20 min 0.014±0.006 6±3% 0.20±0.02 79±10% 
30 min 0.002±0.000 1±0% 0.19±0.01 76±6% 
45 min 0.000±0.000 0±0% 0.20±0.02 78±11% 
60 min 0.000±0.000 0±0% 0.21±0.01 85±8% 
aAu remained in supernatants (S1.a+S2.a) relative to the amount of Au in the initially synthesized AuNP solution 
(0.25±0.01 mM). 
bAu in treated suspensions relative to the amount of Au in the synthesized AuNP solution (0.25±0.01 mM).  
cSignificant difference (p<0.05) compared to other tested centrifugation forces or durations based on one-way 
ANOVA with Bonferroni’s multiple comparison post-hoc tests (n≥3). 
* 



































the supernatants (S1.a and S2.a) (Table 4.2). Hence, a centrifugation force of 7000 g 
achieved the highest recovery rate of Au with satisfactory removal of non-AuNP 
components, and was selected for assessing the optimal duration for centrifugation. 
Figure 4.2 shows the effects of five centrifugation durations at a constant g-force 
of 7000 g on removal of non-AuNP components. By following the protocol (Figure 
3.2), the 10-min centrifugation inefficiently removed citrate (Figure 4.2) with 28±9% 
of the synthesized AuNPs remaining in the supernatants (Table 4.2). In comparison, 
the other four durations resulted in satisfactory (~80%) recovery of Au (Table 4.2) 
with almost complete removal of citrate and chloride (100±6%, n=3, Table 4.3). The 
removal efficiencies of ketoglutarate and acetate were variable (>78%±25%) (Table 
4.3), which could be due to their relatively low concentrations in the synthesized 
AuNP solution, challenging the detection limit of instruments (Table A1, appendix A) 
and resulting in larger fluctuation. Hence, centrifugation at 7000 g for 20 min is 
optimal for satisfactory recovery of Au and removal of non-AuNP components. This 
is affirmed by our additional analyses of the treated AuNP suspension that all the non-
AuNP components are below detection limit (Table 4.3), demonstrating successful 
purification of the AuNP suspension. 
Stability of treated AuNP suspension. TEM images showed that after the 
centrifugation process, AuNPs in the treated suspension remained with a size of 20 
nm (not shown). All the AuNP sizes discussed for stability in this section represent 
hydrodynamic diameters measured using a dynamic light scattering (DLS) analyzer 
(90 Zetaplus, Brookhaven Instrument Corp., USA). Since AuNPs in the synthesized 
solution were of 21.1±2.8 nm (n=6), a standard deviation of >2.8 nm from the 
averaged size of the treated AuNPs was taken as a substantial change in size. Figure 
4.3 shows the temporal trend in size of treated AuNP suspension stored in the dark 
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TABLE 4.3 Removal efficiencies (%) and concentration (mM) of non-AuNP components.  
Experimental condition Citrate Chloride Ketoglutarate Acetate 
mM % (RSD) mM % (RSD) mM % (RSD) mM % (RSD) 
Synthesized AuNP solution 
G-force (g) (for 20 min) 





 1.17±0.04 119±13 (11%) 0.04±0.01 58±25 (43%) 0.17±0.02 52±18 (35%) 
5000  1.33±0.02 103±6 (6%) 1.09±0.04 112±13 (12%) 0.06±0.02 91±44 (48%) 0.21±0.01 65±19 (29%) 
7000  1.35±0.04 104±7 (7%) 1.14±0.04 116±12 (10%) 0.10±0.02 138±66 (48%) 0.25±0.02 78±25 (32%) 
9000  1.29±0.02 100±6 (6%) 1.12±0.07 114±16 (14%) 0.05±0.03 76±56 (74%) 0.24±0.05 74±34 (46%) 
11,000  1.31±0.06 101±9 (9%) 1.11±0.04 113±12 (11%) 0.05±0.02 77±52 (68%) 0.23±0.03 73±29 (40%) 





 1.08±0.03 111±12 (11%) 0.09±0.02 120±55 (46%) 0.20±0.04 63±27 (43%) 
20  1.35±0.04 104±7 (7%) 1.14±0.04 116±12 (10%) 0.10±0.02 138±66 (48%) 0.25±0.02 78±25 (32%) 
30  1.33±0.03 103±7 (7%) 1.10±0.02 112±10 (9%) 0.10±0.02 135±63 (47%) 0.19±0.02 58±21 (36%) 
45  1.35±0.01 104±5 (5%) 1.09±0.01 112±10 (9%) 0.11±0.03 159±77 (48%) 0.19±0.05 59±29 (49%) 














a Significant difference (p<0.05) compared to other tested centrifugation forces or durations based on one-way ANOVA with Bonferroni’s multiple comparison post-hoc tests (n=3). 
b The analyzed non-AuNP components were in the supernatants resulting from additional centrifugation of the purified AuNP suspension. 















FIGURE 4.3 Size (hydrodynamic diameter) of treated AuNP suspensions stored in the dark at 
4°C and room temperature (23°C) (n≥3). 
 
under two conditions, at 4°C and at room temperature (23°C). The treated AuNP 
suspension stored at 4°C remained stable for 20 days with sizes ranging from 
20.9±0.3–23.7±1.8 nm until the 21st day (31.1±2.8 nm) (Figure 4.3). Such a low 
storage temperature preserving the integrity of the treated AuNPs for 20 days could be 
due to little external energy and a small solid fraction (2.6×10
-9
) in the treated 
suspension, indicating a large distance between individual AuNPs and a small 
probability for encounter among AuNPs. The solid fraction is derived from a number 
concentration of 6.2×10
11
#/mL which is calculated based on the mass of 20-nm 

























at room temperature, 23°C
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On the other hand, storage under room temperature caused a noticeable growth in 
the size of the treated AuNP suspension from the 6
th
 day, with a large variation in 
sizes (Figure 4.3). If the change in size between days 6 and 15 followed a linear 
fashion (Figure 4.3), the treated AuNPs appeared to increase in size at a rate of 13.1 
nm per day (R
2
=0.99). This is expected because higher temperatures (e.g., room 
temperature) could supply sufficient kinetic energy, encouraging the aggregation of 
AuNPs. Interestingly, after the averaged size of aggregated AuNPs reached 
142.8±62.5 nm on the 15
th





 day, respectively (Figure 4.3). Dark precipitates were observed at the 
bottom of the vial from day 15 which were likely large AuNP aggregates settling out 
of the treated suspension. This could leave smaller NPs of a lower number 
concentration in the suspension. 
Oxidation state of AuNPs. All the scanned AuNP samples exhibited major 
components of 4f5/2 and 4f7/2 at respective binding energy of 87.71 and 84.00 eV 
(Figure 4.4), consistent with the atomic state of bulk Au (NIST), demonstrating that 
the 20-nm AuNPs characterized in this study remained the same whether they were 
aerosolized in air or heated at 500
o
C. This can be mainly attributed to the relatively 
large size of the 20-nm AuNPs. Ono et al. (2006) showed that when AuNP clusters 
are <6 nm, the Au-Au binding energy shifted positively, which is consistent with the 
observations of a substantial decrease in Au-Au bond length for AuNPs of <3 nm 
(Miller et al. 2006). These may explain why the AuNPs of a larger size of 20 nm 
remain insensitive to oxidation, similar to bulk Au. This is important when AuNPs are 
employed for any application under an aerobic environment. Overall, compared to 
other chemically unstable NPs (e.g., Fe, Al, Cu, Co and Ni) that could be oxidized at 
room temperature (Cabot et al. 2007; Nakamura et al. 2007) and at elevated 
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temperature (100-500°C) (Chernavskii et al. 2008; Railsback et al. 2010), or release 
metal ions and induce toxicity (e.g., CuO, ZnO, and CdSe) (Derfus et al. 2004; Chen 
et al. 2006; Franklin et al. 2007), AuNPs examined in this study can be an appropriate 
reference material without interference of intrinsic toxicity to evaluate effects or 
functions of other NPs.  
 
FIGURE 4.4. XPS of Au4f spectra of (a) treated AuNP suspensions after freeze drying, (b) 
AuNPs aerosolized from the synthesized solution (c) AuNPs aerosolized from the treated 
suspensions, and (d) treated AuNPs after heat treatment at 500°C. 







4.2 Inhalation exposure in vivo  
4.2.1 Translocation and effects of AuNPs 
Characterization of NPs in the exposure chamber. During the inhalation 
exposure of rats to airborne AuNPs, overall size distribution and number 
concentrations monitored at various locations of the exposure chamber were similar 
with a relative standard deviation smaller than 4% (n=120), indicating that airborne 
NPs in the chamber were evenly distributed. The averaged total number concentration 







airborne particle concentrations along roadsides (10
4–106 #NPs/cm3) when vehicular 
exhausts substantially contributed to the measured airborne particles (Kittelson et al. 
2004). In the exposure chamber, the monitored NPs spanned a size range of 9.8–414.2 
nm, with a peak diameter around 76–79 nm (7.7×104 #NPs/cm3). Majority of NPs 
(>75%) in the exposure chamber were within 30–110 nm.  
Figure 4.5 shows background interference due to NPs originating from ultra pure 
water during exposure tests; these airborne particles peaked at 18 nm (over a range of 
9.8–414.2 nm). Since the size distribution of the background interference was almost 
outside of the size range of airborne NPs in the chamber during the exposure tests, 
this interference appeared to be less than significant. In addition, the background NPs 




) of the total number concentrations 
of airborne NPs during the exposure tests, which is within the deviation (15%) among 
daily monitored number concentrations of NPs in the chamber. Hence, the effects of 
the background particles attributing to ultra pure water on airborne NPs, which rats 
were exposed to, can be marginal.  
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FIGURE 4.5 Averaged size distribution of NPs (n>1100, SD= ±15%) during exposure tests. 
Biodistribution of Au after inhalation exposure.  
Five days exposure compared to unexposed animals. Significant accumulation of 
gold was detected in the lung (125.7±25.9 ng Au/g tissue) and olfactory bulb 
(12.1±4.1 ng Au/g tissue) (Table 4.4). 
Fifteen days exposure compared to unexposed animals. Significant accumulation 
of Au was detected in over 20 organ and tissues, with a concentration ranging from 
8.8±5.8 ng Au/g (for pancreas) to 387.5±130.8 ng Au/g (for lung). Of the above 
tissues, the highest concentrations of gold were observed in (decreasing order of 
concentration): lung (387.5±130.8 ng/g), esophagus (44.9±21.9 ng/g), tongue 
(42.0±6.7 ng/g), kidney (27.3±3.2 ng/g), aorta (25.3±9.4 ng/g), spleen (25.0±2.1 
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NPs during AuNPs exposure
NPs generating from ultrapure water
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ng/g), septum (21.7±4.3), heart (19.3±3.2 ng/g) and blood (18.7±0.9 ng/g) (Table 4.4). 
Negligible differences were observed between the AuNPs-exposed and non-exposed 
rats, in levels of other metals such as aluminum, arsenic, beryllium, chromium, 
copper, cobalt, manganese, nickel, lead, zinc, and vanadium in the lung (data not 
shown). This indicates minimum interference from other metals, in our analyses of the 
health effects of AuNPs.  
Fifteen days exposure compared to five days exposure. Significantly greater levels 
of Au were detected in many organs after 15 day exposure, compared to 5 days 
exposure. The skin showed the highest incremental increase (>5 times higher 
accumulation), followed by bone (3.5 times more), aorta, tongue, and esophagus (>2.5 
times more). This shows that incremental uptake of AuNPs through skin exposure is 
most sensitive to duration of exposure to airborne NPs, which is expected since skin is 
in direct contact with AuNPs in the exposure chamber. The substantial increase in 
bone is surprising. The olfactory bulb showed similar uptake of Au after 5 or 15 days 
exposure (Table 4.4). 
This study aimed to examine the biodistribution and effects of inhaled AuNPs in 
rats. A large increase in Au uptake was observed in the lung after 5 days of exposure. 
This is expected, since previous study (Takenaka et al. 2006) showed that a single 
inhalation exposure of 5-8 nm AuNPs results in greatest accumulation (1945±57 ng) 
in the lung. A further increase in Au concentration in the lung was observed after 
inhalation exposure to AuNPs for 15 days, as well as significant increase in other 
organs that previously showed negligible Au accumulation after 5 days of exposure, 
including the esophagus, tongue, kidney, aorta, spleen, septum, heart, blood, bladder, 
entorhinal cortex, testis, skin and adrenal gland. The results indicate a cumulative 
effect of AuNPs exposure. Other than the lung, esophagus, and tongue, which are 
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Table 4.4 Biodistribution of Au in rats after 5 days and 15 days of AuNPs exposure. 
System Organ Unexposed controls 5 days AuNPs exposure (ng/g) 15 days AuNPs exposure (ng/g) 
Respiratory Lung 5.5 ± 4.4 125.7 ± 25.9* 387.5 ± 130.8*# 
Cardiovascular Heart 4.1 ± 2.6 4.8 ± 1.1 19.3 ± 3.2*# 
 Aorta 2.7 ± 2.6 5.9 ± 4.4 25.3 ± 9.4*# 
 Blood 5.8 ± 3.0 4.9 ± 1.6 18.7 ± 0.9*# 
     Digestive Tongue 9.0 ± 1.9 11.2 ± 2.4 42.0 ± 6.7*# 
 Oesophagus 9.4 ± 12.6 5.8 ± 3.2 44.9 ± 21.9*# 
 Stomach 4.2 ± 4.0 6.5 ± 12.7 10.0 ± 5.0 
 Small intestine 0.9 ± 0.8 1.6 ± 0.7 4.7 ± 0.8*# 
 Cecum 2.7 ± 2.2 2.4 ± 1.3 4.8 ± 1.3 
 Colon 1.3 ± 1.3 2.1 ± 1.0 7.2 ± 2.8*# 
     Exocrine/Endocrine/Immune Liver 2.9 ± 2.6 3.5 ± 2.3 7.8 ± 3.1*# 
 Pancreas 1.5 ± 1.0 1.8 ± 0.8 8.8 ± 5.8*# 
 Spleen 3.6 ± 2.9 4.8 ± 1.9 25.0  ± 2.1*# 
 Adrenal gland 7.5 ± 7.7 5.9 ± 1.7 12.9 ± 2.5*# 
     Musculoskeletal/Skin Bone 0.6 ± 0.3 0.8 ± 0.5 9.4 ± 2.5*# 
 Skeletal muscle 1.6 ± 1.3 2.3 ± 1.0 6.3 ± 1.4*# 
 Skin 2.3 ± 0.3 2.0 ± 0.4 15.0 ± 3.3*# 
     Nervous Olfactory bulb 4.4 ± 4.4 12.1 ± 4.1* 13.1 ± 4.7*# 
 Septum 11.7 ± 2.2 14.8 ± 6.4 21.7 ± 4.3*# 
 Entorhinal cortex 11.8 ± 1.3 10.8 ± 2.2 17.1 ± 2.9*# 
 Neocortex 8.0 ± 5.8 4.5 ± 0.7 9.3 ± 3.0 
 Hippocampus 9.2 ± 7.5 13.5 ± 6.1 12.9 ± 3.1 
 Striatum 20.3 ± 15.8 20.6± 12.0 9.3 ± 0.9 
 Thalamus/hypothalamus 6.7 ± 5.0 7.7 ± 4.6 11.9 ± 2.2 
 Brainstem 14.7 ± 16.2 5.4 ± 1.7 9.0 ± 0.7 
 Cerebellum 4.7 ± 3.6 5.2 ± 2.0 9.6 ± 0.5*# 
     Urinary Kidney 6.3 ± 4.1 10.1± 12.7 27.3 ± 3.2*# 
 Bladder 6.6 ± 5.8 5.7± 1.8 17.9 ± 3.2*# 
     Reproductive Testis 5.0 ± 4.2 3.3 ± 2.1 16.3 ± 6.4*# 
Values indicate mean concentration and standard deviation (ng/g of tissue) (n=4) in each case. Analyzed by one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. 
p<0.05 was considered significant.  
* indicates significant increase compared to unexposed controls.  
# indicates significant increase in the 15-day AuNPs-exposed rats compared to the 5-day AuNPs-exposed rats. 
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directly exposed to AuNPs through inhalation or ingestion, the kidney showed the 
next highest accumulation of AuNPs. This could be related to its function as a filter 
for blood, and provides evidence that AuNPs could translocate from the lung to the 
bloodstream and other organs. In contrast to the kidney and spleen, the liver showed 
little accumulation of Au. This may be due to differences in expression of a metal 
sequestering protein, metallothionein, in these organs. The rate of metallothionein 
gene transcription and metallothionein expression remain high after exposure to 
metals such as mercury in the kidney, but decrease rapidly in the liver (Zalups and 
Koropatnick 2000). 
Interestingly, little accumulation of Au was detected in most parts of the brain 
regardless of exposure duration. This is likely due to the blood brain barrier. The 
exceptions were the olfactory bulb, septum, entorhinal cortex and cerebellum. The 
finding of increased Au in the olfactory bulb after 5 days exposure, and in the 
olfactory bulb, septum and entorhinal cortex after 15 days exposure, supports the view 
that AuNPs could, with time, be transported from the olfactory bulb to other parts of 
the brain (Oberdörster et al. 2004; Elder et al. 2006; Zhang et al. 2006). The septum 
and entorhinal cortex receive direct neuronal projections from the olfactory bulb, and 
are important in attention and new memory formation. The Au measured in 
unexposed tissue samples is likely due to noise of the experimental procedures, 
including microwave-assisted extraction and ICP-MS analysis. 
Microarray analysis. Many genes were significantly upregulated or 
downregulated by more than two folds in the lung or kidney of the AuNPs-exposed 
rats (data not shown). However, genes that showed the greatest changes (10 fold or 
greater) were mostly downregulated (Table 4.5). In the lung, these included many 
genes related to muscle, including phosphoglycerate mutase 2, myosin heavy chain 
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polypeptide 6 and myozenin 2, and several genes related to secretion, including 
palate, lung, and nasal epithelium carcinoma associated protein, secretoglobin, family 
3A, member 1, chloride channel calcium activated 3, and glycoprotein 2 (zymogen 
granule membrane) (Table 4.5). The lung and kidney of AuNPs-exposed rats both 
showed more than 10 folds downregulation in RT1 class II, locus Bb, and two 
subunits of cytochrome c oxidase. Significantly decreased expression of the gene for 
thyroid hormone responsive protein was also found in the kidney of the AuNPs-
exposed rats (Table 4.5). 
The results of microarray analysis of the AuNPs-exposed lung was striking, in that 
it showed significant downregulation of many genes related to muscle. These included 
proteins related to myofibrils, such as myosin, troponin, tropomyosin, or muscle 
metabolism, including myoglobin and creatine kinase. These observations suggest 
changes in smooth muscle in the conducting portion of the respiratory tree and/or 
pulmonary vessels after AuNPs exposure. Carbon nanotubes affects smooth muscle 
growth in vitro (Raja et al. 2007), whilst titanium dioxide nanoparticles (NanoTiO2) 
induce emphysema-like lung injury in mice (Chen et al. 2006), that might be due to 
effects on smooth muscle. Further studies are hence necessary to examine lung 
smooth muscle function after AuNPs exposure. It may also be important to examine 
changes in muscle in other organs that have a high proportion of this tissue, such as 
the esophagus, aorta, and heart. Several genes related to secretion, including palate, 
lung, and nasal epithelium carcinoma associated protein, secretoglobulin, and chloride 
channel calcium activated 3 were also downregulated in the lung. This might affect 
mucus secretion in the airway. 
One gene, RT1 class II, locus Bb, was downregulated by more than 10 folds, in 
both lung and kidney of AuNPs-exposed rats. This is a rat MHC class II analog and 
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Table 4.5 Genes that are changed by >10 folds in the lung and kidney in AuNP-exposed rats compared to 
control rats,p<0.05. 
Organ Fold Change Gene Symbol Description 
Lung -51.3±0.0 Pgam2 phosphoglycerate mutase 2
a
 
-46.6±0.1 Myh6 myosin heavy chain, polypeptide 6
a
 













-38.0±0.1 Cox6a2 cytochrome c oxidase, subunit VIa, polypeptide 2 
-33.6±0.3 Scgb3a1 secretoglobin, family 3A, member 1
b
 
-32.2±0.0 Clca3_predicted chloride channel calcium activated 3 (predicted)
b
 
-30.9±0.1 Myh6 ; Myh7 




-30.0±0.1 Gp2 glycoprotein 2 (zymogen granule membrane)
b
 






-21.7±0.1 Clca3_predicted chloride channel calcium activated 3 (predicted)
b
 
-19.0±0.2 Tnnt2 troponin T2, cardiac
a
 
-18.2±0.1 Tpm1 Tropomyosin 1, alpha
a
 
-17.4±0.1 Ckmt2 Creatine kinase, mitochondrial 2, sarcomeric 
-16.8±0.1 Tna_predicted 
tetranectin (plasminogen binding protein) 
(predicted) 
-15.4±0.1 Sln_predicted sarcolipin (predicted)
a
 
-15.0±0.1 Csrp3 cysteine-rich protein 3 
-15.0±0.2 Smpx small muscle protein, X-linked
a
 




bile acid-Coenzyme A: amino acid N-
acyltransferase 
    
Kidney -44.6±0.0 RT1-Bb RT1 class II, locus Bb
c
 








-14.6±0.9 Thrsp thyroid hormone responsive protein
e
 
-12.1±1.8 Scd1 stearoyl-Coenzyme A desaturase 1 
-10.5±0.0 Stmn2 stathmin-like 2 
11.3±13.3 isg12(b) putative ISG12(b) protein 
10.5±13.0 G1p2_predicted 
interferon, alpha-inducible protein (clone IFI-
15K) (predicted) 
10.2±15.3 RGD:1359153 similar to ubiquitin specific protease UBP43 
Values are fold change, and standard deviation. A negative value indicates downregulation in the exposed organ, and vise 
versa. 
aindicate genes related to muscle; 
bindicate genes related to secretion;  
cindicate genes related to antigen presentation;  
dindicate genes related to mitochondrial function;  
eindicate genes related to growth. 
 
functions to present peptides processed from extracellular proteins to helper T cells to 
initiate an immune response. Two subunits of cytochrome C oxidase were also 
significantly downregulated in the lung and kidney of AuNPs-exposed rats. This 
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might affect mitochondrial respiratory function. The AuNPs-exposed kidney also 
showed significant downregulation of thyroid hormone responsive protein. A recent 
study showed that nanoTiO2 induced changes in large numbers of genes, including 
placenta growth factor and other chemokines and activation of pathways involved in 
cell cycle, apoptosis, chemokines, and complement cascades in the lung of mice 
(Chen et al. 2006). 
4.2.2 Size effects of AuNPs 
NPs in the exposure chamber. Inhalation exposure was carried out by 
aerosolizing purified (treated) 7- and 20-nm AuNP suspensions to assess effects of 
primary size on consequent biodistribution in rats. An ultracentrifuge (Himac 
CP90WX, Hitachi, Tokyo, Japan) operating at centrifugation energy of 66,000 g was 
employed to separate 7-nm AuNPs from non-Au components in synthesized AuNP 
solution. The adopted centrifugal energy (66,000 g) is nearly 10 times higher than the 
centrifugation energy (7000 g) employed to purify 20-nm AuNPs. Table 4.6 shows 
the detailed chemical composition of purified 7- and 20-nm AuNP suspensions. After 
aerosolization, the corresponding characteristics (e.g., number concentration, peak 
diameter, median diameter) of the airborne NPs in the exposure chamber were 
measured in-situ and real time using SMPS. The amount of non-Au components after 
purification in both treated suspensions was below instrumental detection limit (Table 
4.6), indicating that the airborne AuNP agglomerates comprised minimal amounts of 
non-Au components along with AuNPs in the chamber. The mass concentration of 
employed 7-nm AuNPs (0.13±0.01 mM, n=10) was smaller than that of 20-nm 
AuNPs (0.40±0.03 mM, n=24) to provide airborne AuNPs with similar number 
concentration and size distribution.  
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Table 4.6 Physicochemical property of AuNPs.  
Properties of AuNPs 7-nm AuNP 20-nm AuNP 
Adopted centrifugation energy for purification 66000 g for 20 min 7000 g for 20 min 
Chemical property of AuNPs suspension   
TOC of synthesized AuNP suspension 9.88±0.19 mM (n=3) 9.76±0.47 mM (n=12) 
TOC of treated AuNP suspension  0.05±0.00 mM (n=3) ND 
Au in purified solution (mM) 0.13±0.01 (n=10) 0.40±0.03 (n=24) 
Non-Au components (citrate, chloride, acetate, keto-
glutarate, tannic acid) (mM) 
ND ND 
Physical property of aerosolized AuNPs     















3±0.3  2±0.2 
Number count median diameter (nm), n>2200 45.6±0.5  41.7±0.9  
Geometric standard deviation, n>2200 1.6 1.6 
Peak diameter (nm), n>2200 46.1-51.4 (49.6±1.8) 42.9 - 46.1 (44.1±1.7) 



















The difference of total number concentration between 7- and 20-nm AuNP exposure relative to 20-nm AuNP 
exposure was 14%, smaller than the standard deviation of individual types of airborne AuNPs.
 
bTheoretical calculation assuming bulk density of gold using the formula, (π/6) × dp
3 
× (ρp-ρair) × g where dp,and ρp 
represents diameter and densityof particle. 
During the 15-day inhalation exposure, aerosols in the chamber generated from 










 ±18%, n>2200) (Table 4.6). Size of the airborne NPs 
in the chamber spanned from 10–140 nm with >95% of airborne NPs of <100 nm. 
Airborne 7-nm AuNPs underwent natural agglomeration with a peak diameter around 
46.1–51.4 nm (4.4×104 #NPs/cm3), comparable to the trend of agglomerated airborne 
20-nm AuNPs (42.9–46.1 nm (4.1×104 #NPs/cm3)). Consistent with the peak 
diameter, both types of airborne AuNPs exhibited the same geometric standard 





) (Table 4.6).  
Biodistribution of 7 and 20 nm AuNPs. Although the size distribution of 
airborne AuNPs (as agglomerates) differs from the original size of AuNPs in 
suspension, for the purpose of easy reference, the discussions below simply refer the 
resultant biodistribution according to the original size of AuNPs in suspensions (i.e. 7 
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vs. 20 nm). Table 4.7 summarizes resultant accumulation of Au in 30 organs 
harvested from seven major body systems of rat (respiratory, digestive, immune, 
musculoskeletal, nervous, urinary and reproductive system) after inhalation exposure 
to airborne 7- and 20-nm AuNPs. In addition, Au was quantified in feces and urine 
(excreta) at six time points (1, 5, 7, 10, 12 and 15 day post exposure) as shown in 
Table 4.7. 
Biodistribution of 7-nm AuNPs compared to unexposed controls. Significant 
accumulation of Au was detected in 22 out of 30 organs. The lungs (730.6±55.1 ng/g) 
exhibited the highest accumulation of Au followed by olfactory bulb (9.4±2.8 ng/g), 
hippocampus (8.0±4.6 ng/g), straitum (5.0±2.3 ng/g), frontal cortex (5.0±1.7 ng/g), 
entorhinal cortex (3.6±2.8 ng/g), septum (3.1±1.8 ng/g), cerebellum (1.6±0.6 ng/g), 
aorta (1.6±0.5 ng/g), esophagus (1.5±0.5 ng/g) and kidney (1.4±0.3 ng/g) (Table 4.7). 
Although significant amount of Au was excreted via feces with 5.2±5.6 ng/g after 1-
day exposure and 3.4±2.7 ng/g after 15 daily exposures, Au was not detected in urine 
or bladder at any time points (Table 4.7). This indicates that inhaled 7-nm AuNPs did 
not successfully pass through the glomerular capillary wall of the kidney.  
Biodistribution of 20 nm AuNPs compared to unexposed controls. There are 
18 out of 30 organs exhibited significant accumulation of Au. Consistent with the 
exposure to 7-nm AuNPs, major accumulation of Au was detected in the lungs 
(3117.5±367.2 ng/g) (Table 4.7), in addition to aorta (4.5±2.4 ng/g), olfactory bulb 
(4.5±0.9 ng/g), septum (4.3±6.2 ng/g), entorhinal cortex (3.7±2.1 ng/g), hippocampus 
(3.6±1.0 ng/g), frontal cortex (2.5±0.4 ng/g), esophagus (1.7±0.7 ng/g), cerebellum 
(1.1±0.5 ng/g) and kidney (1.2±0.4 ng/g). Consistent with the results of exposure to 7-





while there was no Au in bladder and urine.  
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Table 4.7 Biodistribution of Au in rat organs after exposure to 7 and 20 nm AuNPs. 
System  Organ (column 2) Unexposed controls 
(ng/g) 
7 nm AuNP exposure  
(ng/g) 
20 nm AuNP exposure 
(ng/g) 
Respiratory Lung§ 0.9 ± 0.8 730.6 ± 55.1*# 3117.5 ± 367.2*# 
     Cardiovascular Heart 0.3 ± 0.2 0.4 ± 0.1 0.2 ± 0.3 
 Aorta§ 0.8 ± 0.6 1.6 ± 0.5* 4.5 ± 2.4*# 
 Blood┴ 0.1 ± 0.0 0.3 ± 0.1*# 0.1 ± 0.0 
 Thymus§ 0.1 ± 0.1 0.3 ± 0.1* 0.9 ± 0.6*# 
     Digestive Tongue═ 0.0 ± 0.1 0.5 ± 0.2*# 0.4 ± 0.4* 
 Oesophagus═ 0.0 ± 0.0 1.5 ± 0.5*# 1.7 ± 0.7*# 
 Stomach═ 0.1 ± 0.1 0.3 ± 0.2*# 0.2 ± 0.1* 
 Small intestine┴ 0.1 ± 0.1 0.5 ± 0.2*# 0.1 ± 0.1 
 Cecum┴ 0.0 ± 0.0 0.1 ± 0.1*# 0.0± 0.0 
 Colon┴ 0.0 ± 0.0 0.2 ± 0.1*# 0.0 ± 0.1 
     Exocrine/Endocrine/Immune Liver═ 0.0 ± 0.0 0.2 ± 0.1*# 0.3 ± 0.1*# 
 Pancreas┴ 0.0 ± 0.1 0.2 ± 0.2*# 0.0 ± 0.1 
 Spleen§ 0.0 ± 0.1 0.2± 0.1* 0.7 ± 0.5*# 
 Adrenal gland═ 0.0 ± 0.0 1.1 ± 0.4*# 0.9 ± 0.2*# 
     Musculoskeletal / Skin Bone 0.2 ± 0.6 0.0 ± 0.0 0.0 ± 0.0 
 Skeletal muscle 0.0 ± 0.1 0.0 ± 0.0 0.1 ± 0.1 
 Skin§ 0.2 ± 0.1 0.0 ± 0.1 0.6 ± 0.2*# 
     Nervous Olfactory bulb┴ 0.0 ± 0.0 9.4 ± 2.8*# 4.5 ± 0.9*# 
 Septum═ 0.0 ± 0.0 3.1 ± 1.8* 4.3 ± 6.2* 
 Entorhinal cortex═ 0.1 ± 0.3 3.6 ± 2.8*# 3.7 ± 2.1*# 
 Frontal cortex┴ 0.0 ± 0.0 5.0 ± 1.7*# 2.5 ± 0.4*# 
 Hippocampus┴ 0.1 ± 0.2 8.0 ± 4.6*# 3.6 ± 1.0* 
 Striatum┴ 0.7 ± 0.7 5.0 ± 2.3*# 1.1 ± 0.6 
 Thalamus/hypothalamus 0.1 ± 0.1 0.2 ± 0.2 0.4 ± 0.3 
 Brainstem 0.1 ± 0.3 0.4 ± 0.6 0.6± 0.9 
 Cerebellum═ 0.1 ± 0.2 1.6 ± 0.6*# 1.1 ± 0.5*# 
     Urinary Kidney═ 0.1 ± 0.1 1.4± 0.3*# 1.2 ± 0.4*# 
 Bladder 0.1 ± 0.1 0.2± 0.2 0.3 ± 0.4 
     Reproductive Testis 0.1 ± 0.1 0.1 ± 0.1 0.2 ± 0.1* 
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Table 4.7 Biodistribution of Au in rat organs after exposure to 7 and 20 nm AuNPs (continued). 
System Feces & Urine  Unexposed controls 
(ng/g) 
7 nm AuNP exposure 
(ng/g) 
20 nm AuNP exposure 
(ng/g) 
Excretory Feces – 1 day post exposure§ 
0.0 ± 0.0 
5.2 ± 5.6* 22.4 ± 11.4*# 
 Feces – 5 day post exposure§ 2.3 ± 1.2* 33.5 ± 13.9*# 
 Feces – 7 day post exposure§ -NA- 8.2 ± 2.7* 
 Feces – 10 day post exposure§ 0.9 ± 0.2* 7.5 ± 3.5* 
 Feces – 12 day post exposure§ 4.7 ± 2.0* 8.1 ± 5.4* 
 Feces – 15 day post exposure§ 3.4 ± 2.7* 7.2 ± 6.2* 
      Urine  – 1 day post exposure 
0.3 ± 0.4 
0.3 ± 0.1 0.1 ± 0.1 
 Urine  – 5 day post exposure 0.2 ± 0.1 0.1 ± 0.0 
 Urine  – 7 day post exposure -NA- 0.2 ± 0.2 
 Urine  – 10 day post exposure 0.2 ± 0.1 0.2 ± 0.2 
 Urine  – 12 day post exposure 0.2 ± 0.1 0.2 ± 0.1 
 Urine  – 15 day post exposure 0.2 ± 0.1 0.2 ± 0.2 
Values indicate mean concentration and standard deviation (ng/g of tissue) (n=7) in each case. Analyzed by independent t-test and one-way ANOVA 
with Bonferroni’s multiple comparison post-hoc test. p<0.05 was considered significant.  
* indicates significant increase compared to unexposed controls based on independent t-test. 
# indicates significant increase compared to unexposed controls based on one-way ANOVA with Bonferroni’s multiple comparison post-hoc test. 
§ indicates significant increase of Au in 20 nm AuNPs-exposed organs compared to 7 nm AuNPs-exposed organs based on independent t-test. 
┴ indicates significant increase of Au in 7 nm AuNPs-exposed organs compared to 20 nm AuNPs-exposed organs based on independent t-test. 




Comparison of 7 nm AuNP exposure with 20 nm AuNPs. There was 23% of (7 
out of 30) organs showing no uptake of Au during both exposure studies (Table 4.7). 
30% of organs (9 out of 30) retained similar amounts of Au regardless of the size of 
airborne AuNPs (as indicated by “═”, Table 4.7). Although the inhalation doses of 
AuNPs during the 15-day exposure were similar, inhaled 7-nm AuNPs were 
accumulated in more organs (22 organs) compared to 20-nm AuNPs (18 organs) 
(Table 4.7). In fact, 30% of (9 out of 30) harvested organs exhibited significantly 
higher (mass) uptake of 7-nm AuNPs than that of 20-nm AuNPs (as shown by “┴” in 
column 2, Table 4.7). Nevertheless, 17% (5 out of 30) of organs exposed to 20-nm 
AuNPs exhibited accumulated more (mass) Au (as shown by “§” in column 2, Table 
4.7).  
When the accumulated mass of Au was converted to equivalent number 
concentration (# particles/g of tissue) of original size (spherical 7- or 20-nm AuNPs) 
based on a bulk density (19.3 g/cm
3
)), all organs exhibited significantly higher 
accumulation of 7-nm AuNPs (4×10
11
 times in cecum - 4×10
9
 times in muscle) than 
that of 20-nm AuNP (Table 4.7). Despite of the differences in apportionment, both 
mass- and number-concentration-based Au accumulation in organs illustrated that 
inhaled airborne AuNPs aerosolized from 7-nm AuNP suspensions were distributed to 
more organs than those from 20-nm AuNPs. Although other studies showed that 
smaller AuNPs undergo widespread organ distribution compared to larger AuNPs 
through three different routes such as oral, i.v. injection and intratracheal instillation 
(Hillyer and Albrecht 2001; De Jong et al. 2008; Sonavane et al. 2008; Semmler-
Behnke et al. 2008), most (3 out of 4) studies controlled dose (in terms of mass) to 
examine the effects of size on biodistribution, and introduced more number of smaller 
AuNPs into the body compared to larger AuNPs. Thus, the attribution of wider 
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distribution of smaller AuNPs to size deserves reconsideration. The present study 
shows that at a similar number concentration and surface area, inhaled 7-nm AuNPs 
exhibited wider distribution than that of 20-nm AuNPs, indicating that original size of 
AuNPs outweighs agglomerate size to determining resultant biodistribution.  
Accumulation in lung. It is expected that the lungs exhibited the highest 
accumulation of Au regardless of the size of inhaled AuNPs (Table 4.7) since lung is 
the primary target organ and the first entry portal through inhalation exposure 
(Takenaka et al. 2006; Yu et al. 2007). Compared to olfactory bulb which is the organ 
accumulated second largest amounts of AuNPs, the lungs accumulated >77 times and 
>690 times more Au mass when rats were exposed to 7- and 20-nm AuNPs. 
Converting the accumulated mass to numbers of AuNPs showed that exposure to 7-
nm AuNPs uptake > 5×10
9 
times higher in the lungs compared to that of 20-nm AuNP 
exposure. This is contrast to the trend of accumulated mass of Au in lung (as 
illustrated below) which suggests a possibility of disintegration of agglomerated 
airborne AuNPs to its original or relatively smaller size after inhalation exposure 
although this requires to be verified in a further study. 
Despite the same dosage of particle population (1.3 – 1.4×106 #NPs/cm3) (Table 
4.6), this study showed that accumulation of 20-nm AuNPs in the lungs was 4 times 
higher than that of 7-nm AuNPs (Table 4.7). A mathematical model predicting 
regional deposition of inhaled NPs in the human lungs (International commission on 
radiological protection, 1994) showed that ~ 50% (by number) of inhaled 20-nm NPs 
could efficiently deposit in the alveolar region, while 20-30% (number fraction) of 
inhaled 5- to 10-nm NPs settled in the alveolar region (Oberdörster et al. 2005). 
Although the fractional deposition of AuNPs in the lung determined by the present 
study (based on weight) is not directly applicable to fractional deposition of NPs 
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predicted by the mathematical model (ICRP 1994, based on number or radioactivity), 
this study showed that 20-nm NPs deposited more in the lungs than NPs <10 nm. 
In addition to the deposition, the larger amount of Au in the lung after exposure to 
20-nm AuNPs could also be caused by less efficient translocation of AuNPs to other 
organs (such as liver, kidney) resulting less biodistribution of 20-nm AuNP compared 
to 7-nm AuNP. This can be supported by the observations through intratracheal 
instillations, where particulates in the lungs undergo clearance mechanisms similar to 
inhaled aerosols; at 24 h post instillation, Semmler-Behnke et al. (2008) found that 
none of instilled 18-nm AuNPs undergo translocation, while 10% of instilled 1.4-nm 
AuNP were translocated to other organs (such as kidney and uterus).  
Accumulation in brain. Inhalation exposure of 7- and 20-nm AuNPs resulted in 
significant accumulation of Au at respective of seven and six parts in the central 
nervous system (CNS) where olfactory bulb showed the highest uptake. Regardless of 
types of NPs, the uptake of inhaled NPs in olfactory bulb was consistently reported (> 
430 ng C/g at 7-day, >1500 ng Mn/g at 12-day, 13 ng Au/g at 15-day post inhalation 
exposures) (Yu et al. 2007; Oberdörster et al. 2004; Elder et al. 2006). The presence 
of Au in many parts of CNS in this study indicates that inhaled AuNPs can be further 
translocated from olfactory bulb through neuronal pathway. Interestingly, after 
inhalation exposure, relative to the accumulated Au in olfactory bulb (by weight), the 
fraction of 7-nm Au accumulated in three regions of CNS, hippocampus (80%), 
frontal cortex (50%), and cerebellum (20%) was similar to that resulting from 
inhalation exposure to 20-nm AuNPs. Interestingly, accumulation of NPs in frontal 
cortex and cerebellum seem to have proportional correlation with olfactory bulb 
regardless of types of engineered NPs. Through inhalation exposure for 12 
consecutive days, the amount of inhaled manganese (Mn) oxide NPs with a diameter 
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of 30 nm accumulating in the individual frontal cortex and cerebellum was around 
one third of that in the olfactory bulb (Elder et al. 2006). Through 6-h inhalation 
exposure, carbon NPs (36-nm diameter) accumulated in cerebellum at 7-day post 
exposure was around half of that in olfactory bulb (Oberdörster et al. 2004). 
It should be noted that the significant accumulation of inhaled NPs in 
hippocampus in this study was observed for the first time. In a recent study, Wang et 
al. (2008) showed that through intranasal instillation of high doses of 80 and 155 nm 
TiO2, accumulation of NPs was observed in hippocampus, in addition to olfactory 
bulb. The same study also showed that on the 30
th
 day post instillation, the 
accumulated TiO2 in hippocampus (>250 ng Ti/g) induced lesions on the neural cells 
and significantly increased lipid peroxidation. Since hippocampus plays a critical role 
in learning and memory, further tests are necessary to examine the implications 
associated with the accumulation of inhaled AuNPs in brains.  
Differing from Au accumulation in the lungs, inhalation exposure to 7-nm AuNPs 
resulted in >2 times of accumulated (by weight) in olfactory bulb, hippocampus, 
frontal cortex and >4 times in straitum than the exposure to 20-nm AuNPs (as shown 
by “┴” in column 2, Table 4.7) although the accumulation of Au in septum, entorhinal 
cortex and cerebellum was similar for inhalation exposure to both 7- and 20-nm 
AuNPs (Table 4.7). The higher uptake of 7-nm AuNPs by brain than that of 20-nm 
AuNPs (Table 4.7) could be due to smaller inertia of 7-nm AuNPs (23 times smaller 
than 20-nm AuNPs, Table 4.6), allowing them to more easily follow the air stream 
and reach olfactory bulb. Converting the accumulated mass to numbers of AuNPs 
(Table 4.7) shows that accumulation of 7-nm AuNPs in all parts of the brain (1×10
11 
times in straitum – 1.7×1010 times in septum) was significantly higher than that of 20-
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nm AuNPs, suggesting potential significant impacts of inhaled nano-sized NPs on 
brain. 
Systemic translocation. In addition to the lungs, the presence of significant 
amounts of Au in aorta, liver, spleen, adrenal gland and kidney after exposure indicate 
that inhaled 7- and 20-nm AuNPs translocated from the lungs to other organs. While 
exposure to 20-nm AuNPs resulted in three times higher accumulation in individual 
aorta (4.5±2.4 ng/g) and thymus (0.9±0.6 ng/g) than exposure to 7-nm AuNPs, Au 
was detected in blood (0.3±0.1 ng/g) after the exposure to only 7-nm AuNPs (Table 
4.7). This indicates that smaller AuNPs (7 nm) may have longer residence time in the 
blood than larger AuNPs (20 nm). Consistent with the previous inhalation study (Yu 
et al. 2007), little accumulation of Au was detected in liver after exposure to both 7- 
or 20-nm AuNPs.  
Excretion. Au in fecal excretion appeared to increase from day 1 to day 5 and 
reached a plateau on day 7 onwards (7.2±6.2 – 8.2±2.7 ng/g) while there was none in 
the urine (Table 4.7). Inhaled 7- or 20-nm AuNPs were excreted in fecal from day 1 to 
day 15 (Table 4.7) demonstrating that clearance of Au via feces is a major excretion 
pathway. The fecal excretion may be partially due to the clearance of NPs from 
alveolar to gastro-intestinal (GI) tract followed by excretion via feces (Oberdörster et 
al. 1994), in addition to through the pathway of ingestion of AuNPs during the whole-
body inhalation exposure. Interestingly, the present study showed that inhalation 
exposure to 20-nm AuNPs exhibited enhanced excretion of Au via feces during the 
15-day exposure compared to the exposure to 7-nm AuNPs (Table 4.7). This suggests 
that clearance through GI tract via feces is probably more efficient for larger AuNPs.  
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Differing from the excretion of Au in feces, inhaled Au was not detected in urine 
throughout the study but there was a significant accumulation of Au in kidney (Table 
4.7), indicating the failure of inhaled AuNPs in blood to pass through kidney. This 
seems to be similar to other studies reporting that NPs of HD > 5.5 nm accumulated in 
kidney without undergoing renal clearance (Yang et al. 2007; Choi et al. 2007; Choi 
et al. 2009). Although the renal clearance for injected quantum dots (QDs) may not be 
directly applicable to that of inhaled AuNPs in this study, the threshold HD size of 5.5 
nm suggested by Choi et al. (2007) for the renal clearance seems to be consistent with 
results of studies examining instilled AuNPs. For example, Au was detected in urine 
at 24 h post instillation of 1.4-nm AuNPs in the lung whereas instilled 18-nm AuNPs 
were not excreted via urine (Semmler-Behnke et al. 2008). In this inhalation study, 
the size of AuNPs are at least 7 nm, larger than threshold HD size (5.5 nm), which 
may prevent excretion of AuNPs from urinary system. 
In addition to the HD, the surface charge of AuNPs bounded with proteins also 
affects the glomerular filtration of AuNPs; since glomerular basement membrane 
(GBM) is rich in negative charge, AuNPs coated with serum proteins with positive 
surface charge could pass through GBM, while AuNPs coated with serum proteins 
with negative charge would repel from GBM without undergoing glomerular 
filtration. Hence, if the initial interactions of AuNPs with the lung surfactant and 
subsequent translocation rendered AuNPs with negatively charged surface, excretion 
of AuNPs via renal excretion would be unlikely.  
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4. 3 Intravenous injection exposure in vivo 
Biodistribution of Au after i.v. injection  
One day post-injection. Table 4.8 summarizes biodistribution of Au accumulated 
in more than 25 organs and tissues harvested from nine major body systems (nervous, 
respiratory, cardiovascular, digestive, immune, musculoskeletal, urinary, reproductive 
and excretory systems) at four time points after a single injection of AuNPs. One day 
after i.v. administration, the liver exhibited the highest uptake of Au (49.4±50.4 ng/g) 
followed by the spleen (9.5±6.4 ng/g), lung (4.7±2.6 ng/g), adrenal gland (2.8±2.2 
ng/g), bone (2.1±1.8 ng/g), tongue (1.9±0.9 ng/g), cecum (0.9±0.5 ng/g) and muscle 
(0.4±0.0 ng/g). The kidney showed non-significant amounts of Au, whilst Au was 
detected in the urine (1.7±0.7 ng/g) and feces (0.1±0.1 ng/g) at this time.  No Au was 
found in any of the brain areas measured at any time point (Table 4.8). 
One week post-injection. The levels of Au in the liver (64.8±39.7 ng/g), spleen 
(8.4±5.0 ng/g), lung (2.8±1.2 ng/g) and adrenal gland (1.7±1.9 ng/g) remained high. 
Although four organs (tongue, cecum, bone, muscle) showed significant accumulation 
of Au at one day post- injection, they showed little Au accumulation one week later.  
Interestingly, Au accumulation in lung decreased nearly two times compared to one 
day post-injection. The kidney and testis showed insignificant levels of Au. The level 
of Au in urine (0.8±0.1 ng/g) was substantially decreased (> 2 times) compared to one 
day post-injection (1.7±0.7 ng/g). The level in feces (0.1±0.0 ng/g) varied to a limited 
extent (Table 4.8). 
One month post-injection. The levels of Au in the liver (60.3± 19.9 ng/g), spleen 
(9.1±2.7 ng/g) and adrenal gland (5.5±3.6 ng/g) remained high. The level of Au in
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Table 4.8 Biodistribution of Au in rats at four time points after a single i.v. injection. 
System Organ Controls (ng/g) 1 Day (ng/g) 1 Week (ng/g) 1 Month (ng/g) 2 Month (ng/g)  
Respiratory Lung 1.5 ± 1.0 4.7 ± 2.6*# 2.8 ± 1.2* 3.1 ± 1.9 1.3 ± 0.8 
Cardiovascular Heart 1.7 ± 0.9 0.8 ± 0.5 1.5 ± 0.6 1.1 ± 0.7 0.4 ± 0.2 
 Aorta 1.8 ± 1.3 0.6 ± 1.4 0.8 ± 0.9 4.1 ± 1.9*# 0.9± 0.5 
 Blood 0.6 ± 0.1 0.7 ± 0.3 0.3 ± 0.1 0.5 ± 0.2 1.8 ± 0.5*# 
 Thymus 0.8 ± 0.2 0.7 ± 0.6 0.5 ± 0.3 11.7 ± 22.9 0.9 ± 0.3 
       Digestive Tongue 0.3 ± 0.4 1.9 ± 0.9*# 0.5 ± 0.3 1.3 ± 0.6*# 0.8 ± 0.2* 
 Esophagus 0.8 ± 1.0 0 ± 0 0.1 ± 0.2 5.0 ± 4.3*# 1.9 ± 0.5 
 Stomach 0.3 ± 0.3 0.5 ± 0.2 0.5 ± 0.6 0.9 ± 0.3* 0.7 ± 0.4 
 Small intestine 0.4  ± 0.1 0.9 ± 0.7 0.3 ± 0.2 0.7 ± 0.3 1.0 ± 0.2* 
 Cecum 0.2 ± 0.3 0.9 ± 0.5*# 0.1 ± 0.1 0.6 ± 0.2* 0.5 ± 0.0 
 Colon 0.4 ± 0.6 0.3 ± 0.4 0.0 ± 0.0 1.4 ± 1.4 0.9 ± 0.2 
       Exocrine/Endocrine/Immune Liver 0.4 ± 0.1 49.4 ± 50.4* 64.8 ± 39.7*# 60.3 ± 19.9* 72.2 ± 40.5*# 
 Pancreas 1.4 ± 0.8 0.7 ± 0.4 1.7 ± 0.9 2.3 ± 0.8 1 ± 0.3 
 Spleen 0.5 ± 0.1 9.5 ± 6.4*# 8.4 ± 5.0*# 9.1 ± 2.7*# 8.9 ± 4.9*# 
 Adrenal gland 0.0 ± 0.0 2.8 ± 2.2* 1.7 ± 1.9* 5.5 ± 3.6*# 0.7 ± 0.4* 
       Musculoskeletal / Skin Bone 0.4 ± 0.5 2.1 ± 1.8*# 0.0 ± 0.1 0.9 ± 0.5 0.1 ± 0.1 
 Muscle 0.1 ± 0.3 0.4 ± 0.0* 0.1 ± 0.1 0.6 ± 0.5 0.3 ± 0.1 
 Skin 0.9 ± 0.4 0.9 ± 0.2 0.5 ± 0.3 0.6 ± 0.3 1.7 ± 1.1 
       Nervous Olfactory bulb 1.9 ± 1.1 1.1 ± 1.0 0.4 ± 0.5 2.5 ± 0.7 3.6 ± 2.4 
 Frontal cortex 1.5 ± 0.5 0.7 ± 0.1 0.2 ± 0.1 0.6 ± 0.2 0.4 ± 0.3 
 Hippocampus 0.9 ± 0.3 1.4 ± 0.7 0.4 ± 0.4 1.5 ± 1.5 0.0± 0.1 




1.1 ± 0.3 0.8 ± 0.2 0.3 ± 0.1 0.7 ± 0.2 0.5 ± 0.4 
 Brainstem 1.4 ± 1.0 1.1 ± 0.5 0.5 ± 0.4 2.7 ± 2.1 0.1 ± 0.1 
 Cerebellum 0.8 ± 0.4 1.4 ± 0.4 0.4 ± 0.1 0.4 ± 0.1 0.2 ± 0.1 
       Urinary Kidney 0.7 ± 0.2 1.0 ± 0.4 0.4 ± 0.2 3.4 ± 1.2*# 5.5 ± 2.5*# 
 Bladder 1.1 ± 0.8 0.7 ± 0.4 0.5 ± 1.0 0.8 ± 0.4 1.0 ± 0.5 
       Reproductive Testis 0.4 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 0.6 ± 0.2* 0.6 ± 0.1* 
       Excreta Feces 0.00 ± 0.00 0.1 ± 0.1* 0.1 ± 0.0* 0.00 ± 0.00 0.01 ± 0.04 
 Urine 0.6 ± 0.1 1.7 ± 0.7*# 0.8 ± 0.1* 0.3 ± 0.1 0.5 ± 0.1 
Values indicate mean concentration and standard deviation (ng/g of tissue) (n=6) in each case.  p<0.05 compared to the control during the comparison of 1 day, 1 week, 1 
month & 2 month. 
*indicates significant increase compared to non-injected controls based on independent-t test;. 
# indicates ANOVA with Bonferroni’s multiple comparison post-hoc test.  
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the kidney (3.4±1.2 ng/g) and testis (0.6±0.2 ng/g) increased substantially compared 
to earlier time points, coincident with decreased levels of Au in urine and feces. 
Organs in the digestive tract, i.e., esophagus (5.0±4.3 ng/g), stomach (0.9±0.3 ng/g), 
and cecum (0.6±0.2 ng/g) showed small but significant accumulation of Au, 
compared to controls (Table4.8). 
Two months post-injection. The levels of Au in the liver (72.2±40.5 ng/g) and 
spleen (8.9±4.9 ng/g) increased, whilst the level in the adrenal gland (0.7±0.4 ng/g) 
decreased significantly from the peak concentration at one month post-injection 
(5.5±3.6 ng/g) to 0.7±0.4 ng/g. Significant amounts of Au was found in the tongue 
(0.8±0.2 ng/g) and small intestine (1.0±0.2 ng/g). The kidney (5.5±2.5 ng/g), blood 
(1.8±0.5 ng/g) and testis (0.6±0.1 ng/g) accumulated substantial amounts of Au at this 
time.  Insignificant amounts of Au were found in the urine and feces at this time, as in 
the 1 month post-injected specimens (Table 4.8). 
Au was rapidly and consistently accumulated in liver and spleen soon after the 
injection with a concentration of 49.4±50.4 to 72.2±40.5 ng/g and 8.4±5.0 to 9.5±6.4 
ng/g, from day 1 to 2 months (Table 4.8). Both liver and spleen retained larger 
amounts of Au than other organs throughout the period of two months post-injection. 
This is consistent with several studies showing that the intravenously injected NPs are 
accumulated in the liver and spleen for long durations regardless of their size, shape, 
dose and types of materials. Injection of 10 µg of [
14
C-taurine]-multi-walled 10–20 
nm carbon nanotubes in mice resulted in 80% and 5% of the administered multiwalled 
carbon nanotubes being retained in the liver and spleen respectively at a nearly 
constant level throughout 28 days (Deng et al. 2007). Moreover, a single i.v. injection 
(40 pmol) of quantum dots 705 (CdSe/ZnS) (13 nm) coated with methoxy 
polyethylene glycol 5000 resulted in accumulation in liver (29–40% of injected dose) 
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and spleen (4.8–5.2% of injected dose) over 28 days (Yang et al. 2007). Injection of 
iron oxide (11±2 nm) coated with oleic acid and pluronic acid (10 mg Fe/kg) in rats 
also resulted in 50% and 25% of the injected dose in liver and spleen respectively, 
after 21 days (Jain et al. 2008). Injection of AuNPs (77–108 µg) of four sizes (10, 50, 
100 and 250 nm) in rats resulted in accumulation mainly in the liver (20–46% of 
injected dose) and spleen (1.2–2.2% of injected dose) after 24 hours (De Jong et al. 
2008). Approximately 35% of intravenously injected (30 – 53 µg) Au nanorods 
(length: 65±5 nm and width: 11±1 nm) was accumulated in liver and 2% was 
accumulated in spleen 3 days after injection (Niidome et al. 2006). 
Intravenously injected 40-nm AuNPs were reported to be removed from the 
circulation primarily by Kupffer cells in the liver, and remained as clusters even after 
six months (Sadauskas et al. 2009). The significant and persistent accumulation of 
AuNPs in liver and spleen through i.v. exposure could be due to their fenestrated, 
discontinuous endothelia which allow NPs up to 100 nm in diameter to exit from the 
bloodstream into the parenchyma (Garnett and Kallinteri 2006). In addition, organs of 
the reticuloendothelial system (RES) including the liver and spleen can efficiently 
accumulate NPs via opsonization; that is, NPs could bind to antibody in the plasma 
and are subsequently recognized by the phagocyte-rich RES (Garnett and Kallinteri 
2006). This may explain the persistent accumulation of AuNPs in liver and spleen 
over two months in this study.  The adrenal glands showed a small but significant 
accumulation of Au (0.7±0.4 – 2.8±2.2 ng/g) throughout the study. 
The level of Au in the lung decreased from 4.7±2.6 at one day to 2.8±1.2 ng/g at 
one week post-injection. This is consistent with the results of other studies which 
showed significant uptake of Au in the lung (35–1740 ng/g), one day after injection of 
different sized AuNP (10, 50, 100 and 250 nm) (De Jong et al. 2008). Accumulation 
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of Au-Au2S NPs was also detected in the lung at one day- and one week post-
injection (Huang et al. 2008). The present results add to these findings, by showing 
continual decrease of AuNPs in the lungs with time after an initial peak. At 1- and 2-
month after injection, the amounts of Au in lung were comparable with that of control 
samples. These findings indicate that the lung could serve as a “reservoir” for NPs 
after acute exposure, and there is significant translocation of NPs out of the lungs 
through lymphatic vessels (Videira et al. 2002; Videira et al. 2006) and/or the 
bloodstream to other organs with time. No noticeable Au was found in any of the 
brain regions measured at any time. This is consistent with the results of previous 
injection tests using larger AuNPs (>50 nm) although smaller AuNPs (10 nm) were 
translocated into the brain (De Jong et al. 2008). This suggests that the ability of the 
blood brain barrier (BBB) to restrict passage of NPs was size-dependent, with 
particles below a threshold of 20 nm having access into the brain. 
At one day and one week post-injection, no accumulation of Au was found in the 
kidney, and Au was excreted in the urine (0.8±0.1 at one day and 1.7±0.7 ng/g at one 
week). The rapid excretion of Au is consistent with a previous report that 77% of 
injected AuNPs (1.9 nm) was efficiently cleared through the kidney and excreted 5 
hours after i.v. injection in mice (Hainfeld et al. 2006). Rapid clearance of 
zwitterionic coated quantum dots (4.36 – 5.52 nm) was also observed within 4 hours 
after i.v. injection (Choi et al. 2007). It is unclear how the 20nm-AuNPs are filtered 
from the bloodstream, since the effective pore size of the filtration barrier i.e. 
glomerular basement membrane (GBM) and podocytes is approximately 8 nm 
(Guyton and Hall 2006). The fact that the AuNPs are excreted, however, suggests that 
factors other than pore size may be important in the filtration of NPs. For example, 
the effective filtration pore diameter of 8 nm applies to proteins which have negative 
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charges and are effectively repelled from the barrier. Since freshly washed AuNPs are 
neutral to lightly negatively charged (data not shown), they may not be so effectively 
repelled, and manage to pass through the barrier. 
The accumulation of Au in the kidney increased with time after 1-week time 
points which was inversely correlated to the level of Au in urine. This is similar to a 
previous report of accumulation of 13-nm quantum dots 705 (1.5–9.2%) in kidney but 
no excretion in the urine, up to 28 days after injection in mice (Yang et al. 2007). One 
possibility is that AuNPs could gradually be coated with serum proteins, thus altering 
their shape, charge and hydrodynamic diameter. Any negatively charged proteins on 
the AuNPs may cause the particles to be repelled from the negatively charged GBM. 
Any agglomeration of AuNPs may also render the particles too large to pass through 
the filtration barrier. Moreover, gradual accumulation of NPs in the kidney over 
months might diminish the permeability of GBM and podocytes, further reducing the 
excretion of AuNPs. Together, these mechanisms could reduce the excretion of 
AuNPs into the urine at 2 months after i.v. injection, and result in significant increase 
in blood Au levels (1.8±0.5 ng/g). As in the kidney, significant accumulation of Au in 
the testis took place only after 1-2 months post-injection.  This raises concern in view 
of a recent report of spermatotoxicity of 9-nm AuNPs (Wiwanitkit et al. 2009). 
Differing from 15-day inhalation exposure to AuNPs which resulted in relatively 
little accumulation of Au in the liver, a single i.v. injection of AuNPs (this study) 
yielded a large amount of Au (up to 72.2 ng/g) two months after AuNP injection. One 
possible explanation is that inhaled AuNPs translocate relatively slowly from the 
lungs to the bloodstream and are phagocytosed by the RES in the spleen, whereas 
AuNPs introduced via bolus i.v. injection could momentarily saturate the uptake 
capacity in the spleen, thus allowing uptake in the liver. Another possibility is that 
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interaction of AuNPs with alveolar fluid in the lungs during inhalation exposure or 
proteins in the blood during i.v. injection could have different effects on surface 
properties of the NPs, leading to differences in tissue uptake of AuNPs. More studies 
are needed to examine why inhalation vs. i.v. injection results in such different 
accumulation of Au in liver. Another difference between inhalation exposure and i.v. 
injection is the level of AuNPs in the lung. Since the lung is a portal of entry of 
AuNPs through inhalation, it is expected to show greater levels of Au through this 
route than i.v. injection. Inhalation exposure also resulted in accumulation of AuNPs 
in the olfactory bulb (13.1±4.7 ng/g), septum (21.7±4.3 ng/g) and entorhinal cortex 
(17.1±2.9 ng/g) (Yu et al. 2007), whereas no Au was detected in the olfactory bulb 
when AuNPs were introduced through i.v. injection. This supports the hypothesis that 
AuNPs enter the olfactory bulb through the olfactory nerves or associated lymphatic 
channels during inhalation exposure (Yu et al. 2007; Elder et al. 2006; Oberdörster et 
al. 2004). 
Microarray analyses 
Liver. The liver showed many up- and downregulated genes with greater than two 
fold change and p<0.05 after AuNP injection (Table 4.9 and 4.10). Analysis of gene 
function by DAVID software showed that the functional categories with the highest 
number of differentially expressed genes were those related to basic cellular 
metabolism such as the cytochrome P450 subfamily and cellular lipid metabolic 
processes. The gene which showed the greatest fold-change increase in expression in 
the liver after AuNP treatment was P450 family 1 subfamily a, polypeptide 1 
(Cyp1a1). In addition, other members of the P450 family also showed singinificant 
increase in expression, including cytochrome P450, family 4, subfamily a, 




cytochrome P450 family 3, subfamily a, polypeptide 13, whilst one member, 
cytochrome p450 family 2, subfamily C, polypeptide 40 showed decrease in 
expression. 
Table 4.9 Upregulated Genes (≥ 2 folds) in liver of 2 months post-injected rats with AuNPs, p<0.05.  




cytochrome P450, family 1, subfamily a, polypeptide 1 Cyp1a1 27.9 ± 13.9 1.8E-05 
D site albumin promoter binding protein Dbp 10.2 ± 13.1 0.0046 
Erythrocyte protein band 4.1-like 4a (predicted) Epb4.1l4a_predicted 4.8 ± 2.8 0.0042 
period homolog 2 (Drosophila) Per2 3.9 ± 0.6 0.0026 
Interleukin 7 Il7 3.2 ± 2.7 0.022 
period homolog 3 (Drosophila) Per3 3.1 ± 1.1 0.0018 
squalene epoxidase Sqle 2.9 ± 0.7 0.00084 
guanine nucleotide binding protein, alpha transducing 3 Gnat3 2.8 ± 0.4 0.0021 
glutamic pyruvic transaminase 1, soluble Gpt1 2.8 ± 0.4 0.00038 
cadherin 17 Cdh17 2.8 ± 1.0 0.0029 
histidine decarboxylase Hdc 2.7 ± 1.2 0.013 
hydroxysteroid (17-beta) dehydrogenase 7 Hsd17b7 2.7 ± 0.3 1.0E-05 
Alcohol dehydrogenase 1 Adh1 2.7 ± 0.6 0.0092 
WAP four-disulfide core domain 3 (predicted) Wfdc3_predicted 2.6 ± 0.4 0.0016 
DNaseII-like acid DNase Dlad 2.6 ± 2.0 0.039 
sterol-C4-methyl oxidase-like Sc4mol 2.5 ± 0.7 0.0014 
ubiquitin-activating enzyme E1-like (predicted) Ube1l_predicted 2.5 ± 0.8 0.015 
hydroxysteroid (17-beta) dehydrogenase 2 Hsd17b2 2.5 ± 0.3 0.0014 
serine protease inhibitor, Kazal type 1 Spink1 2.4 ± 0.3 0.00014 
hairy and enhancer of split 6 (Drosophila) (predicted) Hes6_predicted 2.4 ± 0.5 0.0034 
heat shock protein, A (predicted) Hspa9a_predicted 2.4 ± 1.3 0.026 
Glycerol-3-phosphate dehydrogenase 1 (soluble) Gpd1 2.4 ± 1.7 0.040 
cytochrome P450, family 4, subfamily a, polypeptide 10 ; 
cytochrome P450, family 4, subfamily A, polypeptide 22 
Cyp4a10 ;  
Cyp4a22 
2.4 ± 0.6 0.0036 
Sorting nexing 24 (predicted) Snx24 2.3 ± 0.9 0.012 
thyroid hormone responsive protein Thrsp 2.3 ± 0.5 0.0018 
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide Adh7 2.3 ± 0.6 0.00059 
dodecenoyl-coenzyme A delta isomerase Dci 2.3 ± 0.7 0.010 
cytochrome P450, family 3, subfamily a, polypeptide 13 Cyp3a13 2.2 ± 0.8 0.024 
germinal histone H4 gene Hist1h4b 2.2 ± 0.5 0.0012 
interleukin 1 family, member 8 (predicted) Il1f8_predicted 2.2 ± 0.6 0.0012 
Isopentenyl-diphosphate delta isomerase Idi1 2.2 ± 0.8 0.0052 
ornithine aminotransferase Oat 2.1 ± 0.8 0.011 
Basic helix-loop-helix domain containing, class B2 Bhlhb2 2.1 ± 0.2 0.0082 
2,4-dienoyl CoA reductase 1, mitochondrial Decr1 2.1 ± 0.7 0.011 
solute carrier family 16 (monocarboxylic acid transporters), 
member 10 
Slc16a10 2.1 ± 0.1 0.00012 
coagulation factor C homolog (Limulus polyphemus) (predicted) Coch_predicted 2.1 ± 0.9 0.034 
membrane interacting protein of RGS16 Mir16 2.1 ± 0.4 0.0030 
cytochrome P450, family 8, subfamily b, polypeptide 1 Cyp8b1 2.1 ± 0.3 0.036 
regulated endocrine-specific protein 18 Resp18 2.1 ± 0.7 0.028 
HRAS-like suppressor (predicted) Hrasls_predicted 2.0 ± 1.0 0.040 
formin binding protein 4 (predicted) Fnbp4_predicted 2.0 ± 0.5 0.0054 
choline dehydrogenase Chdh 2.0 ± 0.3 0.0013 
BCL2/adenovirus E1B 19kDa-interacting protein 1 Bnip1 2.0 ± 0.6 0.017 
fatty acid synthase Fasn 2.0 ± 0.4 0.016 
Thyrotroph embryonic factor Tef 2.0 ± 0.1 0.0049 
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The functional category of genes which contained the greatest number of 
differentially expressed genes in the liver was related to lipid metabolic processes 
(Table 4.9). These include: squalene epoxidase, hydroxysteroid (17-beta) 
dehydrogenase 7; alcohol dehydrogenase 1, sterol-C4-methyl oxidase-like; and 
hydroxysterol (17-beta) dehydrogenase 2, all of which were upregulated in the AuNP 
treated rats. 
Table 4.10 Downregulated Genes (≥ 2 folds) in liver of 2 months post-injected rats with AuNPs, p<0.05. 
Gene Gene symbol Fold change p value 
cytoplasmic linker 2 Cyln2 -2.0 ± 0.0 7.20E-06 
solute carrier family 6 (neurotransmitter transporter, taurine), 
member 6 
Slc6a6 -2.1 ± 0.2 0.040 
Lipin 1 (predicted) Lipin-1 -2.2 ± 0.2 0.028 
secreted acidic cysteine rich glycoprotein Sparc -2.2 ± 0.1 0.0066 
Mitogen-activated protein kinase kinase kinase kinase 4 (predicted) Mekk4 -2.2 ± 0.2 0.019 
procollagen, type I, alpha 2 Col1a2 -2.2 ± 0.0 0.00024 
budding uninhibited by benzimidazoles 1 homolog (S. cerevisiae) 
(predicted) 
Bub1_predicted -2.3 ± 0.0 0.043 
nucleolar and spindle associated protein 1 (predicted) Nusap1_predicted -2.3 ± 0.2 0.045 
polycystic kidney disease 1 homolog Pkd1 -2.5 ± 0.1 0.0034 
polo-like kinase 4 (Drosophila) (predicted) Plk4_predicted -2.5 ± 0.2 0.017 
cyclin B1 Ccnb1 -2.5 ± 0.1 0.016 
collagen, type 1, alpha 1 Col1a1 -2.5 ± 0.1 0.0055 
integral type I protein RGD:1303327 -2.7 ± 0.2 0.013 
cyclin B2 (predicted) Ccnb2_predicted -2.7 ± 0.1 0.047 
hypoxia up-regulated 1 Hyou1 -2.7 ± 0.2 0.029 
kinesin family member 20A (predicted) Kif20a_predicted -2.7 ± 0.1 0.026 
pituitary tumor-transforming 1 Pttg1 -2.8 ± 0.2 0.026 
topoisomerase (DNA) 2 alpha Top2a -3.3 ± 0.0 0.030 
phosphoserine aminotransferase 1 Psat1 -3.3 ± 0.1 0.014 
Neuronal PAS domain protein 2 (predicted) Npas2 -3.4 ± 0.2 0.0034 
Beta-microseminoprotein Msmb -3.6 ± 0.1 0.0016 
ribonucleotide reductase M2 Rrm2 -3.6 ± 0.1 0.0050 
Wingless-type MMTV integration site family, member 2B Wnt2b -3.7 ± 0.3 0.043 
wingless-type MMTV integration site 5A Wnt5a -4.0 ± 0.3 0.040 
topoisomerase (DNA) 2 alpha Top2a -4.4 ± 0.1 0.032 
Calcium channel, voltage-dependent, beta 2 subunit Cacnb2 -4.6 ± 0.2 0.015 
cyclin-dependent kinase inhibitor 3 (predicted) Cdkn3_predicted -4.6 ± 0.1 0.010 
popeye domain containing 2 Popdc2 -4.8 ± 0.2 0.038 
suppressor of cytokine signaling 2 Socs2 -6.0 ± 0.1 0.0079 
cytochrome P450, family 2, subfamily c, polypeptide 40 Cyp2c40 -6.8 ± 0.1 0.025 
carboxypeptidase B1 Cpb1 -6.8 ± 0.3 0.035 
protein regulator of cytokinesis 1 (predicted) Prc1_predicted -6.9 ± 0.1 0.0026 
probasin Pbsn -9.4 ± 0.1 0.043 
Ttk protein kinase (predicted) Ttk_predicted -15.8 ± 0.0 0.013 
 
The functional category with the next highest number of differentially expressed 
genes was related to cell cycle processes (Table 4.10). These include ttk protein 
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kinase (predicted); protein regulator of cytokinesis 1 (predicted); cyclin-dependent 
kinase inhibitor 3 (predicted); pituitary tumor transforming 1; and cyclin B2 
(predicted), all of which were downregulated in nanogold treated rats. 
Spleen.  More downregulated- than upregulated genes were found after AuNP 
injection (Table 4.11). The functional categories with the greatest number of 
differentially expressed genes were those related to response to external stimulus, 
response to wounding, defence response, wound healing and blood coagulation. These 
include: serine (or cysteine) proteinase inhibitor, clade B, member 2; s100 calcium 
binding protein A8 (calgranulin A); glycoprotein 5; coagulation factor xiii, Al 
subunit; s100 calcium binding protein A9 (calgranulin B). All the above genes were 
downregulated in the AuNP treated rats. 
 
Table 4.11 Gene expression changes by ≥ 2 folds in spleen of 1 month post-injected rats with AuNPs, p<0.05. 
Gene Gene symbol Fold change p value 
zinc finger protein HIT-4 RGD:628674 3.1 ± 0.7 0.0091 
aldo-keto reductase family 1, member B8 Akr1b8 2.4 ± 1.0 0.0076 
Basophilic leukemia expressed sequence 06 (Bles06)  Bles06 2.2 ± 0.6 0.0053 
homeo box D3 Hoxd3 2.2 ± 0.4 0.019 
basic helix-loop-helix domain containing, class B5 (predicted) Bhlhb5_predicted 2.2 ± 0.3 0.0061 
cholinergic receptor, nicotinic, alpha polypeptide 5 Chrna5 2.1 ± 0.2 0.029 
serum amyloid P-component Sap 2.0 ± 0.3 0.011 
protein kinase, cAMP dependent regulatory, type II beta Prkar2b -2.0 ± 0.1 0.0037 
solute carrier family 6 (neurotransmitter transporter, serotonin), 
member 4 
Slc6a4 -2.1 ± 0.1 0.0084 
septin 5 5-Sep -2.1 ± 0.1 0.00045 
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 Hmgcs2 -2.1 ± 0.2 0.011 
Kinesin family member 9 (predicted) Kif9 -2.1 ± 0.2 0.020 
potassium voltage-gated channel, shaker-related subfamily, 
beta member 1 
Kcnab1 -2.1 ± 0.1 0.00046 
mast cell protease 10 Mcpt10 -2.1 ± 0.3 0.038 
purinergic receptor P2X, ligand-gated ion channel, 1 P2rx1 -2.1 ± 0.1 0.0013 
Nucleotide binding protein 2 (predicted) Nubp2 -2.1 ± 0.1 0.00043 
ankyrin repeat domain 11 (predicted) Ankrd11_predicted -2.1 ± 0.1 0.0047 
Major histocompatibility complex, class II, DM beta Hla-dmb -2.1 ± 0.1 0.0064 
Thrombospondin 2 (predicted) TSP-2 -2.1 ± 0.1 0.0062 
annexin V-binding protein ABP-10 RGD:621413 -2.2 ± 0.2 0.035 
WD repeat domain 33 (predicted) Wdr33_predicted -2.2 ± 0.1 0.00012 
pleckstrin homology domain containing, family C (with FERM 
domain) member 1 (predicted) 
Plekhc1_predicted -2.2 ± 0.1 0.0012 
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Table 4.11 Gene expression changes by ≥ 2 folds in spleen of 1 month post-injected rats with AuNPs, p<0.05 
(continued). 
Gene Gene symbol Fold change p value 
CWF19-like 2, cell cycle control (S. pombe) (predicted) Cwf19l2_predicted -2.2 ± 0.1 0.00031 
Abelson helper integration site 1 RGD:1303040 -2.2 ± 0.1 0.0029 
coagulation factor II (thrombin) receptor-like 3 F2rl3 -2.2 ± 0.1 0.0037 
fetal Alzheimer antigen (predicted) Falz_predicted -2.3 ± 0.1 0.0049 
peptidoglycan recognition protein 1 Pglyrp1 -2.3 ± 0.1 0.00060 
phospholipase A2, group IIA (platelets, synovial fluid) Pla2g2a -2.3 ± 0.2 0.0081 
procollagen, type XI, alpha 1 Col11a1 -2.3 ± 0.2 0.015 
peroxisomal membrane protein 4 Pxmp4 -2.3 ± 0.2 0.047 
glycoprotein Ib, beta polypeptide Gp1bb -2.4 ± 0.1 0.00017 
glycoprotein 9 Gp9 -2.4 ± 0.1 0.00051 
lysyl oxidase Lox -2.4 ± 0.0 0.0013 
spectrin beta 4 (predicted) Spnb4_predicted -2.4 ± 0.3 0.043 
Immunoglobulin superfamily, member 4B (predicted) Cadm3 -2.5 ± 0.3 0.039 
coagulation factor 5 F5 -2.5 ± 0.1 0.0020 
CXXC finger 4 Cxxc4 -2.5 ± 0.1 0.0053 
arachidonate 12-lipoxygenase (predicted) Alox12_predicted -2.6 ± 0.0 0.00010 
gamma-aminobutyric acid A receptor, alpha 1 Gabra1 -2.6 ± 0.1 0.0040 
Low density lipoprotein receptor-related protein 6 (predicted) Lrp6 -2.6 ± 0.2 0.014 
cerebellin 2 precursor protein (predicted) Cbln2_predicted -2.6 ± 0.1 0.00044 
Metallothionein Mt1a -2.6 ± 0.3 0.034 
S100 calcium binding protein A9 (calgranulin B) S100a9 -2.7 ± 0.2 0.011 
Coagulation factor XIII, A1 subunit F13a -2.7 ± 0.1 0.00029 
serine (or cysteine) proteinase inhibitor, clade B  (ovalbumin), 
member 10 
Serpinb10 -2.7 ± 0.1 0.0046 
Solute carrier family 18 (vesicular monoamine), member 2 Slc18a2 -2.8 ± 0.1 0.0042 
PHD finger protein 17 (predicted) Phf17_predicted -2.9 ± 0.1 0.025 
glycoprotein 5 Gp5 -2.9 ± 0.1 0.0021 
S100 calcium binding protein A8 (calgranulin A) S100a8 -2.9 ± 0.3 0.028 
mast cell protease 8 Mcpt8 -3.0 ± 0.2 0.050 
Abl-interactor 1 Abi1 -3.0 ± 0.2 0.040 
lipocalin 2 Lcn2 -3.0 ± 0.2 0.031 
serine (or cysteine) proteinase inhibitor, clade B, member 2 Serpinb2 -3.1 ± 0.1 0.00087 
SRY-box containing gene 30 (predicted) Sox30_predicted -3.1 ± 0.2 0.029 
Neuronal PAS domain protein 2 (predicted) Npas2 -3.2 ± 0.2 0.011 
killer cell lectin-like receptor, family E, member 1 Klre1 -3.9 ± 0.3 0.039 
Phosphatidylinositol glycan, class N (predicted) Pign -4.5 ± 0.3 0.023 
Protein tyrosine phosphatase, receptor type, M Ptprm -5.1 ± 0.2 0.039 
defensin, alpha 5, Paneth cell-specific Defa -6.1 ± 0.3 0.036 
defensin alpha 7 Defa7 -6.7 ± 0.3 0.034 
tetranectin (plasminogen binding protein) (predicted) Tna_predicted -9.0 ± 0.2 0.041 
 
 
Liver and spleen. There were few genes that showed greater than two-fold change 
in both liver and spleen.  We therefore applied a less stringent filter of 1.5 fold (and 
p<0.05) for genes that were altered in common between these two organs (Table 
4.12). The functional category with the greatest number of differentially expressed 
genes was DNA dependent transcription.  This included basic helix-loop-helix 
domain containing, class B3; neuronal PAS domain protein 2 (predicted), period 
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homolog 2 (Drosophila), and d site albumin promoter binding protein.  Of these, D 
site albumin binding protein, period homolog 2 (Drosophila), basic helix-loop-helix 
domain containing, class B3, and neuronal PAS domain protein 2 (predicted), as well 
as cytochrome P450, family 8, subfamily b, polypeptide 1, are involved in the 
circadian rhythm. Together, the microarray results show that the liver and spleen 
show changes in different categories of genes after AuNP treatment, although 
circadian rhythm genes are altered in both these two organs. 








D site albumin promoter binding protein Dbp 10.24 ± 13.1  1.9 ± 0.2  
period homolog 2 (Drosophila) Per2 3.9 ± 0.6  1.6 ± 0.5  
cytochrome P450, family 8, subfamily b, 
polypeptide 1 Cyp8b1 2.1 ± 0.4  1.6 ± 0.2  
HRAS-like suppressor (predicted) 
Hrasls_ 
predicted 2.0 ± 1.0  1.9 ± 0.5  
Basic helix-loop-helix domain containing, 
class B3 Bhlhb3 1.5 ± 0.3  1.5 ± 0.2  
collagen, type 1, alpha 1 Col1a1 -1.7 ± 0.1  -1.5 ± 0.1  
Phosphofructokinase, liver, B-type Pfkl -1.8 ± 0.1  -1.8 ± 0.0  
procollagen, type IV, alpha 1 (predicted) 
Col4a1_
predicted -1.9 ± 0.1  -1.5 ± 0.1  
secreted acidic cysteine rich glycoprotein Sparc -2.2 ± 0.1  -1.5 ± 0.1  
Neuronal PAS domain protein 2 (predicted) Npas2 -3.4 ± 0.2  -3.2 ± 0.2  
 
Genes which were altered in the liver after AuNP treatment were analysed. The 
greatest increase was found with cytochrome P450 family 1 subfamily a, polypeptide 
1 (Cyp1a1). In addition, several other members of the cytochrome P450 family, 
including members of CYP4a and CYP3 were significantly upregulated and one 
member was downregulated after AuNP injection. This suggests that toxic metabolic 
genes/pathways are induced when rats are exposed to low levels of AuNPs. 
Cytochrome P450s are localized in the inner membrane of mitochondria or the 
endoplasmic reticulum of cells, and catalyze multiple reactions, which accounts for 
their central importance in metabolizing and detoxification of extremely large number 
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of endogenous and exogenous molecules. In the liver, these substrates include 
metabolic products, drugs and toxic compounds. Genes related to lipid metabolic 
processes were also altered after AuNP injection. Squalene epoxidase catalyzes the 
second committed (and likely rate-limiting) step in cholesterol biosynthesis from 
farnesyl pyrophosphate (Chugh et al. 2003), and sterol-C4-methyl oxidase-like is 
involved in the formation of lathosterol, also during cholesterol biosynthesis (Porter 
and Herman 2011). 
The downregulated genes in the liver include many which are related to cell cycle 
processes. TTK is a protein kinase detectable in all proliferating human cells and 
tissues, and expression of the TTK gene is markedly reduced or absent in resting cells 
and in tissues with a low proliferative index. Cyclin proteins form complexes with 
members of the p34cdc2 kinase family and they are essential components of the cell 
cycle regulatory machinery. Cyclin B1–Cdk1 is the key initiator of mitosis. Pituitary 
tumor-transforming 1 (PTTG1)/securin is a putative oncoprotein that is overexpressed 
in various tumor types.  Based on the proposed function of these genes, we postulate 
that there is inhibition of cell cycle processes in the liver after AuNP treatment. 
S100 calcium binding protein A8 and A9 (calgranulin A and B) are proteins that is 
made in large amounts in inflammatory diseases such as rheumatoid arthritis, and 
some types of cancer. Coagulation factor XIII, A1 subunit plays a role in blood 
coagulation. Based on the proposed function of these genes, we believe that there 
could be reduced response to external stimulus in the spleen after AuNP treatment. 
The Neuronal PAS domain protein 2 (predicted) is the liver homolog of CLOCK 
gene expressed in the suprachiamatic nucleus in the brain, which encodes proteins 
regulating circadian rhythm. The CLOCK protein seems to affect both the persistence 
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and length of the circadian cycle. CLOCK forms part of a basic-helix-loop-helix 
transcription factor. BMAL-1 dimerizes with CLOCK in vivo and transactivates gene 
expression of Period and Timeless in drosophila by binding to E-box elements in their 
promoters (Ishida et al. 1999). BMAL1-CLOCK also regulates Cryptochrome genes 
(e.g., Cry1, Cry2) and Period genes (e.g., Per1, Per2, Per3) in mammals. The BMAL-
CLOCK complex itself is regulated by the expression of Per and Cry genes. There is 
evidence that the profile of gene expression in the mouse liver is strongly influenced 
by the circadian rhythm (Akhtar et al. 2002; Panda et al. 2002; Duffield 2003), and it 
is possible that this could be affected by AuNPs. 
The findings of microarray analyses need to be further validated in future studies, 
however, to precisely quantify gene expression at both mRNA and protein levels, 
together with the functional studies on the encoded proteins and their roles in 
metabolism.  Nevertheless, it is hoped that these data could serve as a reference for 




CONCLUSIONS AND FUTURE WORK 
5.1 Conclusions and implications 
The major conclusions of this work are itemized under three components of (1) 
Characterization, purification and stability of AuNPs, (2) Biodistribution of AuNPs 
after inhalation and injection exposure, and (3) Gene expression changes after 
inhalation and injection exposure. 
(1) Characterization, purification and stability of AuNPs: 
 Chemical components of synthesized AuNP solution was quantified as citrate 
(1.30±0.05 mM), chloride (0.98±0.07 mM), ketoglutarate (0.07±0.02 mM) and 
gold (0.25±0.02 mM). An intermediate, keto-glutaratic acid is decomposed to 
acetate (0.32±0.08 mM) during the reduction.  
 Quantified non-AuNP components with a newly speciated byproduct (acetate) 
complete the stoichiometric equation of AuNP synthesis through the citrate 
























 An optimal purification of AuNPs was achieved by centrifugation operating at 
7000 g for 20 min which satisfactorily recovers ~ 80% of AuNPs without 
detectable impurities. 
 Storage of purified AuNPs in the dark at 4 °C prolongs the stability of the 
purified AuNP suspensions up to 20 days. 
 Purified AuNPs persist in their atomic status without being oxidized even after 
they were aerosolized in air or heated at 500°C.  
(2) Biodistribution of AuNPs after inhalation and injection exposure 
i. inhalation exposure  
 Biodistribution of Au in rats after 5 day inhalation exposure showed 
significant accumulation of Au in lung (125.7±25.9 ng/g) and olfactory bulb 
(12.1±4.1 ng/g). 
 After15 day inhalation exposure, significant translocation of Au from the lung 
(387.5±130.8 ng/g) to >20 secondary organs (including spleen, kidney, aorta, 
esophagus, spleen, septum and blood) was observed.   
 Inhalation exposure to airborne NPs originating from 7-nm AuNPs resulted in 
distribution in more organs than that from 20-nm AuNPs, particularly in the 
brains, including olfactory bulb, hippocampus, frontal cortex, straitum and 
cerebellum.  
 Inhalation exposure to both 7-nm and 20-nm AuNPs resulted in significant 
accumulation in the lung (>730.6±55.1 ng/g) followed by olfactory bulb 
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(>4.5±0.9 ng/g) with systemic translocation and accumulation of Au in aorta, 
spleen and kidney.  
 The presence ofAu in blood (0.3±0.1 ng/g) was observed after 15-day 
inhalation exposure to 7-nm AuNP only. 
 Excretion of Au in feces was detected at entire timeframe during 15 day 
exposure of both 7- and 20-nm AuNP exposures, while more 20-nm AuNP (in 
terms of mass) were excreted via feces than 7-nm AuNPs. There was no 
observable urinary excretion of both 7- and 20-nm AuNPs. 
 Despite the similar doses of 7 or 20-nm AuNP agglomerates in terms of size 
distribution and number concentrations, the different trend in biodistribution 
suggesting disintegration of inhaled agglomerates to its primary size that 
affected clearance in the lungs and translocation to secondary target organs. 
ii. injection exposure  
 Accumulation of AuNPs in liver (49.4±50.4 – 72.2±40.5 ng/g) and spleen 
(8.4±5.0 – 9.5±6.4 ng/g) was rapid and persistent throughout the post-injection 
observation (1 day - 2 months). 
 Significant accumulation of Au in kidney (up to 5.5±2.5 ng/g) and testis (up to 
0.6±0.1 ng/g) occurred from 1 month post-injection when Au level in urine 
and feces decreased. Significant increase of Au in blood occurred 2 months 
after injection, coincident with the delayed accumulation in kidney. 
 Au accumulation in lungs was found at 1 day post injection but decreased 
within a week. No accumulation of Au was found in the brain. 
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 The major differences in biodistribution resulting from inhalation vs. injection 
route of exposure are summarized in Table 5.1 as follows: 
Table 5.1 Main differences in biodistribution resulting from injection vs. inhalation exposure 
Organs i.v. injection exposure 15-day inhalation  exposure 
Liver up to 72.2 ng/g                   > 0.3 ng/g  
Lung 4.7 ng/g                              <   
(rapid decrease) 
3117.5 ng/g 
Brain None                                   < Noticeable accumulation (ng/g) 
 Olfactory bulb (4.5) 
 Hippocampus (3.6)  
 Frontal cortex (2.5)  
Feces 0.1 ng/g                               < 86.8 ng/g  
 
(3) Gene expression changes after inhalation and injection exposure 
i. inhalation exposure  
 After inhalation exposure to 20-nm AuNPs, lungs and kidneys showed 
significant downregulation in respective 22 and 9 genes, which are related to 
smooth muscles, mitochondrial respiratory function, antigen recognition and 
thyroid responsive function. 
ii. injection exposure  
 Microarray results of liver showed 46 upregulated genes and 34 
downregulated genes. Upregulated genes were mainly associated with 
metabolizing and detoxification of endogenous and exogenous molecules, 
lipid metabolic processes, while downregulated genes were mainly related to 
cell cycle process.  
 Intravenously injected AuNPs caused 54 downregulated genes and 7 
upregulated genes in spleen. Downregulated genes were mainly associated 
with response to external stimulus, wound healing and blood coagulation. 
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 Circadian rhythm gene, which governs 24 h cycle activity in human body were 
commonly altered in both liver and spleen. 
Implications  
 Results of this work imply that exposure through inhalation and injection of 
NPs may lead to wide distribution and accumulation in human bodies. This is 
directly concerning workers handling nanomaterials and patients undergoing 
biomedical diagnosis or treatments involving NPs.  
 Exposure to airborne nano-sized particles outdoors and indoors could also 
make several human organs (e.g., lungs and brains) more vulnerable to inhaled 
NPs. In particular, epidemiological studies have already shown significant 
correlation between ultrafine particle exposure and adverse health effects of 
human beings (Schulz et al. 2005; Ibald-Mulli et al. 2002). 
 Nevertheless, precaution and further studies are needed to extrapolate the data 
provided in this study to human body for various biological differences (e.g., 
the dimension of the respiratory tract, breathing patterns, retention, 
translocation, etc.) (Möller et al. 2009). 
 
5.2 Recommended future work 
In view of the massive needs of data and knowledge on potential impacts of 
engineered NPs, the future work can be a wide open field and is impossible to be 
comprehensively covered in this section. Hence, the research topics below are 
suggested based on immediate relevance to the completed work in this thesis and 
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areas with least data yet high feasibility, including (1) effects of size on gene 
expression of hippocampus, (2) Effects of size and doses of AuNPs through inhalation 
exposure, (3) Effects of surface charges of AuNPs through inhalation exposure, and 
(4) Effects of shape of AuNPs through both injection and inhalation exposure.   
(1) Effects of size on gene-expression of hippocampus 
The present study shows that inhalation exposure to both 7- and 20- nm AuNPs 
accumulated in hippocampus. Further study is needed to investigate the associated 
changes in gene expression of this part of brain through microarray analysis. Results 
of the analysis can be a basis to design experiments of testing alteration in the 
functions (such as comprehension) related to hippocampus. 
(2) Effects of size and doses through inhalation exposure 
To use AuNPs as a therapeutic or diagnostic agent through inhalation, it is 
important to obtain effects of dose (in terms of number concentration) of AuNPs. 
While whole-body inhalation exposure chamber (WBIEC) can simulate inhalation 
exposure without straining rodents, its large volume demands large quantity of NPs, 
and poses difficulties of controlling airborne size distribution, as well as varying 
exposure doses. On the other hand, a directed-flow nose-only inhalation exposure 
chamber (NOIEC) with proper design and characterization provides an avenue to 
achieve the desired tests. Although NOIEC has several limitations (such as restrained 
stress), directed-flow NOIEC chamber requires relatively fewer NPs (Phalen et al. 
1984) and can achieve concentrations of airborne NPs covering a wide range (number 
concentrations and surface areas). NOIEC also provides the possibility of supplying 
airborne NPs that are of better controlled size with minimal agglomeration.  
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(3) Effects of surface charge of AuNPs through inhalation exposure 
Surface charge is an important factor influencing deposition, translocation and 
toxicity of engineered NPs (Cohen et al. 1998; Araujo et al. 1999; Nemmar et al. 
2003). Through in vitro studies, Goodman et al. (2004) showed that positively 
charged AuNPs induced more cytotoxicity than AuNPs with negative or neutral 
charged surface. In addition, the correlation between surface charge of AuNPs and 
resultant biodistribution is needed to effectively engineer AuNPs for use in 
nanomedicine applications. 
To carry out the proposed studies, charge over airborne AuNPs can be 
manipulated as positive or negative followed by characterization using a Faraday cup 
electrometer and a scanning mobility particle sizer to obtain charge distribution as a 
function of size. Following the optimization of generation of airborne AuNPs with 
desired charge, inhalation exposure can be conducted to examine effects of charge 
over AuNPs on biodistribution and associated changes in gene expression.  
(4) Effects of shape of AuNPs through injection and inhalation exposure 
The appealing properties of tunable surface plasmon resonance of Au nanorods as 
a function of their aspect ratio are of clinical significance which makes them popular 
and use as biomedical therapeutic/imaging agents (Burda et al. 2005; Murphy et al. 
2008). Although it has been shown that the adsorption of serum proteins on rod-
shaped vs. spherical shaped AuNPs exhibited different profiles (Chithrani and Chan 
2007), the biodistribution of spherical vs. rod-shaped AuNPs has not been explored. 
Hence, exposing spherical and rod-shaped AuNPs through inhalation and injection 
following the adopted experimental procedures as employed in the present study will 
provide knowledge on shape-dependent effects. Concurrent monitoring of airborne 
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spherical vs. rod-shaped AuNPs will also provide evidence of how the aerodynamic 
properties (such as size distribution and coagulation) are correlated with the shape 
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Table A. Instrumental detection limit of non-Au components  
Non-Au components Limit of detection 
Citrate < 327 ppb (1.7 µM) 
Chloride < 61 ppb (1.7 µM) 
Ketoglutarate < 100 ppb (0.7 µM) 
Acetate < 72 ppb (1.2 µM) 
Total organic carbon 90.9 ppb (7.6 µM) 
